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PREFACE 
This thesis is divided into eight chapters, including this one: 
Chapter 1: 
This is an introductory chapter that addresses the background, rationale and relevance of the study as 
well as the proposed aim and objectives. The general outline and structure of the thesis concludes this 
chapter.  
Chapter 2:  
This chapter provides a comprehensive literature review on the ZIKV epidemic and the urgent 
research currently underway toward the development of FDA approved inhibitors of the virus. 
Included in this chapter is the epidemiology, historical background, life cycle, viral diagnostics, 
modes of transmission, ZIKV-linked neurological diseases, viral characteristics (mechanistic and 
structural), viral/host drug targets, specifically the NS5 and NS3 protein and the design of potential 
inhibitors in ZIKV rational drug design and discovery. 
 
Chapter 3:  
This chapter conceptualizes computer-aided drug design by discussing a various molecular modeling 
and molecular dynamic techniques and applications. The computational tools needed to investigate 
comparative enzymatic structural/conformational characteristics as well as methods used to analyze 
binding affinity are elucidated upon.  
 
Chapter 4:  (Published work- this chapter is presented in the required format of the journal and 
is the final version of the accepted manuscript) 
This chapter demonstrates a unique route map entitled  “Zika virus drug targets: a missing link in 
drug design and discovery – a route map to fill the gap”, demonstrating potential drug targets, 
strategies for design and computational software available to design a homology model. Also 
presented is a 3D homology model of the ideal ZIKV target, the non-structural protein 5 in which the 
active binding sites of each domain of the protein were identified and structure-based virtual 
screening allowed for the identification of possible NS5 RdRp small molecule inhibitors. This article 
has been published in RSC Advances (IF = 3.289). It should be noted that the publication was 




Chapter 5: (Published work- this chapter is presented in the required format of the journal and 
is the final version of the submitted manuscript) 
This chapter investigates the second objective of the thesis and is entitled “Zika Virus NS5 Protein 
Potential Inhibitors: An Enhanced In silico Approach in Drug Discovery.” The study implements an 
optimized and proven screening technique in the discovery of two potential small molecule inhibitors 
of ZIKV MTase and RdRp. This in silico “per-residue energy decomposition pharmacophore” virtual 
screening approach will be critical in aiding scientists in the discovery of effective inhibitors of ZIKV 
targets. This article has been published in Journal of Biomolecular Structure and Dynamics (IF = 2.3). 
 
Chapter 6: (Published work- this chapter is presented in the required format of the journal and 
is the final version of the submitted manuscript) 
This chapter, “Delving into Zika Virus Structural Dynamics- A Closer look at NS3 Helicase Loop 
flexibility and its Role in Drug Discovery”, assesses the third objective of the thesis: to identify the 
structural properties of the ZIKV NS3 Helicase when bound to ATP-competitive inhibitor, NITD008. 
In this study, comparative molecular dynamic simulations were employed for Apo and bound protein 
to demonstrate the molecular mechanism of the Helicase, thus assisting in the design of effective 
inhibitors against this detrimental viral target. The article has been published in RSC Advances (IF = 
3.289). 
 
Chapter 7:  (Published work- this chapter is presented in the required format of the journal and 
is the final version of the submitted manuscript) 
This chapter is entitled “Characterizing the Conformational Features and Ligand Binding Landscape 
of Zika NS3 Helicase- Promising Lead Compounds as Potential Inhibitors”, elucidates on binding 
landscape of the ATPase and ssRNA site by demonstrating the chemical characteristics of potent 
flavivirus lead compounds, Lapachol, HMC-HO1α and Ivermectin at the respective NS3 Helicase 
binding site. This article has been published in Future Virology (IF = 0.886). 
 
Chapter 8:  
This is the final chapter that proposes future work and concluding remarks. 
 V 
ABSTRACT 
The re-emerging Zika virus has evolved into a catastrophic epidemic during the past year, with an 
estimated 1.5 million reported cases of Zika infections worldwide, since the 2015 outbreak in Brazil. 
The virus has received considerable attention during 2016 with a flood of new discoveries, from 
evolving modes of viral transmission to viral-linked neurological disorders, unique specificity to host 
cells and increasing mutation rates. However, prior to the devastating 2015 outbreak in Brazil, the 
virus was classified as a neglected pathogen similar to Dengue and the West Nile virus.  
 
Despite the wide-scale research initiative, there is still no cure for the virus. There are currently 
vaccine clinical trials that are on-going but there has not been a breakthrough with regard to small 
molecule inhibitors. A lot of experimental resources have been allocated to repuposing FDA-approved 
drugs as possible inhibitors, however, even some of the most potent flavivirus inhibitors have adverse 
toxic effects. The first crystal structure of the zika virus was released in May 2016 and since then, six 
viral protein structures have been made available. Due to this lack in structural information, there is 
little known regarding the structural dynamics, active binding sites and the mechanism of inhibition of 
ZIKV enzymes.  
 
This study delves into the structural characteristics of three of the most crucial enzymatic targets of 
the zika virus, the NS5 RNA-dependent RNA polymerase and Methyltransferase as well as the NS3 
Helicase. With emerging diseases, such as ZIKV, computational techniques including molecular 
modeling and docking, virtual screening and molecular dynamic simulations have allowed chemists to 
screen millions of compounds and thus funnel out possible lead drugs. These in silico approaches 
have warranted Computer-Aided Drug Design as a cost-effective strategy to fast track the drug 
discovery process. 
 
The above techniques, amongst numerous other computational tools were employed in this study to 
provide insights into conformational changes that elucidate potential inhibitory mechanisms, active 
site identification and characterization and pharmacophoric features leading to promising small 
molecule inhibitor cadidates.  
 
The first study (Chapter 4), provided a comprehensive review on potential host/viral targets as well as 
provided a concise route map depicting the steps taken toward identifying potential inhibitors of drug 
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targets when no crystal structure is available. A homology model case study, of the NS5 viral protein, 
was also demonstrated. 
 
The second study (Chapter 5) used the validated NS5 homology model to investigate the active sites 
at both the RNA-dependent RNA polymerase and Methyltransferase domains and subsequently 
employ a generated pharmacophore model to screen for potential inhibitors.  
 
Chapter 6 reports the third study, which investigates the structural dynamics and in turn, the possible 
mechanism of inhibition of the ZIKV NS3 Helicase enzyme when bound to ATP-competitive 
inhibitor, NITD008. The study also provides insight on the binding mode at the ATPase active site, 
thus assisting in the design of effective inhibitors against this detrimental viral target. 
 
Chapter 7 maps out the binding landscape of the ATPase and ssRNA site by demonstrating the 
chemical characteristics of potent flavivirus lead compounds, Lapachol, HMC-HO1α and Ivermectin 
at the respective NS3 Helicase binding sites.  
 
This study offers a comprehensive in silico perspective to fill the gap in drug design research against 
the Zika virus, thus giving insights toward the structural characteristics of pivotal targets and 
describing promising drug candidates. To this end, the work presented in this study is considered to be 
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1.1 Background and Rational 
 
The re-emerging Zika virus (ZIKV) has evolved into a catastrophic epidemic during the past year, 
with an estimated 1.5 million reported cases of ZIKV infections worldwide, since the 2015 
outbreak in Brazil (Kollman et al. 2016). The arthropod-borne virus, together with Dengue, 
Japanese Encephalitis and West Nile virus, form part of the flavivirus genus, predominately found 
in the tropics. However, recent reports have evidenced new modes of transmission of ZIKV, 
including congenital, perinatal and sexual transmission, thus sanctioning the rapid spread of the 
virus on a global scale (Turmel et al. 2016; Tilak et al. 2016 Singh et al. 2016; Incicco et al. 
2013; Gourinat et al. 2015; D’Ortenzio et al. 2016; Foy et al. 2011).  
 
During ZIKV replication, the structural proteins (Capsid, membrane, pre-membrane and envelope 
protein) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) of the 
virus prove to be imperative for the replication of the RNA genome, virion assembly and invasion 
of the innate immune system (Noble et al. 2010; Mahfuz et al. 2014; Zanluca et al. 2016). By 
developing inhibitors against ZIKV-specific proteins, viral replication may be terminated with 
minimal adverse effects to the host. Of the ZIKV proteins, the NS3 and NS5 play a central role in 
viral RNA replication and maturation (Bollati et al. 2010). The NS3 protein is made up of two 
functional domains being the protease that is responsible for posttranslational cleavage of the 
nonstructural proteins at five sites on the protein chain and the helicase at the C-terminal being 
responsible for RNA binding and ATP hydrolysis (Chen et al. 2010; Murray et al. 2009; Kwong 
et al. 2005). The largest non-structural protein being the NS5 protein is made up of an N-terminal 
methyltransferase and a C-terminal RNA-dependent RNA polymerase that allow for 5’UTR 
capping and RNA synthesis, respectively (Murray et al. 2009; Bollati et al. 2010; Perera et al. 
2008; Medin & Rothman 2016).  
 
As of March 2016, International health associations announced ZIKV as a public health 
emergency based on growing evidence of the virus being linked to congenital neurological 
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diseases such as Guillain-Barŕe, cranial nerve dysfunction and Microcephaly (Broxmeyer & 
Kanjhan 2016; WHO 2016; Palomo 2016; Rasmussen et al. 2016). In response to the devastating 
consequences of antenatal infection, the scientific community invested significant research 
toward preventative and curative strategies, including vaccine and chemotherapeutic 
development. Although preventative clinical trials are under way, there are still no FDA approved 
small molecule inhibitors against the virus (Cohen 2016; Malone et al. 2016).  
 
One of the most problematic tasks researchers have had to overcome is the ability of the virus to 
target neuronal cells, as inhibitors will not only need to be target-specific, effective and have 
minimal toxicity, but it will also have to pass through the blood-brain-barrier (Plourde & Bloch 
2016; Anaya et al. 2016; Bayless et al. 2016; Olagnier et al. 2016; Brault et al. 2016; Li et al. 
2016; Nowakowski et al. 2016). Novel drug discovery and development, from design to the 
market, may take from anything between 10-20 years. With minimal literature available 
evidencing ZIKV’s mechanism of action on host cells and evolving mutations of the virus, 
developing a novel drug that meets all the requirements of a ZIKV inhibitor may be laborious and 
costly.  
 
Computer-Aided Drug Design is a cost-effective strategy to fast track the drug discovery process. 
Computational methods and resources may be implemented in most stages of drug discovery 
from identifying targets, to drug optimization and preclinical testing (Lu et al. 2012; Huang et al. 
2010; Song et al. 2009; Anderson 2003). With emerging diseases, such as ZIKV, computational 
techniques including molecular modeling and docking, virtual screening, identification of 
pharmacophoric hot spots and molecular dynamic simulations allow chemists to screen millions 
of compounds to funnel out possible lead drugs which may then be validated experimentally. This 
strategy overcomes the concept of “shooting in the dark” with experimental screening, thus 
reducing the drug discovery time-line. 
 
In this study, due to the lack of fundamental research in the previously neglected tropical disease, 
we have utilized key computational techniques to fill the gap in drug design research against 
ZIKV, thus giving insights toward viral drug targets and designing potential inhibitors against 
this new epidemic.  
 3 
1.2 Aim and Objectives 
 
The primary purpose of this thesis is to identify and characterize the principal target proteins of 
ZIKV and subsequently utilize Computer-Aided Drug Design techniques to investigate potential 
small molecule inhibitors against these proteins. 
To accomplish this, the following objectives were outlined:  
1. To create a concise route map depicting the steps taken toward identifying potential inhibitors 
of drug targets with no 3D crystal structure by: 
 
1.1. Providing a comprehensive review on ZIKV including potential viral/host targets. 
1.2. Creating a homology model and classifying the active sites of the essential ZIKV NS5 
protein (prior to the release of the 3D crystal structure). 
1.3. Identification of potential inhibitors against the NS5 RNA-Dependent RNA polymerase 
from commercially chemical databases by performing structure-based virtual screening. 
 
 
2. To utilize the in silico “Per-residue Energy Decomposition Pharmacophore” virtual screening 
technique to propose potential NS5 Methyltransferase (MTase) and RNA-Dependent RNA 
polymerase (RdRp) inhibitors. This may be achieved by: 
 
2.1. Performing molecular dynamic simulations to create molecular dynamic ensembles of 
potent flavivirus inhibitors in complex with Mtase and RdRp. 
2.2. Quantifying individual amino acid interactions towards total binding free energy based 
on the MM/GBSA approach, thus designing a pharmacophore model of each complex 
established from ligand-enzyme interactions. 
2.3. To subject the pharmacophore-based leads and search the Zinc Database for structure-
based scaffolds against the respective enzyme to estimate their binding affinities. 
2.4. Validating the most favorable ligands by assessing the stability and binding free energy 
of each system following exposure to molecular dynamic simulations. 
2.5. Computing the physicochemical descriptors as well as predicting the pharmacokinetic 




3. To investigate the structural dynamics and in turn, the mechanism of inhibition of the ZIKV 
NS3 Helicase enzyme when bound to ATP-competitive inhibitor, NITD008. This will 
provide insight on the binding mode at the ATPase active site, thus assisting in the design of 
effective inhibitors against this detrimental viral target. These objectives are achieved by: 
 
3.1. Combining molecular docking with classical comparative molecular dynamic 
simulations of 100 ns for the free enzyme state as well as a NITD008-bound complex. 
3.2. Utilizing a wide variety of post-molecular dynamic analysis techniques to characterize 
the binding landscape of the enzyme and to demonstrate any structural alterations in 
ZIKV NS3 Helicase loop flexibility subsequent to NITD008 binding. 
 
 
4. To map out the binding landscape of the ATPase and ssRNA site by demonstrating the 
chemical characteristics of potent flavivirus lead compounds, Lapachol, HMC-HO1α and 
Ivermectin at the respective NS3 Helicase binding sites. Insights into the structural and 
binding features of the ATPase and ssRNA site may be established by: 
 
4.1. Implementing molecular docking to identify structurally favorable molecules from a 
library of flavivirus lead compounds. 
4.2. Utilizing the enhanced technique of Accelerated molecular dynamic simulations to 
validate molecular docking and to assess free-binding energy of the systems by 
employing the MM/GBSA and per residue decomposition analysis.  
 
1.3 Novelty and Significance of Study 
 
The ZIKV has received considerable attention during 2016. However, prior to the devastating 
2015 outbreak in Brazil, the virus was classified as a neglected pathogen similar to Dengue and 
the West Nile virus (Brasil et al. 2016).  In recent months, there has been a flood of new 
discoveries regarding the virus, from evolving modes of viral transmission to viral-linked 
neurological disorders, unique specificity to host cells and increasing mutation rates (Sironi et al. 
2016; Cox et al. 2016; Pylro et al. 2016; Plourde & Bloch 2016; Passi et al. 2017; Li et al. 2016; 
Olagnier et al. 2016; Bayless et al. 2016; Anaya et al. 2016).   
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Fundamental structural and molecular research into the viral targets of ZIKV came into effect in 
the last year, with the first crystal structure being released in May 2016 (Song et al. 2016).  The 
lack in literature regarding the structural dynamics, active binding sites and the minimal 
understanding of the mechanism of inhibition of ZIKV enzymes prompted us to design a 
technical route-map toward the design and discovery of potential inhibitors against ZIKV. The 
study also reported a homology model of the ZIKV NS5 protein, identifying possible binding 
sites at the MTase and RdRp domains. This was the first account of structure-based virtual 
screening against the RdRp enzyme, thus assisting scientists from different research domains in 
designing potential small molecule inhibitors against the viral target. 
The scientific community have taken large strides toward developing a effective inhibitor against 
ZIKV, with preventative clinical trials underway (Marston et al. 2016). However, there is still no 
available FDA approved inhibitor against the virus. We chose to provide insights into the 
structural dynamics and binding affinities of crucial ZIKV drug targets, being the NS5 MTase 
and RdRp, as well as the NS3 Helicase. By characterizing the active sites’ structural and 
functional composition, potential small molecule inhibitors may be developed. With the use of 
CADD techniques, a comprehensive in silico perspective is offered to shed light on possible 
structural characteristics that allow for the inhibition of these enzymes as well as amino acid 
residues implicated in enzyme activity. Defining the binding landscape will offer prospective 
design of selective and unique inhibitors with critical pharmacophoric features that will aid in 
developing targeted and effective small molecule inhibitors.  
To this end, the work presented in this thesis is considered to be a fundamental platform in the 
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2. Background on the Zika Virus 
2.1 Introduction 
 
The World Health Organization, during 2016, declared ZIKV as a public health emergency due to 
the virus spreading explosively on a global scale (WHO, 2016). The Zika virus is characterized as 
an arthropod-borne virus from the flavivirus genus and is closely related to the other mosquito-
borne viruses including Dengue, Yellow fever and West Nile. As with other flaviviruses, the 
primary vector is the aedes Aegypti mosquito found in tropical and sub-tropical areas. The initial 
symptoms of ZIKV infection in adults were mild influenza-like symptoms that lasted 
approximately a week. However, as with most viral infections, mutations are eminent, leading to 
the escalation in virulence and transmission. Scientific communities are in a race to characterize 
and understand this previously neglected pathogen due to increasing evidence of its responsibility 
in fetal neurological disorders including microcephaly and Gullian-Barrè syndrome (Ramharack 
& Soliman 2016).  
 
This chapter contextualizes the ongoing ZIKV research, including the previous outbreaks and the 
pathogenesis and life cycle of the virus. The structural characteristics of ZIKV will also be 
reviewed, thus distinguishing possible viral targets in the design of effective and non-toxic 
therapeutics.   
 
2.2 Epidemiology and Transmission 
The Zika virus was first isolated from a pyrexial rhesus monkey in 1947 in Entebbe, Uganda. In 
1948, a second isolation was made from the same forest on a group of Australopithecus africanus 
mosquitoes. Due to both these isolations being from the same Zika forest, the virus was labeled as 
the Zika virus (Dick et al. 1952). Although isolations of the virus were analyzed, researchers only 
detected the virus in humans in 1952 when neutralizing antibodies were picked up in infected 
sera. Scientists Boorman and Porterfield subsequently studied the transmission of viruses from 
mosquito to primates and based on further isolations from both mosquito and monkey concluded 
that mosquitoes acted as vectors for ZIKV (Boorman & Porterfield 1956). 
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From the 1950s to 2006, ZIKV infection reports were minimal, with sporadic cases in Asian and 
African countries including Malaysia, Indonesia, Thailand, Pakistan, Nigeria, Senegal, Cameroon 
and Uganda (Passi et al. 2017). The first infectious occurrence of ZIKV was in 2007 in the Yap 
Islands, Micronesia. Although 80% of the population reported ZIKV symptoms, the virulence 
was not fatal and there were no hospitalizations (Faye et al. 2014; Singh et al. 2016; Boeuf et al. 
2016; Duffy et al. 2009). In 2010, a handful of confirmed ZIKV cases were reported in 
Cambodia, with similar clinical characteristics to the outbreak in the Yap islands (Heang et al. 
2012).  In October 2013, a ZIKV strain analogous to that detected in Cambodia, emerged in 
French Polynesia with an estimated 19 000 ZIKV infections identified over a two month period 
(Chen & Hamer 2016; Singh et al. 2016). 
 
In May 2015, the ZIKV containing its most virulent strain yet, began its rampage in Brazil. To 
date, there are close to 1 million cases of ZIKV infection and a third of microcephaly reports in 
Brazil are linked to perinatal ZIKV transmission (Boeuf et al. 2016; Bogoch et al. 2016; Lissauer 
et al. 2016). By March 2016, the WHO declared the virus as a public health emergency due to the 
rapid transmission of the virus to non-endemic regions (WHO 2016a). By November 2016, the 
virus spread to over 66 countries globally, including Florida, Miami, Singapore, Tonga, Fiji and 






Figure 2.1: Time-line demonstrating the historical outbreaks of ZIKV and the increase in 
virulence with each strain (Image prepared by author). 
!
The rapid spread of the virus across continents is primarily due to vector transmission via the 
Aedes aegypti or Aedes albopictus mosquito. These Vectors are endemic to tropical and sub-
tropical, however, due to evolving climates, the mosquitoes have expanded their habitat, thus 
increasing the number of mosquitoes as vectors of flaviviruses (Centers for Disease Control 2016; 
Shapshak et al. 2016). Another reason for the continental dissemination of the virus is the 
identification of new modes of viral transmission. Recent studies have evidenced ZIKV to be 
transmitted in a similar fashion to that of the detrimental Human Immunodeficiency Virus (HIV), 
that is, from mother to fetus via perinatal transmission, blood transfusion and sexual transmission 
(Hamel et al. 2015; Petersen et al. 2016).  
 
2.3 Characterizing ZIKV 
To date, since the re-emergence of ZIKV and its association with microcephaly and Gullian-Barrè 
syndrome, remarkable efforts have been made in order to provide a better understanding into the 
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major physiological and molecular mechanisms underlying this infectious disease (WHO 2016b). 
Fundamental knowledge on the ZIKV structure and life cycle is crucial in designing anti-ZIKV 
therapeutics as well as exploring the structural implications of ZIKV drug resistance mutations. It 
is evident by the adverse implications of the Brazilian strain, that the ZIKV is highly mutable, 
fortifying the challenge of designing efficient inhibitors against the virus.  The virus is broadly 
classified into an East/West African and Asian/Brazilian strains based on sequence resemblance 
and symptomatic characteristics (Cox et al. 2016). 
 
2.3.1 Life Cycle of ZIKV 
 
Subsequent to viral entry into host, the Zika virion attaches to the surface of target cells by 
interactions between the envelope protein and the host cell surface receptors. The host cell 
receptors that have been evidenced to mediate virion endocytosis include phosphotydylserine 
receptor, AXL, as well as DC-SIGN, TIM-1 and Tyro3. Virions undergo this receptor-mediated 
endocytosis and are internalized to the cell cytoplasm. The viral envelope is then uncoated and 
the viral RNA is released into the cell cytoplasm. The viral RNA is then translated produce a 
large polyprotein at the endoplasmic reticulum and is subsequently cleaved into the individual 
viral proteins, leading to the replication of the viral genome. The viral RNA as well as the 
structural and non-structural proteins, and some host proteins are involved in the packaging of the 
viral complex into vesicles and assemble by budding into the endoplasmic reticulum, whereas 
immature viral particles utilize the host secretory pathway, where virion maturation occurs 
followed by release from the cell (T. Naga Ravikiran , T. Nagamounika 2016; Brasil et al. 2016; 
Gerold et al. 2017; Nugent et al. 2016; White 1977; Medin & Rothman 2016). The ZIKV has 
been evidenced to target a variety of cell types including dendritic cells, human dermal 
fibroblasts, epidermal keratinocytes and neuronal progenitor cells (Galán-Huerta et al. 2016; 




Figure 2.2: Zika Virus Life cycle from vector to host transmission and replication (Adapted from 
(Screaton et al. 2015)). 
 
2.3.2 Structural Characteristics of ZIKV  
The ZIKV is an enveloped icosahedral virus that is made up of a single-stranded, positive-sense 
genome.  The enveloped virion comprises of an 11 kilobase genome consisting of 10,794 
nucleotides encoding 3,419 amino acids (Hayes 2009). The open reading frame (ORF) of the 5’ 
and 3’ untranslated region (UTR) encodes a polyprotein that is cleaved into three structural 
proteins being the capsid, precursor membrane, and envelope. Seven non-structural (NS) proteins 
are also found in this assembly, namely, NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 (largest 
viral protein) (Haddow et al. 2012; Boeuf et al. 2016), in which the genomic protein organization 
is 5’-C-prM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3’ (White et al. 2016). The genomic 
RNA of ZIKV contains an m7gpppAmpN2 at the 5’ end and lacks a poly-A tail at the 3’ end 
(White et al. 2016; Cox et al. 2016). There is also a highly conserved 90-120-nucleotide strand 
near the 3’end that develops into a hairpin loop that is crucial for replication (Passi et al. 2017; 
Mumtaz et al. 2016). Of the non-structural proteins, NS1, NS3 and NS5 are highly conserved 
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whereas the NS2a, NS2b, NS4a and NS4b are small and hydrophobic (Galán-Huerta et al. 2016). 
Of critical importance is the proteolytic cleavage of prM to give the pr and M protein, which is 
produced by furin-like protease located in the trans-Golgi network during the egress of the 




Figure 2.3: Cleaved ZIKV polyprotein demonstrating available protein crystal structures (PDB 
codes: 5IY3, 5JHM, 5JMT, 5T1V, 5KQR, 5U04) (Prepared by Author). 
!
2.3.3 ZIKV Pathogenesis and Clinical Features 
Although isolated in the early 1900s, many of the distinguishing clinical and pathogenic features 
have only been discovered in recent years. Initially, the clinical characteristics of the virus were 
minor, consisting of flu-like symptoms including swollen lymph nodes, maculopapular skin 
rashes and joint pains (Mahfuz et al. 2015; Singh et al. 2016; Plourde & Bloch 2016). Current 
research has now associated the virus with multiple-organ failure and thrombocytopenic purpura 
(Miner & Diamond 2016). The virus has also been evidenced to cause uveitis, a inflammatory eye 
disease in adults (Furtando et al., 2016) and conjunctivitis in approximately 15% of patients 
(Miner & Diamond 2016). The most detrimental complication surrounding ZIKV infection is its 
ability to target neural progenitor cells, thus leading to fetal central nervous system disorders such 
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as microcephaly and cerebral calcification as well as Gullian-Barrè syndrome which as been 
described in adult infection.  
 
After the local replication in host cells, ZIKV is distributed to the heart, muscle and central 
nervous system, as well as across the placental barrier to the fetus (Singh et al. 2016). Once in the 
amniotic fluid, ZIKV has been shown to infect neural progenitor cells, thus triggering apoptosis 
(programmed cell death) of the host cell (Tang et al. 2016). This could be of the potential 
mechanisms by which ZIKV causes fetal microcephaly (El Costa et al. 2016; Huang et al. 2016; 
Ghouzzi et al. 2017; White et al. 2016). Gullian-Barrè is caused by the demyelination of nerves 
leading to muscle weakness, tingling in arms and legs and in severe cases, paralysis. The ZIKV 
may be able to infect myelin directly or via autoimmune-mediated targeting of neurons and glial 
cells (Miner & Diamond 2016).  
 
A study by Grant et al., 2016, demonstrated the degradation of STAT2 by ZIKV NS5 protein, 
thus inhibiting immune-response cells IFN-1 and the innate immune response. The characteristic 
features of ZIKV, being its ability to pass through the blood-brain-barrier and placental barrier, as 
well as target neuronal cells and dampen the host immune response, allow for its persistence and 
replication in the human host (Grant et al. 2016). Targeting specific key proteins of the virus as 
well as possibly targeting invaded host machinery will allow for the inhibition of the virus, 
halting the progression of any downstream complications.  
 
2.4 Rationale of ZIKV Enzymes as Potential Therapeutic Targets 
Hughes et al. (2010) stated that the potential of a protein as a therapeutic target and its 
effectiveness in drug design is essential for determining the biological utility of the protein 
(Hughes et al. 2011). ZIKV contains a plethora of viral proteins that may act as targets in drug 
design. To identify inhibitors that specifically halt essential steps in the ZIKV life cycle, 
fundamental characteristics of each protein need to be established and essential proteins need to 
be identified.  
 
The ZIKV is composed of an inner shell formed by interacting subunits of the capsid (C) which is 
able to interact with genomic RNA, an intermediate shell composed of the membrane (M) and an 
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outer shell containing the viral glycoproteins (E and prM). Disruption of the structural proteins by 
antibodies or small molecule inhibitors may interfere with structural protein interactions thereby 
inhibiting virion assembly and capsid dimerization (Cox et al. 2016; Ekins et al. 2016; Sironi et 
al. 2016).  
 
Replication of viral RNA requires the activities of several non-structural proteins as well as 
utilization of specific host proteins. The NS1 and NS2a proteins have shown to evade the innate 
immune system by acting as antagonists against Toll-like receptor-3 (TLR3) and interferon (IFN) 
α/β, thus providing a biochemical pathway as a starting point in the design of antivirals against 
these NS proteins (Geiss et al. 2010). The NS4a/b proteins also prove to be potential targets for 
therapeutic intervention as a study by Liang et al (2016) has evidenced the NS proteins to inhibit 
the AKT/mTOR pathway, thus halting neurogenesis and inducing autophagy (Liang et al. 2016). 
Of the non-structural proteins however, the NS3 and NS5 proteins are considered as prime targets 
for antiviral development due to their essential roles in ZIKV RNA replication: 
 
2.4.1 NS5 Protein 
The largest non-structural protein translated from the ZIKV genome, with a molecular weight of 
approximately 103 kDa, is the NS5 protein (Figure 2.4) (Cox et al. 2016). It is comprised of a 
Methyltransferase (MTase) N-terminal RNA capping domain and a C-terminal domain with 
RNA-dependent RNA polymerase (RdRp) enzymatic activity. The ZIKV genome sustains a 
5’cap that is methylated to facilitate stability and evasion of host immune responses. The RdRp 
domain of the NS5 is crucial for RNA replication as it initiates RNA synthesis by generating 
negative-sense RNA from a positive-strand template. The synthesized strand then facilitates the 
generation of a positive-stranded RNA during viral replication (Alshiraihi et al. 2016). The 5’ end 
of the viral RNA molecule includes a methylated cap comprising of a guanine nucleotide tethered 
to the first nucleotide of the RNA. Like all polymerases, the structure of ZIKV RdRp portrays a 
right hand with characteristic fingers, palm, and thumb subdomains. There are two cavities 
located in the thumb subdomain; however, there is no biological relevance of the cavities to date  
(Alshiraihi et al. 2016; Malet et al. 2008 Zou et al. 2011) As mentioned above, there are two 
strains of ZIKV, being the African and Asian/Brazilian Strains, The substitutions between 
African and Asian strains occur mostly on the surface of the RdRp domain. The K/R280N, 
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H449Q, and G587K ZIKV mutations occur in the finger region and two mutations are found in 
the thumb domain (A784S and D867N) (Cox et al. 2016).  
 
The MTase domain of NS5 is a 33 kDa protein comprising of 1-260 amino acids. There are 
multiple active-binding sites, including a positively charged RNA binding site, a site for the 
methyl donor S-Adenosyl Methione (SAM), and a Guanine Triphosphate (GTP) cap-binding 
pocket (Alshiraihi et al. 2016; De Oliveira et al. 2014). The core domain contains four α-helices 
surrounding a seven-stranded β-sheet. The N-terminal segment comprises a helix-turn-helix motif 
followed by a β-strand and an α-helix. The C-terminal region consists of an α-helix and two β-
strands. The functional domain of the MTase is found at the N-terminal region of the protein and 
allows for the methylation of both the N-7 position of the 5’ guanine cap as well as the ribose 2’-
OH position of the first transcribed nucleotide. SAM methionine interacts with S56, D146, G86 
and W87, whereas, D146 is integral to a motif that is essential for N7 and 2′O methylation 
(Bollati et al. 2010; Sampath & Padmanabhan 2009; Cox et al. 2016; Zou et al. 2011). 
 
Figure 2.4: Crystal structure of ZIKV NS5 protein. The protein comprises of three domains, the 
N-terminal Mtase domain (residues 1-262) (red), the C-terminal RdRp domain (residues 273-907) 




2.4.2 NS3 Protein 
The NS3 protein consists of 618 amino acids and a serine-protease domain at its N-terminal and 
an ATP-driven Helicase domain and RNA triphosphate at its C-terminal. The protein is also 
involved in viral assembly independently of the known enzymatic activity mentioned (Lescar et 
al. 2008). During the ZIKV life cycle, the NS3 protein directly interacts with the NS5 polymerase 
to effectively multiply the viral genome. Studies have shown that impairment of either domain on 
either protein lead to non-infectious production of the viral particles.  
 
The catalytic triad, Ser135-His51-Asp7, NS2b/NS3 protease is 375 kDA protein that is dependent 
on the association of the 14 kDA, 40 amino acid NS2b cofactor, for its activity (Bollati et al. 
2010). The two NS proteins are covalently linked via a Gly4-Ser-Gly4 sequence, displaying strong 
peptidolytic activity (Lei et al. 2016). One unique feature of the ZIKV protease is its quasi-
twofold dimer symmetry. In the dimer, the substrate-binding sites of the two monomers along 
with the bound inhibitor face each other. The dimer has an opening on both sides that allows for 
the substrate to be accessed from both active sites (Lei et al. 2016).  The protease functions by 
cleaving the polypeptide chain between bonds NS2a-NS2b, NS2b-NS3, NS3-NS4a and NS4b-
NS5. This cleavage is essential for viral replication as the activities of the NS proteins are 
dependent on their cleavage at precise amino acids (Chen et al. 2016; White et al. 2016). 
 
The ZIKV helicase comes from the superfamily helicases, SF2 and is found at the C-terminal of 
the NS3 protein and requires an ATP-driven molecular motor. The structural characteristics of the 
ZIKV NS3 helicase consists of three domains of approximately 440-450 residues: domain I 
(residues 182-327), domain II (residues 328-480) and domain III (residues 481-617), as well as a 
P-Loop (residues 196-203) which is located at the ATP-binding site of domain I (Jain et al. 2016; 
Hongliang Tian et al. 2016) (Figure 2.5).The stimulation by RNA allows the helicase domain to 
exhibit intrinsic nucleoside triphosphatase activity, which then allows for the unwinding of viral 
RNA to facilitate replication of the viral genome with the NS5 RdRp (H Tian et al. 2016). The 
inhibition of either one of the binding sites, the RNA-binding groove or the ATP-binding site, 




Figure 2.5: Crystal structure of ZIKV NS3 Helicase Protein (PDB code: 5GJC) depicting the 
three domains and two-active binding regions (blue) that form hydrophobic pockets for ATP and 
ssRNA binding (Prepared by Author). 
 
2.4.3 Three-dimensional structures of  ZIKV NS5 and NS3 proteins 
 
Prior to 2016, there were no available crystal structures of any of the ZIKV proteins. However, 
there has been a flood of scientific knowledge released in the past two years regarding the 
fundamental characteristics of ZIKV and the basis for ZIKV rational drug design. This has 
allowed for the release of crystal structures of ZIKV proteins, providing new insights on the 
structural features of these targets. Table 1 summarizes the currently available PDB-deposited 
crystal structures of ZIKV NS5 and NS3 proteins.  
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Table 2.1: Overview of the currently PDB-deposited Crystal Structures of ZIKV NS5 and NS3 
Proteins. 





Reference, Date of 
Publication 
Zika Virus NS5 RNA-dependent RNA 
polymerase 2.31 ZN 5TIT 
Godoy et al (To be 
Published) 
Zika Virus NS5 RNA-dependent RNA 
polymerase 1.9 PO4, ZN 5UO4 
Godoy et al (To be 
Published) 
Structure of Zika virus NS5 3.28 GOL, SAH, SO4, ZN 
5TM
H 
Wang et al (To be 
Published) 
Zika virus NS5 methyltransferase 2.01 CL, GOL, SAM, SO4 5M5B 
Coutard et al (March 
2017)  
Zika virus NS5 Methyltransferase in 




5GOZ Zhang et al (November 
2016) 
Zika virus NS5 Methyltransferase in 
complex with GTP and SAH 2.44 
GTA, NI, 
SAH, SO4 5GP1 
Zhang et al (November 
2016) 
Zika Virus NS5 Protein 3.05 SAH, ZN 5TFR Longnecker et al (To be Published) 
NS5 methyltransferase from Zika virus 
bound to S-adenosylmethionine 1.33 
CL, PO4, 
SAM 5KQR 
Coloma et al 
(September 2016) 







5KQS Coloma et al (September 2016) 
     
Zika NS3 helicase:RNA complex 1.6 ACT, FLC 5MFX 
Jenkins et al (To be 
Published) 
Unlinked NS2b-NS3 Protease from 
Zika Virus and its complex with a 
Reverse Peptide Inhibitor 
1.58 - 5GPI Zhang et al (December 
2016) 
Unlinked NS2b-NS3 Protease from 
Zika Virus in complex with a 
compound fragment 
2.0 7HQ, ACT 5H4I Zhang et al (December 
2016) 
Zika virus NS3 helicase 2.05 K, TRS 5TXG Nocadello et al (To be Published) 
Apo structure 1.4 EDO 5JWH Cao et al (To be Published) 
Apo structure 1.69 ATP, CL, MN 5K8I 





2.5 Targeting Host Proteins in ZIKV Therapy 
During the ZIKV replication cycle, host cell machinery is imperative in the translation of viral 
RNA and maturation of the replicated virus, thus targeting host proteins and pathways may be 
key to effective inhibition of viral replication. 
 
One of the most researched host proteins in flavivirus infection is the endoplasmic reticulum 
glucosidase. These proteins allow for the cleavage of the terminal glucose from the glycan found 
at the glycosylation-site of the prM and envelope protein, thus leading to its maturation of the 
envelope protein (Stahla-Beek et al. 2012). Studies have shown that many flaviviruses, including 
ZIKV, have a N-glycosylation at Asn154 (Ekins et al. 2016; Sirohi et al. 2016).  
Castanospermine (CST) and deoxynojirimycin (DNJ) have been established as potent inhibitors 
of alpha-glucosidases, thus preventing the early stages of glycosylation (Courageot et al. 2000).  
 
Apo structure 1.75 CL, EDO, GSP, MPD 5K8L 
Cao et al (To be 
Published) 
ZIKV NS3 helicase in complex with 
GTP-gamma S and a magnesium ion 1.85 
CL, GSP, 
MG 5K8T 
Cao et al (To be 
Published) 
Apo structure 1.6 ADP, CL, EDO, MN 5K8U 
Cao et al (To be 
Published) 
NS2b-NS3 Protease from Zika Virus 
caught after self-cleavage 1.84 CL 5GJ4 
Phoo et al (November 
2016) 
Zika virus NS2b-NS3 protease in Apo 
form 3.1 - 5T1V 
Nocadello et al (To be 
Published) 
Zika virus NS3 helicase in complex 
with ssRNA 1.7 - 5GJB 
Tian et al (August 
2016) 
Zika virus NS3 helicase in complex 
with ATP 2.2 ATP, MN 5GJC 
Tian et al (August 
2016) 
NS3 Helicase from the French 
Polynesia strain of the Zika virus 1.62 ACT, POP 5JRZ Jain et al (August 2016) 
Zika virus NS2b-NS3 protease in 
complex with a boronate inhibitor 2.7 6T8 5LC0 Lei et al (July 2016) 
Zika virus NS3 helicase 1.8 - 5JMT Tian et al (June 2016) 
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Hamel et al (2015) described the importance of dendritic cell-specific intracellular adhesion 
molecule 3- grabbing non-integrin (DC-SIGN), TIM-1 and TAM receptors in the attachment and 
entry of ZIKV into the host cell before replication can occur (Hamel et al. 2015). Small 
interfering RNA (siRNA) was also shown to completely inhibit the expression of the above 
proteins after 48 hours. Other informative publications on siRNA inhibition of flavivirus host 
machinery include a review by Hirsch (2010), an in silico based experimental study on Dengue 
virus by Noppakunmongkolchai et al (2016) and the silencing of the 3’ UTR of ZIKV genome by 
Shawan et al (2015) (Mahfuz et al. 2015; Noppakunmongkolchai et al. 2016; Hirsch 2010). 
 
A recent study published in June, 20016 by Nature identified host endoplasmic reticulum-
associated signal peptidase complex (SPCS) to be necessary for the proper cleavage of ZIKV prM 
and envelope proteins. The authors also demonstrated that the loss of SPCS signaling leads to a 
dramatic decrease in Dengue, Yellow fever, West Nile, JEV and Hepatitis C viruses (R. Zhang et 
al. 2016). Nowakowski et al (2016) also found membrane receptor AXL to have potential as a 
host target as it facilitates the entry of ZIKV into the host cell (Nowakowski et al. 2016). Wells et 
al (2016) however rejected this theory as he demonstrated AXL-knockout to still allow for ZIKV 
entry. He proposed an attachment factor, TYRO3 to be a possible host target (Wells et al. 2016).  
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2.6 The Scientific Advancements of ZIKV Anti-viral Therapy 
The Asian/Brazilian strain of ZIKV has already been associated with irreversible chronic central 
nervous system (CNS) conditions as mentioned above. The concerns of the scientific and clinical 
community are the consequences of Zika viral mutations, thus suggesting the urgent need for 
viral inhibitors. There have been large strides in vaccine development against the virus but there 
are still no licensed treatments available. Rapid rational drug design and discovery research is 
fundamental in the production of potent inhibitors against the virus that will not just mask the 
virus, but destroy it completely. Recent research has found that one of the characteristic features 
of ZIKV is that it targets neuronal cells (Millichap 2016; Miner & Diamond 2016; Mlakar et al. 
2016; Tang et al. 2016). Consequently, any new drugs that may be discovered will have to pass 
through the blood-brain-barrier. Currently, there are number of promising prevention therapies 
and potential treatment options including small molecules (some of which have previously been 
approved by FDA to treat other diseases), vaccine candidates, and neutralizing purified antibodies 
still being tested. Below are an overview of such experimental therapies: 
 
2.6.1 Preventative Antibodies and Vaccines 
“Prevention is better than cure”, a quote that is true to its meaning. Vaccination is one of the most 
effective forms of protection against a viral infection. Immunization with an inactivated vaccine 
will be the most secure route with ZIKV infection as it will be safe to use by pregnant woman 
(Cohen 2016).  Marston et al., 2016, recently published a set of considerations for developing a 
ZIKV vaccine that will allow for safe and effective control of the virus based on focused planning 
and evaluation (Marston et al. 2016). Mahfuz et al., 2014, began the design of epitope-based 
vaccines against ZIKV envelope glycoprotein; however, this was an introductory approach and 
was not validated in subsequent studies (Mahfuz et al. 2014). In July 2016, a study was done on 
repurposing Dengue virus antibodies as inhibitors of ZIKV at different pH levels. Results showed 
CryoEM structures of potent flavivirus antibody C10 bound to ZIKV envelope protein at pH 6.5 
and pH5.0, suggesting a new candidate in ZIKV vaccine therapeutics (S. Zhang et al. 2016).  
Another monoclonal antibody was identified to bind to the glycan loop of the envelope protein, 
thus potentially inhibiting the binding of ZIKV to host cell receptors (Barba-Spaeth et al. 2016). 
Abbink et al., 2016, showed promising results of a purified inactivated viral vaccine, which 
induced ZIKV-specific neutralizing antibodies and immunized a test group of Rhesus monkeys.  
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A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector 
expressing ZIKV prM-E also produced neutralizing antibodies and completely protected monkeys 
against ZIKV infection. These results are promising and clinical trials are currently underway 
with hopes of a FDA approved vaccine (Abbink et al. 2016; Larocca et al. 2016).  
 
2.6.2 Small Molecule inhibitors 
Antibodies and vaccines are often expensive and require specific conditions for the transport and 
storage of the vaccines. This proves to be problematic in developing countries where funds and 
facilities are limited. Development of small molecule inhibitors cost less, are produced faster, 
they are stored large quantities and are generally more accessible. Due to the rapid spread of 
ZIKV infection on a global scale and the detrimental long-term complications, the scientific 
community has turned to, rather than designing and synthesizing new drugs, to ‘repurpose’ 
flavivirus FDA approved drugs for ZIKV (Mumtaz et al. 2016; Wahid et al. 2016). Table 2 
summarizes the ZIKV drug candidates based on related viral inhibitors.  
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Molecular modeling is one of the most rapid developing scientific fields, as it comprises of a 
wide range of theoretical and computational tools used to model and simulate small chemical and 
biological systems with the purpose of understanding their behavior at an atomistic level (Kore et 
al. 2012).  
 
While experimental techniques can significantly demonstrate the mechanism of action of a 
biological system, the extensive labor, time reservations and financial shortfalls have led research 
communities toward enhanced computational alternatives (Cramer 2004; Lu et al. 2012). The 
discipline of computational chemistry forms part of the nucleus of molecular modeling, allowing 
for significant medical breakthroughs due to immense improvements in computer hardware and 
software over recent decades (Jensen 2007). Starting in the 1960s and progressing rapidly since 
the late 1980s, these computational techniques have provided a robust platform for biomolecular 
structure analysis and drug discovery (Leach 2001; Song et al. 2009).  
 
Rational drug design is based on the fundamental knowledge that the activity of a drug is 
obtained from the binding of the compound to a molecular pocket of the biological target. The 
drug’s chemical and geometric stability at the molecular pocket is complementary to successful 
activity. The computational methods used in rational drug design and structure analysis include: 
protein modeling (homology modeling), sequence diversity analysis, virtual screening and 
molecular docking (Kore et al. 2012; Huang et al. 2010).  
 
There are two essential molecular modeling principles (Figure 3.1) that may be used to establish 
the energetics and conformational changes to the drug-target system: 
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– Quantum Mechanics and 
– Molecular Mechanics.  
 
By combining the above molecular modeling principles with molecular dynamic simulations, the 
target’s flexibility and inhibitor binding landscape may be analyzed (Lewars 2003).  
 
Figure 3.1: The scientific domains in which Applications of Quantum and Molecular Mechanics 
fit into (Prepared by Author).   
 
In this chapter, quantum mechanics, molecular mechanics and molecular dynamic simulations 
will be elaborated on, thus providing insight into the rationale behind the chosen energy 
descriptors for this study. The principle behind each of the computational tools employed in the 





3.2 The Principle of Quantum Mechanics 
 
Quantum mechanics (QM) is one of the most successful branches of physics. The Principles of 
QM were developed during the early 20th century, where 2 types of QM were established. The 
initial development of Matrix mechanics was by German scientists: Planck, Born, Jordan and 
Heisenberg as well English-borne Dirac. Later, in 1926, Erwin Schrödinger developed wave 
mechanics, which now plays a fundamental role in the understanding of quantum phenomena 
(Trabesinger 2009).  
 
The Quantum theory explains the behavioral characteristics of sub-atomic particles, such as 
electrons, at a nano-scopic level (Jensen 2007; Atkins & Friedman 2011). The phenomena of QM 
play important roles in biological processes of molecular biology such as bond forming/breaking, 
atomic transfer and electron excitation. Theoretically, QM calculations can predict any property 
of an individual system in a 3D- space. Electrons are mapped using the continuous electron 
density method and the energetics of the system is calculated using Schrödinger’s wave function 
theory. For larger systems, electron density may be calculated using the earlier released Born-
Oppenheimer approximation theory (Shen et al. 2016; Jakobsson 2001).   
 
Provided below is the basic principle of Schrödinger’s wave function and Born-Oppenheimer 
approximation theory: 
 
3.2.1 The Schrödinger Wave Function 
 
In January 1926, Austrian physicist, Erwin Schrödinger proposed the quantum mechanical model 
of the atom. Expanding on the Bohr atom model, which proposes that electrons are arranged in 
concentric circular orbits around a nucleus, Schrödinger utilized mathematical equations to 
describe the probability of locating an electron on an exact path. The model is portrayed as a 
nucleus that is surrounded by an electron cloud of high and low densities. According to quantum 
mechanics, all particles are described as a wave function with no defined position or momentum 
until they are observed. The probability of each possible observation may be determined by the 
wave function (Leach 2001; Atkins & Friedman 2011).   
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The Schrödinger equation forms the fundamental core of QM, as Schrödinger himself found that 
by adding the properties of an atom, being the mass and charge, to the equation, he was able to 
predict a series of shapes showing the wave pattern of electrons in an atom (Bahrami et al. 2014).  
 
 
Figure 3.2: The Bohr Model demonstrated the atom to have a positively charged nucleus that was 
orbited by negatively charged electrons. This model was corrected by the equation, which 
evidenced electrons to have wave functions dependent on mass and charge of the atom. The two 
models are the fundamentals of what we now know as Quantum mechanics (Prepared by Author). 
 
The Schrödinger wave equation:  
 
!" = !"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.2.1) 
Where H is called the Hamiltonian operator (contains derivatives with respect to atom location), 
E is the energy eigenvalues of the system and ψ is the wave function. In order to replicate a 
relevant physical model of Schrödinger’s equation, the wave function must be continuous, single 
valued, normalized and anti-symmetric. The molecular Hamiltonian operator is the sum of the 
atom’s total potential energy (V) and kinetic energy (T): 
! = ! + !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.2.2) 
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Where H is defined as follows:  
 













!!!!!!!!!!!!!(Eq!3.2.3)!!!!!!!!!!!!!!    
 
The Schrödinger equation is highly complex, thus proving to be in-executable when solving for 
molecular systems, as it may contain thousands of atoms (Nakatsuji 2004; Barde et al. 2015; 
Bahrami et al. 2014). However, another QM theory, The Born-Oppenheimer Approximation, 
compensates for molecular rather than atomic structure.  
 
3.2.2 The Born- Oppenheimer Approximation Theory 
 
In 1927, physicists Max Born and J. Robert Oppenheimer proposed the Born-Oppenheimer 
approximation, which describes the uncoupling of the nuclei wave function to that of the 
electrons (Born & Oppenheimer 1927). Electrons are taken to be of lighter weight than that of 
nuclei, thus having increased velocity and move instantaneously to nuclei movement. Electron 
distribution within a molecule is therefore defined by the location of the nuclei (Liehr 1957; 
Ochkur 1965). This allows for the Schrödinger equation to be solved for the kinetic energy of the 
electrons alone, as the kinetic energy for the nuclei will remain constant.  
 
The difference in velocities of the nuclei and electrons allow for the Born-Oppenheimer 
approximation to be applied, minimizing the complexity of the wave function of the Hamiltonian 
equation (Huang & Yi 2009). The simplified wave function: 
! !!"!# = ! !!"!# !(! !!"#$ !!!!!!!!!!!!!!!!!!(Eq!3.2.3) 
 
Eq 3.2.1 is converted:  
 
!!"! !!"!# = !!!"! !!"!# !!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.2.4)! 
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Where HEN denotes a difference between terms based activity to fixed nuclear positions (VNN) or 
their activity to the non-fixed electron positions. Eq. 3.2.5 shows EEN, which is derived from 2 
sources being the fluctuating electron co-ordinates and fixed nuclear co-ordinates.  
 
!!" + !!! ! !!" = !!!"! !!" !!!!!!!        (Eq!3.2.5)! 
 
We use the electronic Schrödinger equation to describe electronic motion within a molecule. The 
Approximation is seen to be more accurate when applied to ground electronic states. Once the 
equation has been solved, fixed positions of interest of the equilibrated conformation may be 
assessed and the potential energy surface and curve may be constructed (Matsika 2010; Woolley 
1991; Jecko 2014; Lewars 2003).   
 
3.2.3 Potential Energy Surface as an Application of Quantum Mechanics 
 
The potential energy surface is an effective mathematical/graphical representation between 
molecular vibrational motions of a molecule, its geometry as well as its nuclear probability 
distribution by solving the time-dependent Schrödinger equation. The concept of potential energy 
surface arises from the Born- Oppenheimer approximation as explained above, whereby electrons 
vary according to the positional states of the nuclei so that the potential energy surface is taken as 
the potential of an atoms motion to collide with each other in a molecule (Atkins & Friedman 
2011; Woolley 1991; Lewars 2003; Levitt et al. 1995). A potential energy surface displays high 
potential energy regions, indicating high-energy nuclear arrangements or molecular 
conformations and low energy regions indicating low nuclear energy conformations (Figure 3.3). 
This may be utilized in computational chemistry to identify the lowest energy state and the 







Figure 3.3: Graphical representation of a two-dimensional potential energy surface (PES) 
(University of California n.d.).  
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3.3 The Principle of Molecular Mechanics  
One of the main difficulties in chemistry is to be able to understand the chemical characteristics 
of a compound, that is, its reactivity, solubility and stability. To measure these features, 
quantifiable dynamics need to be observed and analyzed from predicted molecular models 
(Boeyens & Comba 2001). 
  
Molecular Mechanics (MM) may be defined as a set of models that utilize an empirical, 
algebraic, atomistic energy function for chemical systems. Also known as molecular force field 
methods, MM have become successful when dealing with large molecules that require multiple 
molecular dynamic calculations such as in biochemistry (Maseras & Morokuma 1995). It utilizes 
classical Newtonian mechanics to describe a large variety of molecular systems, from low 
molecular weight systems such as hydrocarbons, to large biomolecular complexes consisting of 
thousands of atoms such as proteins or membrane fragments (Vanommeslaeghe et al. 2014).  
 
In Molecular mechanics, simple algebraic terms are used to express the total energy of a 
compound without needing to compute wave function or electron density as with quantum 
mechanics (Tsai 2002).  Numerous techniques are utilized in rational drug design that identifies 
potentially desirable compounds prior to experimental testing. Molecular Mechanic simulations 
also allow for the construction of atomistic models based on favorable energy calculations (Poltev 
2015).   
 
3.3.1 Potential Energy Function 
 
As mentioned above, atoms are classified as the “building blocks” in force field methods and 
electrons are not considered to be individual particles. This means that rather than solving the 
Schrödinger equation, explicit bonding information must be provided. In force field methods, 
molecules are described by a “ball and spring” model, with atoms of different sizes and bonds of 
different lengths. It was observed that different molecules might have structural similarity due to 
the atoms they are made up of. The concept was coined “atom types” and is dependent on the 
atomic number and chemical bonding holding it in place (Jensen 2007).  
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The potential energy function (PEF)/ force field energy of a molecular system may be classified 
in terms of a set of force field energy equations that are fundamentally based on classical 
Newtonian physics. These equations are able to calculate not only the energy of a system, but the 
“atom types” that make up the molecule as well (Jensen 2007; Tsai 2002).  
 
The total potential energy comprises of the extended sum of all individual potential intra/inter 
molecular components, including: 
1. Bond stretching (between directly bonded atoms) 
!!! = !∑!! ! − !! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.3.1.1) 
 
2. Angle bending (atoms bounded to same central atoms) 
                 !! = !∑!! ! − !! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.3.1.2) 
 
3. Bond torsion 
!!!!!!!!!!!!!!!!!!!!!!!!! = !∑!![! + !"#(!" − !!)]!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.3.1.3)!!!!!!!! 





! + ! ∑ !!!!!"!"
! !!!!!!!!!!!!!!!!(Eq!3.3.1.4) 
 
Where: Kr, Kθ, Kϕ are force constants for bond, angle, and dihedral angle and ro, θo, ϕo are the 
equilibrium distance, angle and phase angle. Parameter rij is distance, while Aij and Bij are van der 
Waal parameters. D is the molecular dielectric constant; qi and qj are charge points.  
 
In molecular mechanics, atoms are typically treated as spheres and bonds as springs. It is 
important to note that the properties mentioned above are easiest to describe mathematically 
when atoms are taken as spheres with characteristics radii. The final potential energy function 
equation is therefore: 





Figure 3.4: Diagramatic representation of the total potential energy function of a molecule, as 
mentioned above (Prepared by Author). 
 
There are many different force fields currently in use; however, they differ by the functional form 
of each energy term, the number of cross terms and the type of information used for fitting the 
parameters. Two general trends may be noted when designing the force fields: 
1. Force fields used on large systems such as DNA or protein, have a relatively simple 
functional forms with no cross terms and use the Lennard-Jones potential as van der 
Waals energy. These are called harmonic/diagonal force fields. 
2. Force fields used on small to medium size molecules have to maintain a high degree of 
accuracy. These have a number of cross terms and an exponential-type potential for van 
der Waals energy. These are called “Class II” force fields. 
 
Examples of the most widely used and popular force fields are AMBER (Wang et al. 2004), 
GROMOS (Hermans et al. 1984), CHARMM (Brooks et al. 1983), OPLS-AA (Jorgensen et al., 
1996) and ENCAD (Levitt et al. 1995) (Monticelli et al. 2013). For the purpose of this study, the 
harmonic AMBER force field was utilized for the characterization of the molecular systems.  
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3.4 The Principle of Molecular Dynamics 
 
Molecular dynamics (MD) first emerged in the late 1950s where Alder, Wainwright and Rahman 
developed simulation methods for the dynamics of liquids. The computational chemistry domain 
has progressed since then and from the early 1970s, molecular dynamics has become the most 
widely used method to study structure and dynamics of macromolecules such as DNA or protein 
(Tsai 2002). There are two types of simulation techniques, classical MD and Monte Carlo (MC). 
In recent years, numerous hybrid techniques have also been released. One of the major 
advantages of MD over MC is its ability to allow for dynamical properties of a system such as 
rheological properties and time-dependent responses (Nair & Miners 2014). Molecular dynamics 
is especially valuable in biochemistry and molecular biology as it affords the opportunity to 
identify and categorize, on an atomic scale, the dynamic events that may impact a biological 
properties of a system (Jarosaw Meller 2001). 
 
Classical molecular dynamics incorporates Newton’s equations of motion into its computational 
algorithm. Based on this highly evolved mathematical and physical algorithm, MD simulations 
provide high probability real-time conformational and mechanistic observations of many 
chemical reactions on an atomistic level (González 2011). An MD simulation allows us to study 
interacting particles of a system throughout a desired time-period, by producing a dynamical 
trajectory that may be then analyzed. The overall purpose of this computational technique is to 
utilize Newton’s equations to solve and understand the energies and structural dynamics of a 
molecular network system. The following initial particle conditions are required: 
1. Positions and velocities of each particle 
2. A good force field to characterize the forces between atoms, e.g. AMBER or CHARMM 
3. Boundary conditions that need to be engaged 
 




Where ri(t) is the particle position vector, t is time-evolution, m is the mass of the particle and Fi 
depicts the interacting force on the particle.  
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Molecular dynamics, according to Jakobsson et al (2001), may be rationalized into four 
continuous technical steps that are repeated millions of times to generate a trajectory (Jakobsson 
2001). The steps are as follows: 
1. The fundamental requirements (states) of the biomolecular system are defined: 
- The co-ordinates of each atom 
- The bond characteristics between each atom 
- The accelerations of atoms 
2. Each atom’s potential energy is computed. 
3. The energies from step 2 are then utilized to solve the equations of motion.  
4. The new “state” of the system needs to be saved and the atoms co-ordinates changed and 
step forward in the simulation in taken. The cycle then starts back at step 1.  
Once the trajectory is fully generated, quantitative analysis of the system’s time- evolution can 
proceed.  
 
3.4.1 Molecular Dynamics Post-Analysis 
 
Molecular dynamic trajectories are created from the production run of the simulation. The 
trajectories can be defined as sequential snapshots that are characterized by both positional co-
ordinates and velocity vectors and detail the time evolution of the system in phase space 
(Likhachev et al. 2016; Jarosaw Meller 2001).   
When choosing analytical software, three requirements are essential: 
1. Qualitative visualization software that will not only display the trajectory’s video clips, 
but also generates high quality snapshots/images. 
2. The software should have prompt processors that will accommodate large volumes of 
data. 
3. A variety of analysis options should be available on the one program.  
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The selected post-dynamic techniques and calculations should be dependent on the nature of the 
MD study; however, critical quantitative evaluation is necessary to support any visual 
systemization. 
For the purpose of this study, the post dynamic analysis of the trajectories is critical to 
determining the:  
1. energetic and conformational stability of the biomolecular system.  
2. The characteristics of the system’s small molecule binding landscape and the 
thermodynamic energy fluctuations along the system’s clustered trajectory. 
3. dynamic conformational features or variability of the biomolecular system. 
 
3.4.1.1 System Stability 
Convergence: 
Convergence may be used to describe protein dynamics based on bond types and bond angle 
vibrations during the unfolding of a protein. This merging toward equilibrium and the 
representation of a final energetic and conformational plateau is essential for a MD trajectory to 
be accurate and reproducible (Amadei et al. 1999).  It is at this plateau that the protein-ligand 
system is shown to display energetically stable conformations.  
 
Root Mean Square Deviation (RMSD): 
The deviation of a complex may be measured by the spatial difference between two static 
structures of the same trajectory. The RMSD of a trajectory is defined as:  






Where: N is the total number of atoms in the complex, Ri is the vector position of the Cα atom of 
particle i in the reference conformation which is computed after aligning the structure to the 
initial conformation (O) using the least square fitting.  
The average RMSD may be calculated by taking the average over the number of frames in each 
trajectory and can be computed for the receptor, ligand and complex of a system (Kufareva & 
Abagyan 2012).  
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Radius of Gyration (RoG): 
The radius of gyration in a protein may be defined as the root mean square distance of the atoms 
from their common centroid/center of gravity. This allows for the estimation of compactness of a 
protein complex along a trajectory. The RoG of a complex may be based on the following 
reaction:  
 
!!!"# = ! ( !!
!
!!! (!! − !!)!)
!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.6) 
Where: ri is the position of the ith atom and r is the center weight of atom i.  
The average RoG may be calculated by taking the average over the number of frames in a 
trajectory (Lobanov et al. 2008).  
 
3.4.1.2 Thermodynamic Energy Calculations (Free Binding Energy) 
Binding free energy calculations is an important end point method that may elucidate on the 
mechanism of binding between a ligand and enzyme, including both enthalpic and enthropic 
contribution (Ylilauri & Pentikäinen 2013). Estimation of binding free energy leads to 
development of various algorithms and approaches including free energy perturbation, 
thermodynamic integration, linear interaction energy and molecular docking calculations, to 
mention a few. 
 
Of all the free energy calculations, the Molecular Mechanics/Generalized Born Surface Area 
(MM/GBSA) and Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) methods 
have proven to be the most accurate and efficient in estimating binding free energies for 
biological macromolecules. Contradictory to molecular docking, both MM/GBSA and 
MM/PBSA do not rely on a large training set to define different parameters in each energy term. 
The above methods make use of a combination of molecular mechanics terms and the implicit 
solvent model to estimate the absolute free binding energy that is averaged over the number of 
frames in the trajectory (Genheden & Ryde 2015). The free binding energy (ΔG) computed by 
these methods for a protein system (complex, ligand and receptor) can be represented as: 
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∆!!"#$ = !!"#$%&' − !!"#"$%&! − !!"#$%&!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Eq!3.7.1  
∆!!"#$ = !!"# + !!"# − !"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Eq!3.7.2  
!!"# = !!"# + !!"# + !!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Eq!3.7.3  
!!"# = !!"/!" + !!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Eq!3.7.4  
!!" = !"#"#!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Eq!3.7.5  
 
Where: Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy 
contribution from the polar states, GGB/PB and non-polar states, G. The non-polar solvation 
energy, SA. GSA, was determined from the solvent accessible surface area (SASA), using a water 
probe radius of 1.4 Å, whereas the polar solvation, GGB/PB, contribution was estimated by 
solving the GB/PB equation. S and T denote the total entropy of the solute and temperature 
respectively.  
The MM/GBSA and MM/PBSA algorithms postulate quantifiable analysis of the binding affinity 
of the ligand to the protein and therefore are able to rationalize molecular docked structures 
(Godschalk et al. 2013).  
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Figure 3.5: Diagramatic representation of thermodynamic cycle as justified in the equations 
above (Prepared by Author). 
 
3.4.1.3 Conformational Features of System 
Root Mean Fluctuation (RMSF) 
The root mean fluctuation (RMSF) of a protein measures residue’s Cα atom fluctuations based on 
the average protein structure along the system’s trajectory. This extends to postulate the 
flexibility of regions of a protein based on the computed RMSF (Bornot et al. 2011). To calculate 
the standardized RMSF, the following equation is applied:  
!"#$% = ! (!"#$! − !"#$)!!(!"#$) !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Eq!3.8) 
Where: RMSFi is the RMSF of the ith residue, from which the average RMSF is subtracted. This 
is then divided by the RMSF’s standard deviation to yield the resultant standardized RMSF.  
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The above method differs from RMSD and RoG as it is computed as the total residue fluctuation 
along the trajectory and is not analyzed at every frame in the trajectory.  
 
Principal Component Analysis (PCA) 
Principal component analysis (PCA) is defined as a covariance-matrix-based mathematical 
technique that is used to simplify the magnitude of the  data generated from a MD simulation to 
understand correlated motions. In MD simulations of biomolecular systems, the PCA technique 
may be applied when measuring the atomic displacement and the loop dynamics of the protein.  
 
The application of PCA in a MD simulation is known as “essential dynamics” as only 
fundamental motions of a data set are isolated from the millions of conformational snapshots. The 
conformational motions are then filtered from largest to smallest fluctuations and graphically 
depicted using a covariance matrix (Martinez & Kak 2001). The new set of defined co-ordinates 
are defined as the principal components of the data set and ordered such that the first 3-4 
principal components have similar fluctuations as observed in the trajectory (David & Jacobs 
2014). For the purpose of this study, the first 2 principal components were calculated and matrix 
covariance applied to evaluate the overall motion of the protein complexes. 
 
Dynamic Cross Correlation (DCCM) 
Dynamic cross correlation (DCCM) plots are used to quantify residue fluctuations either in or out 
of phase during a simulation.  The cross correlation coefficient varies from -1 (completely anti-
correlated motion) to +1 (completely correlated motion).  The formula used to describe dynamic 
cross correlation is given below: 
!!" = !
< !"#.!"! >




The cross-correlation coefficient (Cij) varies within a range of −1 to +1 of which the upper and 
lower limits correspond to a fully correlated and anti-correlated motion during the simulation 
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process. Where, i and j stands for ith and jth residue respectively and Δri or Δrj represents 
displacement vectors correspond to ith and jth residue respectively.  
Dynamic cross correlation maps have become very successful in quantifying residue motions that 
arise from ligand binding or in the occurrence of protein mutations (Kasahara et al. 2014; Tiberti 
et al. 2015). 
 
3.5 Other Computer-Aided Drug Design Techniques Utilized in the Study  
3.5.1 Homology Modeling  
 
The initial step in molecular modeling and drug design is having a valid 3D structure, from X-ray 
crystallography, Nuclear Magnetic Resonance (NMR) or computational design using homology 
modeling (Soni & Madhusudhan 2017). The aim of homology modeling is to predict a three-
dimensional (3D) model of a biological structure from a template sequence based on the structure 
of one or more homologous viral proteins of which crystal assemblies have been reported 
(Ramharack & Soliman 2016).    
 
Homology modeling has played influential roles in many research areas and has aided in drug 
design by giving insights into spatial conformations and providing a structural template to 
construct novel drugs that are both specific and effective (Krieger et al. 2003).  
 
In order to generate a 3D model of a biological target, a general procedure is followed, with 
validation at each step (Ramharack & Soliman 2016): 
1. A target sequence needs to be identified and utilized to search (Blast) for homologous 
target sequences. 
2. Template structure/s should be selected based on alignment length, sequence identity and 
structural identity.  
3. Alignment between target and template sequences should be prepared. 
4. Homology model should then be built using preferred computational software. 
5. Validation of model may be verified using the predicted 3D structure and a 
Ramachandran plot.  
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The application of homology modeling may facilitate the design of low-resolution 3D structures 
that enable enhanced structural dynamic research of drug-target interactions on a molecular level 
(Hilbert et al. 1993).  
 
3.5.2 Molecular Docking  
 
One of the most popular tools utilized in computational drug design is molecular docking. The 
technique of molecular docking makes use of a multiple methods in the prediction of binding 
affinity and configuration of a complex. Ligand-receptor complexes exemplify the most general 
use of docking, although there are numerous studies that demonstrate protein-protein complex or 
drug delivery complexes such as nanoparticles or aptamers (Meng et al. 2011; Kroemer 2007).  
 
There are two main steps involved in docking: 
1. Sampling conformations of a ligand in the active site of protein- different algorithms may 
be used when sampling the numerous conformations of the docked complex: the “lock 
and key” model which describes the ligand and receptor as rigid structures, or the ligand 
may be flexible either through random or simulation-based methods. The latter algorithm 
is the most commonly used method as it allows for a more realistic fit of the ligand to the 
protein (Meng et al. 2011).  
2. Ranking the different conformations by scoring function- the scoring function may be 
based on statistically preferred contacts, MM force fields or pre-existing protein-ligand 
binding affinities (Meng et al. 2011). 
 
Over the past decade, there has been flood of molecular docking related publications and 
although these papers may add to the structural information about a biological target or new lead 
compound, there are still many inconsistencies that arise (Chen 2015). Frequent criticism 
associated with docking includes incorrect binding sites, choice of docked complex 
(conformational pose) and choice of small molecule (inhibitor or agonist) (Ferreira et al. 2015). 
Due to these concerns, all docked complexes in this study were verified with MD simulations 
were stability of the ligand at the active site was demonstrated.  
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3.5.3 Virtual Screening (VS)  
 
Virtual screening (VS) plays a fundamental role in the drug discovery and development pipeline 
as the technique is defined by the assessment of extensive small molecule libraries in search of a 
new compound on the basis of a biological target. The VS techniques approach allows for the 
filtering of millions of small molecules to a manageable number of compounds that have the 
greatest chance as a lead drug. The method utilizes a wide variety of filters to identify 
biologically active alternatives to current inhibitors based on the “similar property principle”, 
which states that structurally similar molecules tend to have similar properties (Lionta et al. 2014; 
Vyas et al. 2008). 
Virtual screening may be categorized into two approaches: 
1. Structure-based virtual screening (SBVS) identifies energetically advantageous binding 
affinities of ligands into a target’s active binding site. This allows for new insights on the 
nature of the active site and the protein-ligand interactions. The method identifies 
selective molecules from an extensive library of compounds to dock within a target’s 
active site (Kumalo & Soliman 2016).  
2. Ligand-based virtual screening generates libraries of compounds based on a known 
compound or compounds and its illustrative interactions with a particular target (Cele et 
al. 2016). 
Of the approaches, SBVS has been shown to have similar inconsistencies as molecular docking 
and prove to be difficult when designing drugs for emerging diseases (such as this study). The 
LBVS generates large libraries of compounds and thus identifying accurate lead compounds is 
still challenging (Anderson 2003). 
 
Pharmacophore based virtual screening (PBVS) has exhibited numerous benefits in 
computational hit identification and lead optimization. The approach uses pharmacophoric 
features based on a current inhibitor’s functional groups (hydrogen bond donors, hydrogen bond 
acceptors, cations, aromatics, hydrophobic areas). These pharmacophoric features are then 
established as the criteria when searching through extensive small molecule libraries to identify a 
handful of compounds that may be validated as lead compounds. In this study, PBVS has been 
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employed as it has been evidenced to be more reliable than SBVS and LBVS (Kim et al. 2010; 
Sliwoski et al. 2014; Drie 2007).  
Figure 3.6 summaries the computational tools carried utilized in this study.  
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Zika Virus is an emerging virus that has been defined by the World Health Organization as a 
serious global biological-threat. Zika virus is an arbovirus from the flavivirus genus that is linked 
to microcephaly after prenatal transmission from the infected mother and most recently Gullian-
Barrè Syndrome.  The need for innovative research methods is urgent due to the ambiguity 
surrounding Zika virus. The lack of experimental data regarding potential drug targets, strategies 
for design and drug resistance has prompted us to provide a comprehensive framework with 
structured theoretical and technical guidelines on potential drug targets, modeling and design of 
inhibitors against the virus, thus assisting and encouraging scientists from different research 
domains to fill the gap in this research area. We have also represented a 3D homology model of 
the ideal Zika viral target, the non-structural protein 5, identified the active binding sites of each 
domain of the protein and found potential compounds that may act as inhibitors. This report will 












Zika Virus (ZIKV) is a re-emerging arthropod-borne virus that is predominantly found in the 
tropics, however, rapidly evolving climate conditions coupled with increasing distribution of 
Aedes mosquito vectors and emerging modes of transmission of the virus have increased the 
potential to cause outbreaks in previously unaffected areas (1).  The virus is a member of the 
Spondweni sercocomplex of the genus flavivirus, family flaviviradae. Other arboviruses related 
to ZIKV include Dengue virus, Japanese encephalitis viruses and West Nile virus (2,3).  
 
The first cases of the ZIKV infection were reported in Nigera in the 1950’s. Since then, ZIKV has 
shown erratic cases in countries such as Uganda, Tanzania, Egypt, Gabon, and in parts of Asia 
including India and Indonesia, with the most devastating pandemic occurring in Brazil in 2015 
(4,5). Since the outbreak in Brazil, infection has spread rapidly throughout South America and 
Mexico, with Colombia being one of the most-affected countries with over 20,000 suspected 
cases (6). As of June 2016, thirteen countries have reported Central Nervous System (CNS) 
malformations such as microcephaly and Gullian-Barrè syndrome (GBS) which may potentially 
be linked to ZIKV; during the recent circulation of the virus, eight countries had reported cases of 
GBS, where laboratory testing confirmed ZIKV infection in a number of those cases (7). 
Globally, the prevalence of ZIKV infection may be greatly underestimated (Figure 4.1) due to the 
recently verified prenatal and sexual transmission in humans (8), as well as the abstruseness 




Figure 4.1: Global reports of ZIKV transmission, infection and sporadic viral antibody reports 
prior to 2015, as of April 2016 (Adapted from Centers for Disease Control and Prevention).  
 
Most cases of ZIKV have reported febrile flu-like conditions that may be mistaken for other viral 
infections such as yellow fever. Other symptoms include swollen lymph nodes, maculopapular 
skin rashes and joint pains (5,9,10). Current research has raised concerns that the virus could 
cause dramatic increases in microcephaly in newborns after prenatal transmission (6,11–13). 
Complications associated with prenatal infection encompass fetal growth restriction, neurological 
and ocular abnormalities, intracranial calcification and in some cases perinatal death or stillbirth 
(10,14).  
 
The virus is transmitted via an Aedes mosquito vector, congenital and perinatal transmission, as 
well as sexual intercourse (8,11,14–17). Studies have also reported transmission via blood 
transfusion and laboratory exposure (8,18). Commercial assays have been utilized in the 
diagnosis of ZIKV infection, including Real Time Polymerase Chain Reaction (RT-PCR) kits and 
IgM-based Enzyme-Linked Immunosorbent Assay (ELISA) (10,19). Sample DNA and RNA for 
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these kits may be extracted from blood serum, semen, amniotic fluid, plasma, saliva and urine. In 
Dengue infection, NS1 protein may be detected in a host’s blood serum at the onset of clinical 
symptoms, this may prove to be another method by which ZIKV infection may be identified 
(16,20–22). 
 
Although recent publications have described the global spread, pathogenicity and bioinformatics 
of ZIKV and its comparison between other flaviviruses including Dengue, West Nile, Yellow 
fever and Japanese Encephalitis virus (1,3,8,10,13,19,20,23–30), fundamental research into ZIKV 
small molecule drug design will be key in developing inhibitors of target proteins of the virus. 
Ekins et al (2016) described possible drug discovery and potential homology models of multiple 
proteins of ZIKV, however, despite the execution of research methods, there are currently no 
known FDA approved drugs of ZIKV (31).  This prompted us to conduct a concise route map 
depicting the steps taken toward identifying potential inhibitors of drug targets with no 3D crystal 
structure and by following the guide to create a homology model of a non-structural protein of the 
virus, thus assisting scientists from different research domains. These in silico guidelines will be 
vastly beneficial in aiding and accelerating ZIKV experimental drug discovery. 
 
2. Overview of ZIKV protein assembly 
ZIKV is an enveloped virus comprising of an 11 kilobase, single-stranded positive sense RNA 
genome consisting of 10, 794 nucleotides encoding 3, 419 amino acids (25). The open reading 
frame (ORF) of the 5’ and 3’ untranslated region (UTR) encodes a polyprotein that is cleaved into 
three structural proteins being the capsid, precursor membrane, and envelope. Seven non-
structural (NS) proteins are also found in this assembly, namely, NS1, NS2A, NS2B, NS3, NS4A, 
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2K, NS4B, and NS5 (largest viral protein) (24). These viral assembly proteins may act as crucial 
molecules in drug discovery. 
 
3. Potential biological drug targets Against ZIKV 
3.1 Viral Drug Targets  
Hughes et al (2010) stated that the potential of a protein as a therapeutic target and its 
effectiveness in drug design is essential for determining the biological utility of the protein (32). 














Table 4.1: Potential ZIKV target proteins  
*aa- amino acid 
The structural proteins of ZIKV, being the capsid, precursor membrane and envelope form the 
viral particle (33). The envelope (E) protein is the key surface protein as it is able to mediate 
various aspects, including binding and membrane fusion of the viral replication cycle, making it a 
significant target in drug design (5). 
 





 Structural Proteins 
Capsid YP_009227206.1 5IZ7/5IRE 122aa 
Precursor Membrane YP_009227197.1 5IZ7/5IRE 168aa 
Envelope YP_009227198.1 5JHM/5JHL 500aa 
 Nonstructural Proteins 
NS1 YP_009227199.1 5IY3 352aa 
NS2A YP_009227200.1 Not available 226aa 
NS2B YP_009227201.1 Not available 130aa 
NS3 YP_009227202.1 5JMT 617aa 
NS4A YP_009227203.1 Not available 127aa 
2K YP_009227209.1 Not available 23aa 
NS4B YP_009227204.1 Not available 251aa 
NS5 YP_009227205.1 Not available 903aa 
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The nonstructural proteins participate in the replication of the RNA genome, virion assembly and 
invasion of the innate immune system. Of the nonstructural proteins, NS5, NS3 and NS1 have 
shown enzyme activity in other viruses of the flavivirus genus, creating ideal targets in inhibitor 
development (33). 
NS5 is a bifunctional enzyme with a methyltransferase domain at its N-terminal end and a RNA-
dependent RNA polymerase (RdRp) at its C- terminal end. Both N- and C-terminal domains 
contain an S-Adenosyl-methonine-dependent MTase core structure that folds into an α/β/α sheet 
cradled between the N- and C-terminal subdomains (34). The protein engages in virus-host 
interactions and actively interacts with the host environment (1).  To our knowledge, there is 
currently no available 3D crystal structure of the ZIKV NS5 protein. 
 
The NS3 protein is a multifunctional, viral replication protein. The protease comprises of the N-
terminal third of NS3 and nucleotide triphosphatase, the RNA triphosphatase, and finally the 
helicase components. NS3 can be considered a serine protease and contains a classical catalytic 
triad (His-51, Asp-75, Ser-135) (1,35). Agnihotri et al (2012) reported an in silico study in which 
a homology model of the flavivirus NS3 protein was created using 22 species of the flavivirus 
genus. This study is a critical tool in the understanding the flavivirus NS3 protein and thus the 
impact of the protein as a ZIKV target (36). The 3D-crystal structure of the NS3 Helicase protein 
has recently been reported in Protein and Cell where a conserved triphosphate pocket and a 
positively-charged tunnel were identified to be critical for the hydrolysis of nucleoside 
triphosphates and the accommodation of RNA respectively (37). 
 
The 3D crystal structure of the noteworthy NS1 glycoprotein viral target was released earlier this 
year and was classified as a major antigenic marker of ZIKV infection (38). The NS1 is 
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synthesized as a monomer and dimerizes after post-translation modification in the replication 
cycle (39). The mature NS1 protein has significant immune evasive functions on the surface of 
cells, in the extracellular space and in cells by directly regulating the translation of viral RNA. 
Recent studies on Dengue virus have also evidenced NS1 to be associated with vascular leak and 
shock due to the disruption of TLR3 signaling pathways (40). Song et al (2016) reported NS1 to 
display a loop-surface interface with divergent electrostatic potential that may result in unique 
interactions with host machinery compared to that of other flaviviruses (38). This makes ZIKV 
NS1 an ideal target for chemoinformatics studies.  
 
Inhibitors of these viral proteins may be designed using computer-aided drug design techniques to 
select structural molecules that may inhibit the replication of viruses such as ZIKV in a host.  
 
3.2 ZIKV Host Targets  
During the ZIKV replication cycle, host cell machinery is imperative in the translation of viral 
RNA and maturation of the replicated virus, thus targeting host proteins and pathways may be 
key to effective inhibition of viral replication. 
 
One of the most researched host proteins in flavivirus infection is the endoplasmic reticulum 
glucosidase. These proteins allow for the cleavage of the terminal glucose from the glycan found 
at the glycosylation-site of the prM and envelope protein, thus leading to its maturation of the 
envelope protein (41). Studies have shown that many flaviviruses, including ZIKV, have a N-
glycosylation at Asn154 (31,42).  Castanospermine (CST) and deoxynojirimycin (DNJ) have 
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been established as potent inhibitors of alpha-glucosidases, thus preventing the early stages of 
glycosylation (43).  
 
 Hamel et al (2015) described the importance of dendritic cell-specific intracellular adhesion 
molecule 3- grabbing non-integrin (DC-SIGN), TIM and TAM receptors in the attachment and 
entry of ZIKV into the host cell before replication can occur (44). Small interfering RNA 
(siRNA) was also shown to completely inhibit the expression of the above proteins after 48 hours. 
Other informative publications on siRNA inhibition of flavivirus host machinery include a review 
by Hirsch (2010), an in silico based experimental study on Dengue virus by 
Noppakunmongkolchai et al (2016) and the silencing of the 3’ UTR of ZIKV genome by Shawan 
et al (2015) (5,45,46). 
 
A recent study published in June by Nature identified host endoplasmic reticulum-associated 
signal peptidase complex (SPCS) to be necessary for the proper cleavage of ZIKV prM and 
envelope proteins. The authors also demonstrated that the loss of SPCS signaling leads to a 
dramatic decrease in Dengue, Yellow fever, West Nile, JEV and Hepatitis C viruses. This study 
could be a critical cornerstone in targeting host proteins and pathways in ZIKV infection (47). 
 
4. In silico studies conducted on ZIKV  
Prior to 2016, only two in silico reports have been made toward the development of ZIKV 
inhibitors. Computational studies by Shawan et al (2014) showed the viral envelope glycoprotein 
to be the most immunogenic structural protein of the virus, thus, making it a candidate for vaccine 
development (5). Shawan et al (2015) also looked at small interfering RNA (siRNA) in gene 
 70 
silencing of the 3’ UTR of ZIKV genome (48). Following the Brazil outbreak, an influx of 
research output has flooded the scientific community. There has been numerous computational 
studies regarding ZIKV target proteins; crystals structures of the NS1, NS3, envelope and the 2 
cryo-EM structures of the stable virus have been released (37,38,42,49,50). Ekins et al (2016) 
described in silico studies in both drug discovery and the homology models of both structural and 
nonstructural proteins (9,31). There have also been reports comparing the structural and sequence 
conformations of ZIKV to other flaviviruses including Dengue and West Nile viruses (51,52).  
 
5. In silico route map toward the design and discovery of ZIKV 
inhibitors 
 
Rational Drug Design may be classified into two groups, the first being the development of small 
molecules with the desired effects of the target, whose structural information is known and the 
second group being development of small molecules whose cell functions and structural 
information may not be known (53). 
To date, there is no available 3D crystal structure of the ZIKV NS5 protein. This prompted us to 
create a route map (Figure 4.2) describing the techniques of the second group, thereby benefiting 
scientists from different research domains by informing them of fundamental computational 
techniques in the design of novel small drug molecules, allowing for increased output of 
validatory experimentation. 
 
Computer-Aided Drug Design (CADD) represents computational methods and resources used in 
the design and discovery of new therapeutic solutions (54). Numerous bioinformatics tools and 
resources have been developed to advance the drug discovery process (55,56). The recent 
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improvements made in computational chemistry software, CADD and molecular dynamic 
simulations have led to innovative research methods in the pharmaceutical industry (57).  
 
Figure 4.2: Route map toward the in silico design of ZIKV inhibitors using the homology 
modeled viral NS5 protein. Details on how the homology model was created are described under 
section 5.1. 
 
The initial step of any modeling work is having a valid 3D structure, from X-ray crystallography, 
Nuclear Magnetic Resonance (NMR) or computational design using homology modeling. 
Homology modeling is used to predict and generate a plausible 3D structure of ZIKV’s biological 
target from a template sequence based on the structure of one or more homologous viral proteins 
of which crystal assemblies have been reported (Figure 4.3) (58). 
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Figure 4.3: Protocol for building a homology model in our laboratory. 
In order to create a ZIKV target 3D homology model, a typical procedure needs to be followed, 
with validation taking place at each step. Once the 3D structure has been generated and validated 
using 3D profiles and a Ramachandran plot (59), the predicted active binding site of the ZIKV 
target molecule may be identified. If the drug target is an enzyme, such as the NS3 or NS5 protein 
of the ZIKV viral assembly, designed chemical molecules may be able to fit within an active site 
pocket (56). The results establish the locality of possible binding pockets of the protein (60). 
After each pocket has been identified, we can identify the size of a pocket (volume, surface area 
and depth), possible interacting residues and surface atoms (61).  
 
-Identify target sequence 
- Blast for similar template sequences 
 
-Select template structure(s). 
Consideration should be given to alignment length, 
sequence identity, resolution of template structure, 
and consistency of secondary structure between 
target and templates.  
-Align target sequence to template 
sequence(s) 
- Build homology  model 
-Predict secondary 3D structure and verify against homology 
model 
-Plot a ramachandran plot to validate homology model 
Validate(
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Subsequent to the ZIKV protein homology model and target site determination, several paths may 
be utilized in the development of inhibitors. Structure-based virtual screening will assist in 
searching through combinatorial chemistry libraries for molecules that may be potential inhibitors 
of the target protein and automatically dock these molecules into the 3D target’s active pocket at 
a rapid rate (62). Thousands of molecules may be able to match the active site of the target 
protein, thus, a scoring function is utilized to rank ligands based on the free binding energy 
calculated after each docking pose (63,64). Molecules with the lowest free binding energy 
subsequent to screening may be used as inhibitor candidates, which may then be employed in a 
series of validatory molecular dynamic simulations.  
 
Molecular dynamic simulations calculate the trajectory of a generated docking pose by utilizing 
Newtonian mechanics (65). It is an important tool of CADD as it avoids analytic intractability in 
complex systems (57).  Molecular dynamics is not essential in CADD but it can provide 
validation of docking results between a protein and its potential inhibitors (66).  
 
By implementing in silico studies in the design of ZIKV protein inhibitors, putative drug-like 
compounds may be identified and their potency verified using in vitro and in vivo testing.  
 
Studies report that in vitro testing of potential inhibitors may utilize cultured monkey cell lines 
such as LLC-MK2 and Vero (30). Delvichio et al (2016) also reported Choloroquine as potential 
ZIKV inhibitor in Vero, hBMEC, hNSC and mouse neurospheres. Dowall et al (2016) developed 
the first in vivo murine model, where adult female mice were subcutaneously inoculated with 
similar doses of ZIKV from natural infection of a mosquito bite (67,68). This model is a critical 
cornerstone in accelerated testing of new ZIKV inhibitors.  
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Larroca et al (2016) have made a significant contribution to the protection against the ZIKV virus 
by creating the first full-length prM-envelope DNA vaccine. The vaccine is currently undergoing 
clinical trials after the success in an in vivo study using infected mice. This vaccine may be the 
potential ‘holy-grail’ in ZIKV prevention (69). 
 
5.1 A homology model for ZIKV NS5 
In order for CADD of ZIKV to occur, a 3D crystal structure of a target protein is needed. Figure 
4.4 shows the first account of a homology model for the ZIKV NS5 protein, which was created 
and validated as described in our previous publications (Figure 4.4) (60,70). The PDB coordinates 
of the homology model are provided as  
 
Figure 4.4: Homology model of ZIKV NS5 protein. The protein comprises of three domains, the 
N-terminal, methyltrasferase domain (residues 1-262) (green), the inter-domain region (residues 




5.2 Active site identification 
Active site residues need to be identified for the docking of potential inhibitors to the active site 
pocket. The active site residues were determined using Chimera Multi-align Viewer and validated 
using the Site-Hound web program (71). Figure 4.5 highlights the best active sites and active site 
residue numbers of the NS5 protein (Figure 4.5). 
 
Figure 4.5: The potential binding sites, identified by Site-hound (71), of ZIKV NS5 protein. (A) 
Site 1 (Methyltrasferase active binding site) (red) and Site 2 (RdRp active binding site) 
(magenta), (B) active binding site residues of the NS5 protein at Site 1 and Site 2. 
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This homology model will be implemented in the design of small molecules that may act as 
inhibitors of the NS5 protein, thus inhibiting the translation of viral RNA. Experimental drug 
therapy on other flaviviruses (41,72,73) may be used as a guide toward the identification of new 
specified small molecules that inhibit ZIKV replication.  
 
5.3 Possible small molecule inhibitors of NS5 RdRp 
Of the ZIKV target proteins, NS5 RdRp is one of the most favorable for drug discovery due to its 
role in viral replication (1). A study by Eyer et al (2016) looked at an in vitro study of nucleoside 
inhibitors against ZIKV and found one particular molecule, 2-C-Methyladenosine, to show 
promising inhibition of RdRp (74). The purine and hydroxymethyl structural features of 2-C-
Methyladenosine were screened through ZINC database, criteria was imposed to ensure the 
inclusion of the maximum number of compounds, such that compounds had to have an xlog P 
between -4 and 5, a net charge 0, rotatable bonds between 0 and 8, a polar surface area of 
between 0 and 150, have hydrogen bond donors/acceptors between 0 and 10, and polar 
desolvation between 0 and 1 kcal/mol whereas compounds must have an apolar desolvation 
between -100 and 40 kcal/mol. Thereafter, the 4113 hits were downloaded and docked together 
with 2-C-Methyladenosine (Figure 4.6) at the RdRp active site and the nine best docked poses 
comprising the highest binding affinities were reported in Table 2. Table 3 shows the physical 






Table 4.2: Representation of top ten compounds docking to NS5 RdRp  
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Table 4.3: Physical Representation of top ten compounds displaying Molecular weight, xlogP, H-








Further information, including extensive procedures, can be found in our previous publications on 
structure-based enzymatic drug design (58,75). We believe that the robust computational tools 
implemented in the route map will provide a fundamental platform in the development of 
inhibitors against multiple ZIKV target molecules. 
 
6. Proposed computational software that can be used in ZIKV drug 
design and discovery 
 
The software available for techniques used in drug design have simplified the development of 
inhibitors allowing for specific binding to a target molecule, thus, decreasing its biological 
adverse effects (76).  There are various types of software available in structure-based drug design, 












Table 4.4: Proposed computational software used in ZIKV drug design 
 
COMPUTATIONAL 
METHOD SOFTWARE AVAILABLE 
SOFTWARE TO BE 





Insight, Prime, Profit, LOOK, ICM, 
Sybyl, CLUSTALW 
Model construction- 
DS Modeller, Prime, LOOK, ICM, 
Sybyl, MODELLER, MOE, SWISS-







Active Binding Site 
Determination 
CASTp, POOL, PASS, Pocket-
Finder, 3DLigandSite, LIGSITE, 




Molecular Graphic systems 
 
Avogadro, Chemlab, Athena, 
Maestro, Jmol, PyMOL, UCSF 
chimera, VMD, Vimol, Webmol, 
Zeus 
UCSF chimera (12) 
 
Virtual Screening databases 
 
PubChem, MMsINC, ZINC, 
ZincPharmer, 4SC discovery, 
Therapeutic target database, Drug 







PyRx, Autodock Vina, Dock Blaster, 
Vis3d, Schrodinger, GOLD, 
Libdock, FlexX, Glide, Fred, ICM 




The Future of the ZIKV pandemic is uncertain and thus new, accelerated techniques are 
necessary to assist the medical and scientific community in the identification and validation of 
inhibitors to this global threat.  The chemoinformatics discussed in this paper will not only in the 
identification and design of potential ZIKV inhibitors but also in parallel, but may assist in the 
early analysis of potential biological mutations that may occur due to the rapid international 
transmission of this flavivirus.  
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Molecular dynamic simulation 
software 
 
Gromacs, Amber, CHARM, 
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Abstract 
The re-emerging Zika virus is an arthropod-borne virus that has been described to have explosive 
potential as a worldwide pandemic. The initial transmission of the virus was through a mosquito 
vector, however, evolving modes of transmission has allowed the spread of the disease over 
continents. The virus has already been linked to irreversible chronic central nervous system 
conditions. The concerns of the scientific and clinical community are the consequences of Zika 
viral mutations, thus suggesting the urgent need for viral inhibitors. There have been large strides 
in vaccine development against the virus but there are still no FDA approved drugs available. 
Rapid rational drug design and discovery research is fundamental in the production of potent 
inhibitors against the virus that will not just mask the virus, but destroy it completely. In silico 
drug design allows for this prompt screening of potential leads, thus decreasing the consumption 
of precious time and resources. This study demonstrates an optimized and proven screening 
technique in the discovery of two potential small molecule inhibitors of Zika virus 
Methyltransferase and RNA dependent RNA polymerase. This in silico “per-residue energy 
decomposition pharmacophore” virtual screening approach will be critical in aiding scientists in 
the discovery of not only effective inhibitors of Zika viral targets, but also a wide range of anti-
viral agents.  
 
Keywords:  
Zika virus per-residue decomposition based pharmacophore, virtual screening, NS5 protein 






Zika virus (ZIKV) is an arthropod-borne virus that has been described to have potential as a 
worldwide pandemic (Troncoso, 2016). The virus is a member of the spodweni sercocomplex of 
the flavivirus genus and was first discovered in 1947 by its isolation from the Rhesus 766 monkey 
in Uganda (Faye et al., 2014; Haddow et al., 2012). Sporadic cases of the virus have been 
reported in countries such as Uganda, Tanzania, Egypt, Gabon, and in parts of Asia including 
India and Indonesia, with the most devastating epidemic occurring in Brazil in 2015 (Campos, 
Bandeira, & Sardi, 2015; Mahfuz et al., 2015). As of June 2016, eleven countries had reported 
Central Nervous System (CNS) malformations potentially linked to ZIKV. During 2015 and early 
2016, eight countries had reported cases of Gullian-Barrè syndrome (GBS), where laboratory 
testing confirmed ZIKV infection was found in a number of GBS cases (WHO, 2016). 
 
Transmission of the virus was thought to be only via the Aedes mosquito vector but studies 
during 2016, have evidenced congenital, perinatal and sexual transmission (Singh et al., 2016; 
Turmel, Hubert, Maquart, Guillou-Guillemette, & Leparc-Goff, 2016). The virus triggers febrile 
like influenza-conditions in the host, including swollen lymph nodes, skin rashes and joint pains 
(Brito, 2016; Ekins et al., 2016; Shapshak, Sinnott, Somboonwit, & Kuhn, 2015). The concerns 
of the scientific community involve the dramatic increase in ZIKV-related central nervous system 
(CNS) disorders including neonatal-microcephaly and Gullian-Barrè Syndrome (Lissauer, Smit, 
& Kilby, 2016; Panchaud, Stojanov, Ammerdorffer, & Vouga, 2016; Roa, 2016). Complications 
associated with prenatal infection encompass fetal growth restriction, neurological and ocular 
abnormalities, intracranial calcification and in some cases perinatal death or stillbirth (Chibueze, 
Tirado, & Olukunmi, 2016; Singh et al., 2016). 
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The virus is able to enter a host via receptor-mediated endocytosis, followed by fusion from 
within the endosomal cell compartment (Mahfuz et al., 2014). The enveloped virus comprises of 
an 11 kilo base, single-stranded positive sense RNA genome which consists of 10,794 nucleotides 
encoding 3,419 amino acids (Hayes, 2009). The open reading frame (ORF) of the 5’ and 3’ 
untranslated region encodes a polyprotein cleaved into three structural proteins being the capsid, 
premembrane/membrane, and envelope. Seven non-structural proteins may also be found in this 
assembly, namely, NS1, NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5 (largest viral protein) 
(Haddow et al., 2012).  
 
Being the largest and most imperative protein in the genome replication and RNA capping of 
ZIKV, NS5 presents as a novel antiviral target (Tambunan, Zahroh, Utomo, & Parikesit, 2014). 
The protein consists of three domains: a Methyltransferase (MTase) domain at residues 1-262 of 
its N-terminal, an RNA dependent RNA polymerase (RdRp) at residues 273-903 of its C-terminal 
and an inter-domain region at residues 263-272 (Zou et al., 2014).  
 
The MTase domain belongs to the family of S-Adenosyl Methionine (SAM)- dependent enzymes, 
containing a SAM-dependent MTase fold comprising of an α/β/α structure (Zou et al., 2014). The 
MTase domain is one of the key targets in drug design as the enzyme performs nucleoside-2’O 
and N-7 methylation of the viral RNA cap which is essential in the replication of the virus 
(Egloff, Benarroch, Selisko, Romette, & Canard, 2002). Upon the completion of methylation, 
SAM is converted to S-Adenosyl Homocysteine (SAH) and gets released from the MTase domain 
(Brecher et al., 2015). Inhibition of MTase will be detrimental to the progression of ZIKV.  
 
The conserved RdRp domain allows for the initiation of RNA synthesis, generating both plus and 
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minus strand RNAs. As with most polymerases, the structure of the enzyme resembles a shape 
analogous to a right hand with a finger, thumb and palm region (Papageorgiou et al., 2014; 
Shanmugam, Velmurugan, & Gromiha, 2015). The human body does not contain an RdRp 
enzyme or analogues of it, thus inhibitors may not cause severe toxic effects, making it an 
optimal target in drug design (Shanmugam et al., 2015). 
To date, no anti-ZIKV drugs are clinically available, thus, new research methods are being 
developed with the purpose of identifying target molecules. Recent research has found that ZIKV 
targets neuronal cells (Millichap, 2016; Miner & Diamond, 2016; Mlakar et al., 2016; Tang et al., 
2016). Consequently, any new drugs that may be discovered will have to pass through the blood-
brain-barrier. Molecular modeling and computational methods are important tools in the 
development of novel inhibitors of ZIKV (Ekins et al., 2016; Ramharack & Soliman, 2016). A 
number of inhibitors of the flavivirus NS5 protein have been discovered via virtual screening and 
computational analysis (Brecher et al., 2015; Idrus, Tambunan, & Zubaidi, 2012; Lim & Shi, 
2013). Structure-based virtual screening (SBVS) identifies energetically advantageous binding 
affinities of ligands into a target’s active binding site. This allows for new insights on the nature 
of the active site and the protein-ligand interactions (Kumalo & Soliman, 2015). The method 
identifies selective molecules from an extensive library of compounds to dock within a target’s 
active site. Although scoring techniques are used when molecules are docked to the target, 
literature shows that a large number of final hits are generated, as the compounds docked may be 
in various geometric poses (Kroemer, 2007). Ligand-based virtual screening generates libraries of 
compounds based on a known compound or compounds and its illustrative interactions with a 
particular target (Cele, Muthusamy, & Soliman, 2016).  
 
In an attempt to develop pharmacophore based modeling, we previously presented a Per Residue 
Energy Decomposition (PRED) protocol where candidates for SBVS were chosen on the position 
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of 3D moieties with an experimentally known compound, thus creating a pharmacophore model 
based on highly contributing amino acid residues to the bound inhibitor. This approach is based 
on interactions that occur at a molecular level, including charge, hydrophobic interactions and 
hydrogen bonding (Cele et al., 2016). The highly contributing residues are identified based on 
free energy footprints from molecular dynamic and thermodynamic calculations (Cele et al., 
2016; Kumalo & Soliman, 2015; Soliman, 2013). This proves to be an incredibly concise method, 
rather than “shooting in the dark” with millions of available small molecules.  
In our previous work, we created a possible homology model of the NS5 protein containing both 
MTase and RdRp domains (Ramharack & Soliman, 2016). Due to the indeterminateness 
surrounding the ZIKV NS5 protein and potential inhibitors, we will compare our top hits against 
known inhibitors of the flavivirus NS5 protein.  
 
This study will implement the above-mentioned PRED pharmacophore technique in the discovery 
of potential ZIKV NS5 protein inhibitors, thus aiding medicinal chemists in the synthesis of 









2. Computational Methods 
A route map to PRED-based pharmacophore virtual screening approach is depicted in Figure 5.1. 
 
Figure 5.1: A per residue energy decomposition-based approach outline applied in the study.  
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2.1 Homology Modeling and Identification of active binding sites of NS5 
 
In our previous article and during the current study, due to the absence of a crystal structure of 
ZIKV NS5 protein, a homology model was created using the protein sequence obtained from 
NCBI (Accession number: YP_009227205) (Ramharack & Soliman, 2016). The templates for 
sequence alignment were identified from NCBI using BLASTp (accessed on 05 March 2016)  
(Madden, Tatusov, & Zhang, 1996) to find suitable templates, from RCSB protein databank 
(Berman et al., 2002), for homology modeling. Based on the criteria of identity score, e-value and 
query cover accuracy (Table 1), the NS5 protein was modeled by using four crystal structures of 
flavivirus enzymes as templates: Chain A of full-length Japanese Encephalitis Virus NS5 (PDB 
Code: 4K6M_A); Chain A of full-length NS5 from Dengue virus Type 3 (PDB Code: 5CCV_A); 
Chain A of RNA Dependent RNA polymerase domain from Nile West Virus (PDB Code: 
2HFZ_A); and Chain A of Dengue Serotype 3 RNA-dependent RNA polymerase bound to Nitd-
107 (PDB Code: 3VWS_A).  






Query Cover (%) Structural Identity (%) E-Value 
4K6M_A 97 69 0 
5CCV_A 98 67 0 
2HFZ_A 67 72 0 
3VWS_A 68 69 0 
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Homology modeling was performed using the Modeller Software version 9.1 (Eswar et al., 2006) 
add-on in chimera (Yang et al., 2012), in which all three templates were selected to build the 
model. Multiple sequence alignment was performed using the CLUSTALW server (Sievers et al., 
2011), where Chain A of the full-length Japanese Encephalitis Virus NS5 was evidenced to have 
the best template with the highest identity score (Figure S1). The sequence of the target protein 
was uploaded to PSIPRED V3.3 (Buchan, Minneci, Nugent, Bryson, & Jones, 2013) in order to 
obtain a predicted 2D secondary structure of the enzyme. Comparing the homolog to the 
predicted 2D structure and assessment of the bond angles and torsional strain validated the 
homology model. A Ramachandran plot for the analyses of bond angles and torsional strain was 
generated using Maestro (Schrodinger). MolProbity (Chen et al., 2010) results showed 97.2% of 
all residues were in the favored regions and 99.2% of all residues were in the allowed regions, 
which left a list of 7 outliers. The active-site residues were determined using Chimera Multi-align 
Viewer and validated using the SiteHound-web program (Hernandez, Ghersi, & Sanchez, 2009). 
The list shows that none of the active-site residues are part of these outliers. All results can be 
found in our previous article and supplementary material (Figure S5) (Ramharack & Soliman, 
2016). After completion of the study, the crystal structure of the ZIKV NS5 protein was released. 
To validate the homology model of the NS5, it was superimposed with the newly released crystal 
structure (PDB code: 5TFR), showing their structural similarity and validating the model’s use 
for subsequent analysis (Figure 5.2). 
2.2 System Preparation 
 
The NS5 modeled structure was separated into two domains, being the Methyltransferase of the 
C-terminal and the RNA-Dependent RNA polymerase of the N-terminal. Experimental drug 
inhibitors of flaviviruses were chosen to dock within each domain’s active site.  
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2.3 Molecular Docking of Experimental Flaviviruses 
 
Docking of the compounds were conducted using the AutoDock Vina (Trott & Olson, 2010) 
software. The procedure was run using the software default settings. The grid box used to define 
the screening site was elucidated using the AutoDock Vina functionality built into Chimera (Eric 
F. Pettersen et al., 2004). The gridbox size and center parameters for the MTase were x(54,-
63.23), y(80,56.72) and z(54,10.22), respectively and the RdRp gridbox dimensions were x(40, -
9.69), y(38, 20.41), z(40,16.50). AutoDock Vina generated results in the pdbqt format and the 
optimal geometric conformation having the best binding energy was selected from the ViewDock 
feature and saved in complex with the reference enzyme.  The enzyme and ligand for each system 
was prepared using Chimera (Yang et al., 2012) and MMV molecular modeling suites 
(Kusumaningrum et al., 2014) and subsequently subjected to molecular dynamic simulations. 
 
2.4 Molecular Dynamic (MD) Simulations 
 
The MD simulation was performed using the GPU version of the PMEMD engine provided with 
the Amber 14 package. The FF14SB force field of the Amber package (Nair & Miners, 2014) was 
used to describe the complex. 
ANTECHAMBER (Wang, Wang, Kollman, & Case, 2006) was used to generate atomic partial 
charges for the ligands by utilizing the Restrained Electrostatic Potential (RESP) and the General 
Amber Force Field (GAFF) procedures. The Leap module of Amber 14 allowed for addition of 
hydrogen atoms to the systems as well as Na+ and Cl
- counter ions for neutralization.  
The system was suspended implicitly within an orthorhombic box of TIP3P water molecules such 
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that all atoms were within 8 Å of any box edge. 
An initial minimization of 2000 steps was carried out with an applied restraint potential of 500 
kcal/mol Å2 for both complexes. An additional full minimization of 1000 steps was further carried 
out by conjugate gradients algorithm without restrain. 
A gradual heating MD simulation from 0 K to 300 K was executed for 50 ps, such that the system 
maintained a fixed number of atoms and fixed volume, i.e., a canonical ensemble (NVT). The 
solutes within the system are imposed with a potential harmonic restraint of 10 kcal/mol Å 2 and 
collision frequency of 1.0 ps-1. Following heating, an equilibration estimating 500 ps of the each 
system was conducted, the operating temperature was kept constant at 300 K. Additional features 
such as a number of atoms and pressure where also kept constant mimicking an isobaric-
isothermal ensemble (NPT). The systems pressure was maintained at 1 bar using the Berendsen 
barostat.  
The total time for the MD simulation conducted was 5 ns. In each simulation the SHAKE 
algorithm was employed to constrict the bonds of hydrogen atoms. The time step of each 
simulation was 2 fs and an SPFP precision model was used. The simulations coincided with 
isobaric-isothermal ensemble (NPT), with randomized seeding, constant pressure of 1 bar 
maintained by the Berendsen barostat, a pressure-coupling constant of 2 ps, a temperature of 300 
K and Langevin thermostat with collision frequency of 1.0 ps-1.  
Coordinates were saved every 1 ps and the trajectories were analyzed every 1 ps using the PTRAJ 
module employed in Amber14. 
2.5 Binding Free energy Calculations 
 
To estimate the binding affinities of each system, the binding free energies were calculated using 
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the Molecular Mechanics/GB Surface Area method (MM/GBSA) (Genheden & Ryde, 2015). 
Binding free energies were averaged over 5000 snapshots extracted from the 5 ns trajectory. The 
free binding energy (ΔG) computed by this method for each molecular species (complex, ligand 
and receptor) can be represented as: 
1 !∆G!"#$ = G!"#$%&' − G!"#"$%&! − G!"#$%&!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
2 !∆G!"#$ = E!"# + G!"# − TS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
3 !E!"# = E!"# + E!"# + E!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
4 !G!"# = G!" + G!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
5 !G!" = γSASA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
 
The term Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele, and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy 
contribution from the polar states, GGB and non-polar states, G. The non-polar solvation energy, 
SA. 
GSA, was determined from the solvent accessible surface area (SASA), using a water probe 
radius of 1.4 Å, whereas the polar solvation, GGB, contribution was estimated by solving the GB 
equation. S and T denote the total entropy of the solute and temperature respectively. 
To obtain the contribution of each residue to the total binding free energy profile between the 
inhibitors Ribavirin and BG323 with RdRp and MTase respectively, per-residue free energy 
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decomposition was carried out at the atomic level for imperative residues using the MM/GBSA 
method in Amber 14. 
 
2.6 Pharmacophore Model Creation and Library Generation 
 
The inhibitors Ribavirin and BG323 were first simulated at the active site of RdRp and MTase 
respectively, for 5 ns, to create the bound conformation of the ligands. Both these compounds 
have experimentally exhibited ZIKV inhibition in in vitro and in vivo models (Mumtaz, van 
Kampen, Reusken, Boucher, & Koopmans, 2016; Sweeney et al., 2015; Zmurko et al., 2016). 
Per-residue energy decomposition analysis was used to determine the amino acids that contribute 
the most towards ligand binding. The pharmacophoric moieties that interacted with the highly 
contributing residues were then chosen to construct our model. The model was then added to 
ZincPharmer (Koes & Carlos, 2012), with specific selection criteria (molecular weight of <500 
Da, rotatable bonds <6, hydrogen bond donors<5 and hydrogen bond acceptors<10), to screen the 
ZINC database (Irwin & Shoichet, 2005). Lipinski’s rule of five and toxicity (ADMET) 
properties were used as filters to remove nondrug-like hits (Lipinski, Lombardo, Dominy, & 
Feeney, 2012).  
2.7 Structure-based Virtual Screening 
 
The drug-like hits identified using our protocol were subjected to structure-based virtual 
screening. Docking was carried out to differentiate between ligands based on the molecules’ 
geometric characteristics that allow it to bind to the enzyme’s active site (Forli et al., 2016). The 
Docking calculations were performed using Autodock Vina (Trott & Olson, 2010). During 
docking, Gasteiger partial chargers were assigned and the Autodock atom types were defined 
using the Autodock Graphical user interface supplied by MGL tools (Sanner, Olson, & Spehner, 
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1996). The docked conformations were generated using the Lamarckian Genetic Algorithm 
(Morris & Huey, 2009). The Raccoon software was used to convert the files into a compatible 
pdbqt format required for docking. The gridbox was defined using Autodock Vina. The 
calculation reports for each ligand conformation in its respective complex were analyzed to 
obtain affinity energy (kcal/mol). During the docking process, a maximum of 50 conformers was 
considered for each compound. After screening, molecular docking and filtering, the ligand with 
the highest affinity towards the agonist was selected from the library. 
 
2.8 Validation of Docking Approach 
 
Previous experiences have verified that docking may result in the best geometric conformation of 
the docked complex, however, short molecular dynamic simulations may not be able to maintain 
the stability of the complex and thus lead to the molecules being disorientated. Thus, to validate 
the approach applied in this study, the most favorable Mtase and RdRp complex was subjected to 
further molecular dynamics studies (20 ns). The procedure for Molecular dynamics simulation 
was the same as in ‘‘Molecular Dynamics (MD) Simulations’’ Section and thermodynamic 
calculations as ‘‘Binding Free Energy Calculations ’’Section.  
2.9 Assessment of drug likeness 
The online software SwissADME was used to compute the physicochemical descriptors as well 
as predict the pharmacokinetic properties and drug-like nature of the screened compounds 
compared to that of BG323 and Ribavirin. to (Bultet et al., 2016; Daina, Michielin, & Zoete, 
2014). SwissADME utilizes the “Brain Or Intestinal Estimated permeation, (BOILED-Egg)” 




3. Results and Discussion 
 
3.1 Homology Model and Active Binding Site Determination: 
Due to the absence of a crystal structure for the Zika NS5 enzyme, a homology model, having a 
zDope score of -0.76 was generated, and validated using a ramachandran plot. The active site 
residues were determined for both the MTase and RdRp region (Figure S1-3). The comprehensive 
set of results are presented in our previous publication (Ramharack & Soliman, 2016). To further 
validate both the MTase and RdRp, the homology model was superimposed to the newly released 
crystal structure of the Zika NS5 (Figure 5.2), using Chimera (E F Pettersen et al., 2004). 
 
Figure 5.2: Superimposition of homology model (yellow) with the newly released crystal 
structure (green- PDB code: 5TFR), showing their structural similarity and validating the model’s 
use for subsequent analysis. 
 
3.2 PRED Pharmacophore Model: 
In this study, a pharmacophore hypothesis was adopted by utilizing per residue decomposition 
energy-based approach. The structural features of a protein as well as the chemical characteristics 
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of a ligand are employed in the construction of a pharmacophore model. To generate the 
pharmacophore model, a 5ns molecular dynamic simulation was run on complexes (MTase-
BG323) and (RdRp-Ribavirin), followed by PRED computed from MM/GBSA calculations. The 
MM/GBSA approach has proven to be, in principle, accurate in both scoring function and binding 
free energy results (Genheden & Ryde, 2015; Hayes, 2009). This allows for improved 
pharmacophore modeling and thus the generation of a concise library of small molecules.  The 
MTase-BG323 complex showed His104 (-2.176 kcal/mol), Glu143 (-1.846 kcal/mol), Thr210 (-
1.192 kcal/mol), and Lys176 (-1.061 kcal/mol) to be the highest contributing residues to interact 
with the ligand. Strong hydrophobic interactions were formed between Glu143 and the benzene 
ring of BG323, while, energetically favorable residue, Asp140, formed hydrogen bonds with the 
terminal hydroxyl groups of the ligand (Figure 5.3). 
 
 
Figure 5.3: The steps taken toward creating the pharmacophore model from the MTase-BG323 
complex. The yellow circles spotlight the pharmacophoric moieties that were chosen for the 
model, based on the highest contributing residues, depicted in the binding affinity graph.  
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Hydrogen bonds between the RdRp-Ribavirin complex included residues Asn444 (-1.296 
kcal/mol) and His460 (-0.956 kcal/mol), while the contributing residues; namely, GLU573 (-
1.521 kcal/mol), TRP576 (-1.744 kcal/mol) and Cys577 (-2.202 kcal/mol) were involved in 
hydrophobic interactions with the ligand. The features from each complex were used as a query 
on ZINCpharmer (Koes & Carlos, 2012) to create the PRED-based pharmacophore (Figure 5.4). 
Results revealed 18 hits obtained from the MTase-BG323 pharmacophore and 23 hits from the 
RdRp-Ribavirin pharmacophore.  
 
Figure 5.4: RdRp-Ribavirin complex ligplot analysis- creating the pharmacophore model to 
virtually screen for new RdRp potential lead compounds. The yellow circles spotlight the 
pharmacophoric moieties that were chosen for the model based on the highest contributing 
residues, depicted in the binding affinity graph.  
 
 106 
3.3 Molecular Docking 
To further refine and reduce false positives retrieved from the hit compounds, the hits for each 
complex were subjected to molecular docking within the actives sites of MTase (18 hits) and 
RdRp (23 hits). This assessed their geometric feasibility at each domain, leading to only three top 
ranked compounds (Table 2).  Based on the interactions and binding affinities of the respective 
three top ranked compounds to MTase and RdRp, ZINC64717952 and ZINC39563464 were 
chosen as respective top hits. Each complex was subsequently subjected to molecular dynamic 
studies to elucidate on the enzyme-ligand interactions of the two potential inhibitors under virtual 
conditions. 
Table 5.2: Representation of the top three compounds bound to MTase and RdRp. The 





3.4 Molecular Dynamic Simulations and Binding Free Energy Analysis 
The MTase-ZINC64717952 and RdRp-ZINC39563464 complexes were subjected to a 20 ns MD 
simulation in order to check the convergence dynamic stability and to analyze the energetics of 
each complex.  The RMSD profiles of the MTase-complex and RdRp-complex indicate that both 
systems were stable during the simulation (Figure 5.6C and 5.7C).  
MTase-ZINC64717952 Complex: 
The docked MTase-ZINC64717952 complex showed ionic interactions involving seven residues 
common to MTase-BG323 (Glu143, Arg207, Lys176, Thr210, Ile141, Asp140 and Gly142). 
Interestingly, however, a hydrogen bond was noted between the nitrogen of Arg35 and the 
aromatic ring of ZINC64717952, this was peculiar, as Arg35 was not involved in any ionic 
interactions of the MTase-BG323 complex. The MTase-ZINC64717952 complex used Asp140 as 
a hydrogen bond acceptor, whereas, the MTase-BG323 complex depicted hydrophobic 
interactions between Asp140 and the benzene ring of BG323. These ionic bond deviations 
between systems may be due to the size of ZINC64717952 in comparison to BG323. 
ZINC64717952 was significantly reduced in size, containing predominantly the heterocyclic 
rings from the pharmacophore model. Due to the size of ZINC64717952, the nitrogen of aromatic 
ring was allowed to form a hydrogen bond with the amine group (Arg35) further into the 
hydrophobic pocket of MTase. Docking results showed the same binding affinity in both 
complexes, however, receptor residue stability showed increased fluctuations in the 
ZINC64717952-MTase complex compared to the experimental complex (Figure 5.5). The overall 
compactness of the receptor was measured by the radius of gyration (around the Cα atoms) and 
was indicative of greater fluctuations of the MTase-ZINC64717952 complex compared to the 
experimental complex (Figure S6), verifying the RMSF fluctuations seen in Figure 5.5. Although 
ZINC64717952 docked in a structurally favorable manner, MM/GBSA analysis showed free 
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binding energy of the MTase-BG323 complex (-28.70 kcal/mol) to be higher in magnitude than 
that of MTase-ZINC64717952 (-26.50 kcal/mol).  
 
Figure 5.5: The Cα root mean square fluctuations (RMSF) of MTase-BG323 and MTase-
ZINC64717952 during the molecular dynamic simulation. 
 
The tetrazole aromatic ring in ZINC64717952 contains highly active nitrogen atoms, increasing 
electronegativity and steric hindrance (Ostrovskii, Trifonov, & Popova, 2012). The Generalized 
Borne (GB) method is used to calculate the molecular electrostatic forces in solvent. Table 3 
shows ZINC64717952 to have elevated columbic energy, thus leading to increased gas-phase 
energy, validating the free energy analysis (Figure 5.6A) (Genheden & Ryde, 2015). This, 
however, does not rule-out the possibility of ZINC64717952 as a potential inhibitor of the MTase 
enzyme as the intermolecular forces between the receptor and ligand were favorable. This study 
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will have to be evaluated in vitro, where the further analysis may reveal the inhibitory potential of 
the compound.  
 
 
5. 5.6: MTase-ZINC64717952 complex interactions (A) Per-residue decomposition analysis 
showing Arg51 and Glu105 to have the greatest bond fluctuations (B) Ligplot depiction of 
hydrophobic and hydrogen bond interactions in the complex which was validated by (C) The time 










The docked RdRp-ZINC39563464 complex showed ZINC39563464 to interact with nitrogen 
atoms of two residues; Asn444 and His460. Notably, the nitrogen atoms from the same residues 
form hydrogen bonds with the terminal oxygen of the Ribavirin, showing consistent residue 
interactions of the experimental ligand and ZINC39563464. These hydrogen interactions are 
formed from non-covalent bonding of the hydrogen donor (Asn444 and His460) with the 
acceptors (oxygen and nitrogen) of the ligand. This articulates the directionality and specificity of 
the active site’s β-strand recognition of both Ribavirin and ZINC39563464. The complex 
exhibiting a relatively stable RMSD profile during the simulation further validated this (Figure 
5.7C). The pharmacophoric hot spot residue, His442, formed hydrophobic bonds with the 
aromatic rings of both Ribavirin and ZINC39563464. It is noteworthy that four other 
hydrophobic-interacting residues; Cys577, Tryp576, Glu573 and Glu435 were common to both 
ligands, thus stabilizing both energetically favorable ligands in the available hydrophobic pocket. 
Table 4 depicts the analysis of binding free energy by the use of MM/GBSA of the RdRp-
ZINC39563464  
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complex was used to support the docking results.  
Table 5.4: The comparison of RdRp’s binding affinity with Ribavirin and ZINC39563464. 
 
The predicted binding free energy for the complex was -25.04 kcal/mol, which is considerably 
higher in magnitude than that achieved by the RdRp-Ribavirin complex (-16.53kcal/mol), thus 
confirming the docking results and indicating a stronger binding of ZINC39563464 to RdRp 
compared to the experimental ligand (Figure 5.7A and 5.7B). The relatively large size of the 
ligand could explain the increased number of residues encompassing apparent hydrophobic 
interactions with ZINC39563464, and could substantiate the exhibition of stable RdRp residues 
by RMSF profiling (Figure 5.8). As an additional check, the radius of gyration (RoG of the Cα 
atoms) was compared in both simulations to provide a measure of overall compactness of the 
protein (Figure S6).  The fluctuations of RoG stayed with 1 Å in both simulations indicative of a 
stable protein complex with both experimental and screened compound.  
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Figure 5.7: RdRp-ZINC39563464 complex interactions (A) Per-residue decomposition analysis 
showing Arg459 and Glu435 to have the greatest bond fluctuations, (B) Ligplot depiction of 
hydrophobic and hydrogen bond interactions in the complex which was validated by (C) The time 
evolution of RMSD of the C-alpha atom backbone of the MTase-ZINC39563464 complex. 
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Figure 5.8: The stable Cα root mean square fluctuations (RMSF) of RdRp-Ribavirin and RdRp-
ZINC39563464 during the molecular dynamic simulation. 
 
3.4 Assessment of drug likeness 
Ribavirin has a plethora of side effects including thrombocytopenia, myalgia, leucopoenia and 
cognitive impairment (Hinton et al., 2016; Kryger, Wohl, Smith, & Zelikin, 2013; Munir et al., 
2010). This proves to be a challenge when trying to inhibit a virus that already causing these 
symptoms. BG323 is a new compound that has been proven to have potent effects on flavivirus 
NS5 proteins, however, the compound is unable to pass the blood-brain barrier, making it 
difficult to act on ZIKV-targeted neuronal cells (Miner & Diamond, 2016; Tang et al., 2016). The 
possible pro-drugs of ribavirin and BG323, being, ZINC39563464 and ZINC64717952 
respectively, can be described as potential lead compounds after assessment through SwissADME 
(Table 5) (Bultet et al., 2016). 
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Table 5.5: The comparison of drug likeness of the screened compounds compared to that of the 
experimental drugs against ZIKV. 
 
 4. Conclusion 
ZIKV is a rapidly evolving virus that has had detrimental long-term effects over a very short 
period of time. This study proposes two new compounds that have shown promising 
physicochemical properties and strong interactions with ZIKV MTase and RdRp, thus validating 
the PRED model as an effective strategy to enhance typical virtual screening methods for the 
rapid identification of potential lead compounds as inhibitors against pathogenic biological 
targets such as ZIKV. This strategic in silico technique will serve as a beneficial tool to enhance 
drug discovery and decrease excessive wastage of financial and experimental resources by 
synthesizing large numbers of compounds that may not be beneficial in the inhibition of target 
enzymes. The lead compounds, ZINC64717952 and ZINC39563464, have shown substantial 
stability in complex with the target enzymes and thus further experimental analysis is necessary 
for efficacy and toxicity validation.  
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The Zika virus has emerged as a pathogen of major health concern. The rapid spread of the virus 
has led to an uproar in the medical domain as scientists frantically race to develop effective 
vaccines and small molecules to inhibit the virus. In the past year, there has been a flood of Zika 
knowledge published including its characteristics, transmission routes and its role in disease 
conditions such as Microcephaly and Gullian-Barŕe syndrome. Targeted therapy against specific 
viral maturation proteins is necessary in halting the replication of the virus in the human host, 
thus decreasing host-host transmission. This prompted us to investigate the structural properties 
of the Zika NS3 Helicase when bound to ATP-competitive inhibitor, NITD008. In this study, 
comparative molecular dynamic simulations were employed for Apo and bound protein to 
demonstrate the molecular mechanism of the Helicase. Results clearly revealed that NITD008-
binding caused significant residue fluctuations at the P-loop compared to the rigid nature of the 
Apo conformation. The NITD008-helicase complex also revealed residues 339-348 to transition 
from a 310-Helix to a stable α-helix. These protein fluctuations were verified by investigation of 
dynamic cross correlation and principal component analysis. The fundamental dynamic analyses 
presented in this report is crucial in understanding Zika NS3 Helicase function, thereby giving 
insights toward an inhibition mechanism. The information reported on the binding mode at the 








The re-emerging Zika virus (ZIKV) has evolved into a catastrophic epidemic over the past year, 
with scientific community announcing that the long-term effects associated with the virus will 
have to be dealt with in the decades to follow 1. The virus was declared an international public 
health emergency by the World Health Organization 2, based on growing evidence of the virus 
being linked with congenital neurological diseases such as Guillain-Barŕe, cranial nerve 
dysfunction and Microcephaly 3,4. The ZIKV made its devastating re-appearance in Brazil and has 
now spread on a global scale, with an estimated 75 countries with reported mosquito-borne ZIKV 
transmission as of December 2016 5. 
 
Zika virus is an arthropod-borne flavivirus initially discovered in the Zika forest area of Uganda 
in 1947 6. Of the flavivirus genera, ZIKV is most closely related to the Spodweni virus from the 
Spodweni group; however, ZIKV shares structural similarities with other flaviviruses, including 
Dengue virus and West Nile virus 7. The ZIKV genome is made up of structural proteins, being 
the capsid, precursor membrane and envelope form the viral particle and seven non-structural 
proteins, being NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, which participate in the 
replication of the RNA genome, virion assembly and invasion of the innate immune system 8–10. 
In our previous review, we explicated on the key viral target proteins, including the 
multifunctional viral replication NS3 helicase protein11. The ZIKV helicase comes from the 
superfamily helicases, SF2 12, with the inhibition of either one of the binding sites, the RNA-
binding groove or the ATP-binding site (Figure 6.1), leading to the virus becoming incapable of 
sufficient maturation and replication. The structural characteristics of the ZIKV NS3 protein 
includes three domains: domain I (residues 182-327), domain II (residues 328-480) and domain 
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III (residues 481-617), as well as a P-Loop (residues 196-203) which is located at the ATP-
binding site of domain I 12,13.  
The co-crystallization of MnATP-2 and RNA with ZIKV helicase, reported by Tian et al (2016) 
and Cao et al (2016), have paved the way to understanding the mechanism by which these 
substrates bind to the enzyme, initiating viral RNA replication 14,15. Despite the flood of 
integrated knowledge on ZIKV over the past year, the molecular and structural mechanism for 
helicase inhibition is yet to be established 12.  
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Figure 6.1: Cartoon and surface representation of the three domains of the ZIKV helicase and the 
two active-binding regions (yellow) that form profound hydrophobic cavities in the electrostatic 
surface area, allowing ATP and ssRNA to bind.  
 
Another battle being fought by researchers is the discovery of new modes of transmission of the 
virus, from initially being transmitted from vector to host, to now being inclusive of blood 
transfers from host to host as well as secondary sexual transmission 16–18. This has allowed for 
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rapid diffusion of the virus between continents. In the plethora of strategic characteristics of the 
virus, its ability to target neuronal cells has been one of the most problematic tasks that 
pharmaceutical chemists have had to overcome 19–24. The design of ZIKV inhibitors will not only 
need to be target-specific, effective and have minimal toxicity, but it will also have to pass 
through the blood-brain-barrier 25. 
  
Although there are currently vaccine clinical trials under way, there are still no FDA approved 
small molecule inhibitors against the virus 26–30. This may be due to a number of reasons 
including time-consuming experimental testing of large libraries of compounds or minimal 
literature available on the functionality of the virus in host cells. These possible barriers have 
prompted us to utilize computational drug design tools, such as molecular dynamic (MD) 
simulations to explore the conformational landscape of this biological system’s ATP-binding 
region. The crystallographic structures have revealed evidence of residue mobility, including the 
rotation of motor domains, however, the precise structural characteristics of the helicase upon 
small molecule binding, is yet to be determined 12,31–36.  
 
In this study we investigate the conformational changes at the ATP-binding region after a 130   
MD simulation of the free enzyme state as well as a NITD008-bound complex 37. This study will 
be critical in understanding how the ZIKV NS3 helicase functions structurally, thus aiding in the 






1.2 System Preparation  
The ZIKV NS3 helicase in complex with ATP and a magnesium ion (PDB code: 5GJC)14 was 
obtained from RSCB Protein Data Bank 38. The 3-D structure of the experimental ZIKV inhibitor, 
NITD008, was obtained from PubChem39 and prepared on Molegro Molecular Viewer (MMV) 40. 
In the ZIKV crystal structure of the ATP-bound helicase, residues A247-S253 were absent, thus 
the free enzyme (PDB code: 5JMT)13 was utilized in the docking of NITD008. Deng et al (2016) 
reported conclusive in vivo evidence of the inhibition of ZIKV by NITD008. The compound is 
classified as an adenosine nucleoside analog that competitively inhibits ATP, thus sharing an 
active site 37.  
 
1.3 Molecular Docking 
Molecular docking is a conventional method in computational chemistry which is utilized in the 
prediction optimized geometric conformations of a ligand within an appropriate binding site 41. 
The Molecular docking software utilized included Raccoon 42, Autodock Graphical user interface 
supplied by MGL tools 43 and AutoDockVina 44 with default docking parameters. Prior to 
docking, Gasteiger charges were added to NITD008 and the non-polar hydrogen atoms were 
merged to carbon atoms. Water molecules were removed and polar hydrogen was added to the 
crystal structure of the NS3 helicase. NITD008 was then docked into the ATPase binding pocket 
of the NS3 helicase (by defining the grid box with spacing of 1 Å and size of 32 × 26 × 30 
pointing in x, y and z directions). Due to the lack of experimental data describing ZIKV approved 
inhibitors, validation of molecular docking based on the lowest energy pose becomes unreliable 
45. To overcome any experimental bias, the five best conformational poses, based on binding 
affinities (kcal/mol), were subjected to MD simulations. 
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1.4 Molecular Dynamic (MD) Simulations 
Molecular dynamic (MD) simulations provide a robust tool to explore the physical movements of 
atoms and molecules, thus providing insights on the dynamical evolution of biological systems. 
The MD simulation was performed using the GPU version of the PMEMD engine provided with 
the AMBER package, FF14SB variant of the AMBER force field 46 was used to describe the 
protein.  
ANTECHAMBER was used to generate atomic partial charges for the ligand by utilizing the 
Restrained Electrostatic Potential (RESP) and the General amber Force Field (GAFF) procedures. 
The Leap module of AMBER 14 allowed for addition of hydrogen atoms, as well as Na+ and Cl
- 
counter ions for neutralization to both the Apo- and Bound system.  
Both systems were then suspended implicitly within an orthorhombic box of TIP3P water 
molecules such that all atoms were within 10Å of any box edge. 
An initial minimization of 2000 steps was carried out with an applied restraint potential of 500 
kcal/mol Å2 for both solutes, were performed for 1000 steps using a steepest descent method 
followed by a 1000 steps of conjugate gradients. An additional full minimization of 1000 steps 
was further carried out by conjugate gradient algorithm without restrain. 
A gradual heating MD simulation from 0K to 300K was executed for 50 ps, such that the system 
maintained a fixed number of atoms and fixed volume, i.e., a canonical ensemble (NVT). The 
solutes within the system are imposed with a potential harmonic restraint of 10kcal/mol Å 2 and 
collision frequency of 1.0 ps-1. Following heating, an equilibration estimating 500ps of the each 
system was conducted; the operating temperature was kept constant at 300 K. Additional features 
such as a number of atoms and pressure where also kept constant mimicking an isobaric-
isothermal ensemble (NPT). The systems pressure was maintained at 1 bar using the Berendsen 
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barostat.  
The total time for the MD simulation conducted was 130 ns. In each simulation the SHAKE 
algorithm was employed to constrict the bonds of hydrogen atoms. The step size of each 
simulation was 2 fs and an SPFP precision model was used. The simulations coincided with 
isobaric-isothermal ensemble (NPT), with randomized seeding, constant pressure of 1 bar 
maintained by the Berendsen barostat, a pressure-coupling constant of 2 ps, a temperature of 
300K and Langevin thermostat with collision frequency of 1.0 ps-1.  
1.5 Post-Dynamic Analysis 
The coordinates of the free enzyme and NITD008 complex were each saved every 1 ps and the 
trajectories were analyzed every 1 ps using PTRAJ, followed by analysis of RMSD, RMSF and 
Radius of Gyration using the CPPTRAJ module employed in AMBER 14 suit. 
1.5.1 Binding Free Energy Calculations 
Binding free energy calculations is an important end point method that may elucidate on the 
mechanism of binding between a ligand and enzyme, including both enthalpic and enthropic 
contributions 47. To estimate the binding affinity of the docked systems, the free binding energy 
was calculated using the Molecular Mechanics/GB Surface Area method (MM/GBSA) 48. 
Binding free energy was averaged over 15000 snapshots extracted from the 130 ns trajectory. The 
free binding energy (ΔG) computed by this method for each molecular species (complex, ligand 
and receptor) can be represented as: 
∆G!"#$ = G!"#$%&' − G!"#"$%&! − G!"#$%&!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 1  
∆G!"#$ = E!"# + G!"# − TS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 2  
E!"# = E!"# + E!"# + E!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 3  
G!"# = G!" + G!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 4  
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G!" = γSASA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 5  
 
The term Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy 
contribution from the polar states, GGB and non-polar states, G. The non-polar solvation energy, 
SA. GSA, was determined from the solvent accessible surface area (SASA), using a water probe 
radius of 1.4 Å, whereas the polar solvation, GGB, contribution was estimated by solving the GB 
equation. S and T denote the total entropy of the solute and temperature respectively.  
To obtain the contribution of each residue to the total binding free energy profile at the ATPase 
site, per-residue free energy decomposition was carried out at the atomic level for imperative 
residues using the MM/GBSA method in AMBER 14 suit.  
The system displaying the most favorable binding interaction and energy contributions were 
subjected to further analysis.  
1.5.2 Dynamic Cross-correlation Analysis (DCC) 
Dynamic cross correlation is a widespread method in MD simulations in which the correlation 
coefficients of motions between atoms of a protein may be quantified 49. The dynamic cross 
correlation between the residue-based fluctuations during simulation was calculated using the 
CPPTRAJ module incorporated in AMBER 14. The formula used to describe dynamic cross 
correlation is given below: 
!" = ! < Δri.Δrj >





The cross-correlation coefficient (Cij) varies within a range of −1 to +1 of which the upper and 
lower limits correspond to a fully correlated and anti-correlated motion during the simulation 
process. Where, i and j stands for ith and jth residue respectively and Δri or Δrj represents 
displacement vectors correspond to ith and jth residue respectively. The generated dynamic cross 
correlation matrix was constructed in Origin software.  
 
1.5.3 Principal Component Analysis (PCA) 
Principal component analysis (PCA) is a covariance-matrix-based mathematical technique that is 
able to demonstrate atomic displacement and the loop dynamics of a protein 50. Prior to 
processing the MD trajectories for PCA, the trajectories of the free enzyme (Apo) and the 
NITD008-bound complex (Complex) were stripped of solvent and ions using the PTRAJ module 
in AMBER 14. The stripped trajectories were then aligned against their corresponding fully 
minimized structures. PCA was performed for C-α atoms on 900 snapshots each. Using in-house 
scripts, the first two principal components were calculated and the covariance matrices were 
generated. The first two principal components (PC1 and PC2) generated from each trajectory 
were averaged for both the free-enzyme and NITD008-complex. The first two principal 
components (PC1 and PC2) were computed and a 2 X 2 covariance matrix were generated using 
Cartesian coordinates of Cα atoms. PC1 and PC2 correspond to first two eigenvectors of 






Results and Discussion 
3.1 NITD008-NS3 Helicase Complex 
3.1.1 Binding of NITD008 with ZIKV Helicase 
Research into ZIKV inhibitors has been minimal before 2016. However, NITD008, a flavivirus 
adenosine analogue was evidenced, both in vitro and in vivo, to inhibit ZIKV replication. The 
adenosine nucleoside analogue competes with natural ATP substrates, which are incorporated 
into the growing RNA chain. By this substitution, NITD008 is incorporated into the RNA chain, 
thus terminating the RNA elongation and inhibiting ZIKV maturation 37.  
Molecular docking has become a major computational tool that is used to predict the orientation 
of a ligand at a binding site on the receptor. Results from docking often display multiple predicted 
orientations of the ligand within the active pocket 52.   
 
In this study, NITD008 docked at the ATP-binding site in 6 favorable conformations (Figures S2-
S6), with the highest binding-affinity being -8.2 kcal/mol. Scoring functions often attempt to 
reproduce experimental binding affinities, but most software do not always yield the best 
prediction. Validation of the docked structure with experimentally known drugs was also not 
possible due to the lack of FDA inhibitors against ZIKV 45,53,54.  
 
In an attempt to improve the binding affinity prediction of NITD008, all 6 predicted complexes 
were subjected to 130 ns molecular dynamic simulations, allowing for more realistic receptor 
flexibility in an implicit solvent. Each complex was then analyzed using the accurate, 
MM/GBSA, free binding energy calculation to determine the most favorable pose of NITD008 at 
the NS3 ATPase active site 47,55–57.  
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3.1.2 Free Energy calculations 
The total binding free energy for each of the 6 poses of the NITD008- NS3 helicase complex 
were calculated using the MM/GBSA approach to better understand the various energy 
contributions within the binding pocket and assess which binding pose would show the most 
favorable intermolecular interactions at the helicase active site. Per residue decomposition 
analysis was also assessed and the residue-ligand interaction network of each pose were depicted 
as “ligplot” maps (Figures S2-S6). Of the six systems, the pose with the highest docking score, -
8.2 kcal/mol, showed the most favorable free binding energy (-55.90 kcal/mol) supported the 
molecular docking score, indicating a favorable structural pose of NITD008 at the binding site.  
 
The thermodynamic energy contribution of NITD008 to the total binding free energy of the 
complex surmounts to the stability of NITD008 in the ATP binding pocket and thus the stability 
of the complex during the simulation. Table 1 summarizes the free binding energy of the system 










 Table 6.1: Summary of free binding Energy contributions to the NITD008-NS3 Helicase system. 
 
 
Figure 6.2 represents the residue interaction plot of NITD008 within the active site. The active 
site residues Gly199, Lys200 and Glu286 formed stable hydrogen bonds with highly 
electronegative oxygen atoms of NITD008. The residues pocketing NITD008 within the active 
site included Gly197, Ala198, Gly199, Lys200, Thr201, Arg202, Glu288, Gly415, Asn417 and 
Arg456. 
 
It was also interesting to note that the most favorable NITD008-pose shared five active residues 
with the ATP-bound helicase reported by Tian et al (2016). The crystal structure of the ATP-
bound helicase showed Lys200 to stabilize the triphosphate of the ATP 14. The Lys200 of the 
NITD008-bound helicase showed a similar stabilizing hydrogen bond with the terminal hydroxyl 




Figure 6.2: Energy contributions of the highest interacting residues at the ATPase active site. The 
residue ligand interaction network illustrates stabilizing hydrophobic interactions pocketing 
NITD008 at the active site. The highest energy contribution was a hydrogen bond interaction 
shared between Glu286 and the 3rd oxygen of the ribose component of NITD008. 
 
Superimposition of NITD008-docked NS3 helicase with the ATP-NS3 helicase complex 
demonstrated both compounds to bind in a hydrophilic conformation despite the carbon and 
acetylene substitutions at N-7 of the purine and the 2’ position of the ribose, respectively (Figure 
6.3).  
 
The structural similarities between NITD008 and ATP, as well as the active site residue 




Figure 6.3: Superimposed conformation of structurally similar NITD008 and ATP docked at 
ATPase site of ZIKV NS3 Helicase. 
 
 
3.2 Systems Stability 
The length of a MD simulation is paramount when establishing insights into the structural 
dynamics of a biological system. With an extended simulation time, a system is able to reach 
convergence, thus becoming stable. To assure the equilibration of the simulation, the potential 
energy and temperature where monitored (Figure S1). The average potential energy (-145774 
kcal/mol) was measured at 300K, suggesting a stable conformation at this temperature.  
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3.2.1 Stability of NS3 Helicase Apo and Bound System  
The C-α backbone root mean square deviations (RMSD) were monitored throughout the 130 ns 
MD simulation for both the free (Apo) enzyme and the complex. Both systems reached 
convergence after 60 ns (RMSD deviation < 2 Å). It can be noted that the C-α backbone atoms in 
both systems stabilized after a 40 ns time period, although, fluctuations in rigidity did increase 
during the 47-52ns period in the NITD008 complex (Figure 6.4). This could possibly be due to 
the occurrence of conformational changes because of the bond interactions taking place between 
NITD008 and the active site residues as seen in the Per-residue energy decomposition.  
 
Figure 6.4: C-α backbone RMSD for NS3 Helicase Apo enzyme and NITD-complex 
conformation. The average C-α RMSD was calculated to be 3.62 Å and 3.77 Å, respectively. 
Increased fluctuations occurred at 47-52 ns in the NITD008-complex. 
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3.2.2 Conformational Fluctuations of the NS3 Helicase 
To better understand the structural changes that may be occurring upon ligand binding, the root 
mean square fluctuation (RMSF) of the C-α atoms of each residue in the Apo system and 
NITD008-complex were calculated. Figure 6.5 clearly demonstrates greater flexibility of residues 
of the NITD008-complex when compared to the Apo enzyme. Fluctuations take place between 
residues 198-204, which form distinct hydrophobic and hydrogen bond interactions with 
NIT008D at the active site. This region, the P-Loop, is found in all flavivirus helicases and has 
been shown to have flexibility during binding of ATP 14. The P-loop adopts structural 
modifications to accommodate the binding of ATP and Mn2+. This flexibility extends greatly in 
comparison to the Apo enzyme, thus verifying ZIKV P-loop flexibility upon ligand-binding. 
Other fluctuations occurred in domain II, and I around the ATP-active site, at residues 244-248 
and 325-348.  
 
Figure 6.5: The RMSF of Apo enzyme and NITD008-complex. The structural flexibility in 
domain I and II is highly attributed to the binding of NITD008 to the ATP-active site. This is 
substantiated by the average RMSF of the NITD008-complex (2.17 Å), which is significantly 
higher than that of the Apo enzyme (1.90 Å). 
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3.2.3 Distribution of Atoms around the NS3 Helicase Backbone 
The radius of gyration around the C-α atoms can measure the shape and folding of NS3 helicase 
before and after NITD008 binding. The radius of gyration measures the distribution of atoms 
from the center of mass (COM), thus indicating how compact a system is. Both the ApoA (22.05 
Å) and NITD008 (22.17 Å) showed very similar structural compactness, however, there was an 
atomic distribution in the NITD008-complex from 40-58ns (Figure 6.6). This correlates with the 
escalated instability of the complex at 47-52ns demonstrated in the RMSD plot.  
 
Figure 6.6: The radius of gyration (RoG) plot illustrating the difference in enzyme compactness 
of the NITD008-complex compared to the Apo enzyme. 
 
The flexibility calculated from the RMSD, RMSF and RoG encouraged us to explore the dynamic 
structural modifications of the NS3 Helicase after NITD008 binding.  
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3.3 Investigation of the Dynamic Structural features ATP-Active Binding Region  
3.3.1 Loop Flexibility and Distance metrics 
The ZIKV NS3 Helicase is made up of three known flexible loops that are common to all 
flaviviruses: The P-loop (residues 196-203), the RNA-binding loop (residues 244-255) and the β-
hairpin loop (residues 431-444). These loops may vary in size depending on the type of virus; 
however, they all have the same fundamental structural flexibility.  The RMSF plot demonstrated 
major fluctuations at the P-loop as well as the RNA-binding loop, the β-hairpin loop however, 
showed no significant conformational change compared to the Apo enzyme. The plot also 
illustrated a flexible “325-338” region. Figure 6.7 depicts three snapshots of the Apo enzyme and 
NITD008-complex, taking at different intervals along the trajectory. Clear conformational shifts 
are illustrated along the trajectory in both Apo and bound systems.  
 
To further investigate the conformational changes of the NS3 Helicase upon ligand binding, 
dynamic cross-correlation matrix (DCCM) analysis was performed at different conformational 
positions of the Cα backbone atoms of the free protein and ligand-bound complex. Highly 
correlated motions of residues are represented in the red to yellow regions, whereas, the 
negative/anti-correlated movements of residue Cα atoms are represented by blue-navy regions. It 
is evident from the correlation map that more globally correlated motion is observed in the case 
of the free protein, confirming conformational shifts after ligand binding. The latter residues of 
the NS3 Helicase, being residues 500-600, displayed anti-correlated movements in both the Apo 
and Bound complex, supporting the residue fluctuations in Figure 6.5. Figure 6.7 also depicts 
anti-correlation motions at residues “340-390”, which may be explained by the snapshots, in 




Figure 6.7: Structural Flexibility of the P-Loop (196-203), RNA-binding loop (244-255), and the 
310 Helix (339-348) along the trajectory. The RNA-binding loop (orange) showed the loop 
shifting down in the Apo structure but an upward shift in the NITD008- Helicase complex. The 
P-Loop (Yellow) shifted away from the active site in the bound complex but closed in on the 
active site when no ligand was present. In the Apo structure, the helix-loop-helix stayed, with 
vibrational movement during the simulation, although, in the bound complex, the 310 Helix 




The P-loop clearly illustrates that when NS3 Helicase is in its Apo form and exposed to a 130 ns 
simulation, the P-loop closes on the active site by uncoiling the α-helix at Arg203 to form part of 
the loop. The loop tip (Ala198) and the adjacent catalytic residue (Gly451) had an average 
distance of 9.71 Å compared to the NITD008-complex distance of 12.75Å, whereby, as NITD008 
becomes more stable at the active site and forms bond interactions, the P-loop is directed away 
from NITD008 and a larger catalytic space becomes available for the ligand as it forms stable 
hydrophobic interactions deeper within the hydrophobic pocket (Figure 6.8). 
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Figure 6.8: Residue fluctuations at the P-Loop region. The Apo enzyme illustrates closing of the 
loop at the active site due to a vacant hydrophobic pocket. Subsequent to ligand binding and the 
initiation of stabilizing hydrogen and hydrophobic bond interactions, the P-loop shifts down to 
accommodate the ligand, thus increasing the size of the hydrophobic pocket.  
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The “325-348” region demonstrates opposing conformational modifications between the Apo and 
complex systems compared to that of the P-loop. The Distance between the two catalytic residues 
from the loop tips; residue Ser324 and residue Asn448, measured for the Apo and NITD008-
complex was 6.34 Å and 8.34 Å, respectively (Figure 6.9). The NITD008-complex had a greater 
distance between the residues due to the unraveling of 2 β-sheets found in domain II. This led to a 
“325-338” loop shift behind the active site and the “339-348” region being modified from a 310 
Helix to a α-Helix (Figure 6.7). The 310 Helix conversion could be due to many reasons including 
changes in pH, interactions with other proteins and in this case, ligand binding. The ligand-
protein interactions lead to distances between nitrogen and oxygen atoms from the protein 
backbone to fluctuate and as NITD008 moved further into the hydrophobic pocket, these 
fluctuations and hydrogen bond conversions caused the 310 helix to convert to an α-helix. These 
changes are important in illustrated the conformational fluctuations upon ligand binding.  
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Figure 6.9: Residue fluctuations at the “325-348” region. The Apo enzyme illustrates widening 
of the loops of the Apo enzyme. The rear loop shifts down as the P-loop closes in on the active 
site. The largest fluctuation is seen after system stabilization at 40-60 ns.  The NITD008-Helicase 
enzyme shows instability in both loops throughout the simulations, although, there was no 




3.3.2 Principal Component Analysis 
Conformational transitions of the free protein and NITD008-bound complex were characterized 
using PCA, a technique that has been widely employed to present experimentally detected 
conformational variations. Figure 6.10 highlights the motional shifts across two principle 
components in the case of NITD008-bound and unbound NS3 Helicase. It is evident that 
eigenvectors computed from the respective simulations varied immensely between the two 
systems, further elaborating on the dynamic conformational fluctuations from free to ligand-
bound protein. The unbound system shows restricted structural motions of residue Cα atoms, 
whereby the NITD008-bound system shows a larger spatial occupancy, thus substantiating the 
rigidity of the unbound system. This corresponds with the stability of the systems, illustrating 
greater distribution of the atoms around the center of mass and the system stability deviations for 
the NITD008-bound system. Correlation from analysis of both the free and bound protein 




Figure 6.10: Projection of Eigen values of the Cα backbone, during 130 ns simulation, for Apo 
and NITD008-bound conformations of NS3 Helicase along the first two principal components. 
The X- and Y- axis, PC1 and PC2, respectively, represent a covariance matrix after elimination of 
eigenvectors (rotational movements). Each point between the single-directional motions 
represents a unique conformation during the simulation, whereby, similar structural 








The detailed MD analyses provided in this report demonstrate the structural alterations in ZIKV 
NS3 Helicase loop flexibility subsequent to binding of potent inhibitor, NITD008 37. Molecular 
simulations revealed profound motional shifts of the ZIKV P-Loop at the ATPase active site. This 
flexibility was revealed in the RMSF analysis and verified by graphical investigation of the loop 
at different time intervals during the simulation. Investigation into the dynamic cross-correlation 
of the unbound and bound systems as well as a plot of conformational poses along the first two 
principal components resulted in strongly significant structural flexibility of the NITD008-NS3 
Helicase system compared to the rigid unbound protein. The P-loop has demonstrates similar 
motional shifts in other flaviviruses as well as in ZIKV, when natural substrate, ATP binds at the 
active site. The competitive inhibitor, NITD008, has been proven to effectively constrain ZIKV 
replication both in vitro and in vivo. Complex stability measured through the 130 ns simulation 
showed consistency of NITD008 at the ATPase active site and binding free energy calculations 
and residue-ligand networks revealed strong stabilizing hydrophobic and hydrogen bond 
interactions pocketing NITD008 in the active site. Further conformational changes were 
illustrated by the “325-338” loop shift behind the active site and the “339-348” region being 
modified from a fluctuating 310 Helix to a more stable α-Helix.  
Crystallographic studies have identified the P-loop, specifically Lys200, to be critical in 
stabilizing the triphosphate moiety of an NTP, thus allowing flexibility upon ligand binding and 
activation 12–14. To augment these key findings, Lys200 showed strong hydrogen bonds with the 
NTP-analogue, NITD008. Other active-hotspot residues included P-loop residues: Gly197-
Arg202, Ala198, Glu286, Gly415, Asn417 and Arg456. The insights demonstrating the above 
binding landscape of the ZIKV NS3 Helicase will aid researchers in the identification of targeted-
small molecule inhibitors through structure based drug design and to utilize pharmacophore 
models in screening for effective drugs with minimal toxicity.   
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Future experimental analysis is needed to fully understand these loop shifts toward inhibition of 
the enzyme as well as investigations into possible mutational resistance as seen in other flavivirus 
Helicase NTPase sites. 
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Aim: This study aims to provide insight into the binding features of the ATPase and ssRNA sites 
of the NS3 helicase. Methods: Clinically approved flavivirus inhibitors were docked to the 
corresponding active sites of the protein and the three best compounds were validated with 
molecular dynamic simulations. Result: Binding of Ivermectin to ssRNA site and Lapachol and 
HMC-HO1α to the ATPase site allowed for conformational rigidity of the Zika NS3 helicase, 
thus stabilizing residue fluctuations and allowing for protein stability. Favorable free binding 
energies were also noted between compounds and the helicase, thus supporting the intermolecular 
forces at the helicase active site. Conclusion: The pharmacophoric characteristics found in 
Lapachol, HMC-HO1α and Ivermectin may be utilized in the design of a potent hybrid drug that 
is able to show efficient inhibition of a multitude of diseases including the detrimental co-
infection of ZIKV, Dengue and Chikungunya. 
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Zika virus (ZIKV) is a positive-sense, single stranded RNA arbovirus belonging to the genus 
flavivirus and family flaviviridae [1]. The virus was first discovered in a forest in Uganda called 
the Zika forest near lake victoria in 1947, thus coining the virus’s name [2,3]. The virus was then 
isolated in the blood of a sentinel Rhesus monkey during research on the Yellow fever virus [4], 
while a second isolation was done in 1948 at the same site [5]. ZIKV virus has a wide 
geographical distribution including Africa (Uganda, Egypt, Gabon), Asia (India, Malaysia, 
Vietnam, Thailand, Indonesia), and Micronesia [6]. This has been demonstrated through viral 
isolations and serologic studies [7,8]. Although isolations of the virus were analyzed, researchers 
only detected the virus in humans in 1952 when neutralizing antibodies were picked up in 
infected sera. Scientists Boorman and Porterfield subsequently studied the transmission of viruses 
from mosquito to primates and based on further isolations from both mosquito and monkey 
concluded that mosquitoes acted as vectors for ZIKV [1]. 
The rapid spread of the virus across continents is primarily due to vector transmission via the 
Aedes aegypti, Aedes albopictus and Aedes africanus mosquito [2]. These Vectors are endemic to 
tropical and sub-tropical areas. However, due to evolving climates, the mosquitoes have 
expanded their habitat, thus increasing the number of mosquitoes as vectors of flaviviruses [9–
11]. However, other routes of transmission have been reported, including, sexual transmission 
[10,12], perinatal transmission, and blood transfusion [13]. The symptoms following ZIKV viral 
infection are mild headache, maculopapular rash, fever, malaise, conjunctivitis and arthralgia. 
These symptoms are shared with other related flaviviruses, including Dengue virus, Yellow fever 
virus, West Nile, St. Louis encephalitis virus and Japanese Encephalitis virus [15,16]. The most 
recent and devastating outbreak of ZIKV occurred in Brazil, at the end of 2015. The virus has, to 
date, rampaged South America by being evidenced as a leading cause of microcephaly by 
prenatal transmission [17]. Increasing scientific evidence now shows that the virus is able to pass 
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through the blood-brain-barrier and infect neural cells, thus playing a role in diseases such as 
microcephaly and Gullian-Barré Syndrome [18]. 
 
The ZIKV genome contains 10.7kb single stranded RNA, which contains a large polyprotein, 
which cleaves into 3 structural proteins (envelope, E; membrane precursor, PrM; and capsid, C) 
and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), of which, 
the NS3 helicase plays a pivotal role in viral replication and RNA synthesis. Presently, 
researchers are focusing on the structural and non-structural viral proteins for the development of 
drugs [19], due to their crucial characteristics in viral replication [20]. The NS3 helicase (Figure 
7.1) has three domains and two binding sites, being the adenosine triphosphate (ATP) and single 
stranded ribonucleic acid (ssRNA) site [21,22]. Inhibiting both the ATP and ssRNA sites will be 
crucial in the inhibition of the NS3 helicase as studies have shown that each domain may act 
independently from the other [23]. However, the close proximity of the two binding sites can 





Figure 7.1: Structure of NS3 ZIKV Helicase (PBD 5JMT), [21]. Domain 1 (blue: residue 175-
332) and domain 2 (red: residue 333-481) are seen facing each other and domain 3 (green: residue 
482-617) lying above the other 2 domains. The ATP binding site is located in the cleft between 
domain 1 and domain 2 and the ssRNA binding site is located at the tunnel that separates domain 
3 from the other 2 domains [22]. 
 
Due to the rapid spread of the disease on a global scale and the detrimental long-term 
complications, researchers such as Barrows et al (2016) and Xu et al (2016) have turned to 
‘repurposing’ flavivirus FDA approved drugs rather than the lengthy process of designing and 
synthesizing new drugs [4,5]. One of the most widely used antihelminitic drugs, Ivermectin, has 
been evidenced to have potent inhibitory effects on flaviviruses by acting as a competitive 
inhibitor of viral ssRNA at the RNA binding site of the NS3 helicase [6,7]. Barrows et al (2016) 
validated Ivermectin as a potent ZIKV inhibitor in an in vitro screening study, alongside 17 other 
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FDA-approved flavivirus drugs as well as daptomycin, which had no previous anti-viral activity 
[4].  
Another potential drug candidate against ZIKV is the adenosine nucleoside analog, NITD008, 
which has been reported to have competitive inhibitory properties against adenosine substrates in 
vitro and in vivo [8]. However, other reports have also shown elevated toxicity levels in 
preclinical animal testing [9].  
One of the major challenges of ZIKV is its ability to co-infect the host. Multiple cases reporting 
Chikungunya, Dengue and Zika co-infection have been identified, leading to potentially 
exacerbated neurological effects on the host and fetus [10]. By this end, identifying potential 
inhibitors against ZIKV that have already been approved as a Dengue or Chikungunya treatment 
would be beneficial as it would be less toxic than administering multiple drugs to a patient [11].  
Although numerous studies have been released elucidating ZIKV drug discovery, no FDA 
approved drugs are presently available. There is also a lack in literature regarding the structural 
and conformational features of the protein, thus designing effective novel small drug molecule 
inhibitors may be challenging.  
 
In this study, we have utilized clinically approved flavivirus NS3 small molecule inhibitors to 
analyze the binding affinity and stability of the ZIKV NS3 domains via Molecular Dynamics 
(MD) simulations, thus mapping out binding hotspots and landscaping interactions of the 
complexes. 
In addition to this, we will employ Accelerated Molecular Dynamics (aMD) in order to run the 
simulation for a longer time frame to ensure sufficient conformational sampling and accurate 
physical force field. Accelerated MD is an enhanced sampling technique that operates by 
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modifying potential energy, reducing the height of local barriers and accelerating transition 
between different low energy states [25][26]. This will enable the sampling of distinct 
bimolecular conformations and rare barrier-crossing events that cannot be easily accessed in a 


















2. Computational methodology 
2.1 Protein structure preparation 
The crystal structure of the Escherichia coli strain of Zika virus NS3 helicase was retrieved from 
protein data bank (PDB: 5JMT). It was then prepared for molecular docking by stripping it off of 
water molecules using UCSF CHIMERA [28] and adding the necessary hydrogen atoms using 
Molegro Molecular Viewer (MMV) [29]. 
2.2 Molecular docking 
Molecular docking was performed on 10 ligands: 6 Naphthoquinones (Lapachol, Atovaquone, 
Parvaquone, Buparvaquone, α-Lapachone, β-Lapachone)[30], 3 purine nucleoside analogues (1-
(2’-deoxy-α-D-ribofuranosyl)imidazo[4,5-d]pyridazine-4,7(5H,6H)dione)(HMC-HO1α), 1-(2’-O-
methyl- α-D-ribofuranosyl)imidazo[4,5-d]pyridazine- 4,7(5H,6H)-dione(HMC-HO4) and 1-(β-D-
ribofuranosyl)imidazo [4,5-d]pyridazine-4,7(5H,6H)-dione(HMC-HO5)) [31,32] and Ivermectin 
[33]. Each of the compounds were then downloaded from PubChem [34], converted to mol2 
format and assessed using MMV to ensure that they display the correct bond angle and 
hybridization state. The 2D structures of the ligands are given in the supplementary material 
(Figure S1). 
Docking was carried out with the Autodock Vina software [35]. Ivermectin was docked at the 
ssRNA binding site, while the rest were docked at the ATPase binding site. The grid box 
parameters for the 2 sites are given in Figure S2. Of the 10 ligands docked into the active site of 




2.3 Molecular dynamic simulations 
Molecular Dynamic (MD) simulations were performed on the 3 complexes using the graphics 
processor unit (GPU) version of the PMEMD engine provided with the AMBER 14 package 
[36,37].  The Antechamber module was used to generate atomic partial charges for the ligands 
using GAFF force field [38]. The protein was described using the FF14SB of the Amber force 
field [39]. The LEAP module in AMBER 14 was used to generate topologies for the system by 
adding protons and counter ions to neutralize the system [36]. Subsequently, the complexes were 
then solvated in a TIP3P [40] octahedron water box with a distance of 8 Å away from the water 
box edge. The Periodic boundary conditions were employed and the particle-mesh Ewald method 
(PME) in AMBER 14 was used to treat the long-range electrostatic interactions with a non-
bonding cut-off distance of 10 Å. 
Minimization of the systems were performed with a restraint potential of 500 kcal/mol Å2 to treat 
the solute for 1000 steepest descent steps using the SANDER module of the AMBER 14 
program, followed by 1000 steps of conjugate gradient minimization. The systems were then 
minimized over 1000 steps with unrestrained conjugate gradient. Gradually, the systems were 
heated from 0 to 300 K for 50 ps, such that the system maintained a fixed number of atoms and a 
fixed volume, that is, a canonical (NVT) ensemble. 
 The entire system was then equilibrated at 300 K with a 2 fs time step in the NPT ensemble for 
500 ps, and Berendsen temperature coupling [39] was used to maintain a constant pressure at 1 
bar. The SHAKE algorithm [40] was employed on all atoms so as to constrain the bonds of all 
hydrogen atoms. With no restraints imposed, an initial production run was performed for 10 ns in 
an isothermal isobaric (NPT) ensemble using a Berendsen barostat with a target pressure of 1 bar 
and a pressure-coupling constant of 2 ps. The systems were subsequently subjected to 10 ns of 
accelerated MD using a set of parameters calculated from the potential energy of the converged 
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system (Table 1). Coordinates were saved every 1 ps and the trajectories were analyzed every 1 
ps using the PTRAJ module of AMBER 14. Each system was consequently subjected to post 
molecular dynamic analysis including root mean square fluctuation (RMSF), root mean square 
deviation (RMSD) and radius of gyration (RoG). Included in analysis was the ligand-residue 
profile [25]. Visualization of trajectories was conducted in Chimera [28], while the results were 
analyzed and plots were generated with aid of Origin software [41].  
 










Lapachol System -144728 9424.9 1404.4 355.2 
Ivermectin 
System 
-144600 9465.1 1425.2 355.2 
HMC-
HO1αSystem 
-144698 9455.3 1404.4 355.2 
 
2.4 Thermodynamic calculations 
Over the years, molecular mechanics/generalized-born surface area (MM/GBSA) method of 
binding free energy calculations have proved to be a practicable means of understanding the 
ligand-residue landscape binding in various biological macromolecules [42–45]. Therefore, 
MM/GBSA approach was employed to calculate the binding free energies of Ivermectin, 
Lapachol andHMC-HO1α bound to NS3 helicase protein. To achieve this, 1000 snapshots were 
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extracted from each of the 20 ns trajectories. The following equation describes the calculations of 
binding free energy. 
The term Egas denotes the gas-phase energy that consists of the internal energy Eint, Coulomb 
energy Eele, and the van der Waals energies Evdw. Egas was directly estimated from the FF14SB 
force field terms. The solvation free energy, Gsol, is estimated from the energy contribution from 
the polar states, GGB and non-polar states, GSA. The non-polar solvation energy, GSA, is 
determined from the SASA using a water probe radius of 1.4 Å, whereas the polar solvation, 
GGB, contribution is estimated by solving the GB equation. S and T denote the total entropy of 
the solute and temperature, respectively. 
2.5. Per-residue energy decomposition analysis 
Per-residue free energy decomposition was carried out in order to obtain the contribution of each 
residue to the total binding free energy profile between the inhibitors Ivermectin, Lapachol and 









3. Results and Discussion 
3.1 Docking result and validation 
Molecular docking is one of the routinely used methods in molecular modeling and drug design. 
It is used to predict the conformation of small molecule (ligand) within the appropriate binding 
site, making it an important tool in drug discovery [46,47]. Furthermore, molecular docking ranks 
docked compounds based on the binding affinity of the ligand to the receptor (Figure S3). 
In this study, 10 compounds were chosen to dock into the NS3 helicase based on their inhibitory 
characteristics at flavivirus ATPase/ ssRNA sites [30,31,33]. Of the 10 compounds, 3 were 
chosen for subsequent conformational and binding mode analysis. Lapachol and HMC-HO1α 
were chosen from the naphthoquinones and purine nucleoside analogues respectively because 
they portrayed the most optimal docked conformation from the molecular docking studies that 
were carried out. Ivermectin was docked into the ssRNA site due to its high potency as a 
flavivirus inhibitor [33,48]. 
Validation of molecular docking was done by superimposing each of the docked complexes with 
the PDB structures of their natural substrates for ssRNA and ATPase site (PDB code: 5GJB and 
5GJC). The results of the superimposition are shown in Table 2. (5JMT- green, 5GJB and 5GJC - 







Table 7.2: 2D structure, docked complexes and validation of the docked complexes.
 
3.2 Molecular dynamics simulation and post molecular dynamics analysis  
A frequently overlooked side of molecular docking is the flexibility of the binding target. The 
ligand and receptor usually undergo conformational changes before binding and sometimes the 
ligand fits in with little mobility. In order to ensure the stability of the complex, the 3 complexes 
were subjected to aMD [47,49,50]. 
 
3.2.1 Systems stability 
The stability of the systems was investigated by assessing the Root Mean Square Deviation 
(RMSD) with regard to the Cα-backbone atoms of the 3D structure during the simulation (Figure 
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7.2). Equilibrium was attained after 2000 ps and the overall average RMSD value for Lapachol, 
HMC-HO1α and Ivermectin measured 0.98Å, 0.97Å and 0.95Å respectively. The results at the 
ATPase site exhibited similar stability between the HMC-HO1α-ATPase system and the 
Lapachol-ATPase system, whereas, the Ivermectin-ssRNA complex demonstrated the lowest 
average RMSD from all three systems. This is indicative of a more stable complex, justifying 
Ivermectin as a potent flavivirus inhibitor. The RMSD plot further postulates that the binding of 
the three ligands at two different active sites of the protein still allowed for conformational 
rigidity compared to the unstable free protein, which yielded an elevated average of 1.76Å. It can 
therefore be deduced that all three ligands allowed for structural stability of the NS3 Helicase 
protein. 
 
Figure 7.2: C-alpha RMSD backbone Plot for NS3 Helicase free and ligand bound 
conformations. The ligands Lapachol, HMC-HO1α with Ivermectin are seen to stabilize the 
protein as compared to the fluctuating free protein. 
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3.2.2 Root Mean Square Fluctuations (RMSF) 
Root Mean Square of Fluctuations (RMSF) were analyzed to show the mobility of each of the 
residues found in the protein, thereby giving an insight into the flexibility of the protein [51]. 
Figure 7.3 depicts the RMSF of the residues for each system for the duration of the simulation. 
High fluctuations were observed at certain residues for each of the systems, with the free protein 
showing the greatest fluctuations during the simulation (1.61Å). All three ligand-bound systems 
showed C-α residue fluctuations at residues 72-79 and 409-411. The HMC-HO1α-ATPase system 
specifically showed flexibility at the “172-176” region, whereas the Ivermectin-ssRNA illustrated 
the lowest fluctuations of all four systems. This correlates with the RMSD stability of the 
systems, demonstrating the free protein to have highly unstable residues with large fluctuations 
compared to the ligand-bound systems. The RMSF of Ivermectin also correlated with the RMSD 







Figure 7.3: (A) RMSF Plot for Lapachol, HMC-HO1α and Ivermectin systems. Lapachol 
(0.88Å) showed a higher stability at the ATPase site compared to HMC-HO1α (0.90Å) and 
Ivermectin (0.85Å) showed the most favorable stability of all the systems, (B) NS3 Helicase 
residue fluctuations at regions: 1- the “72-79” loop (Navy), 2- the “172-176” helix (Gold) and 3- 





3.3.3 Radius of Gyration 
To further validate the stability of the systems, the overall protein shape and folding was 
measured by analyzing the radius of gyration (RoG) of the protein. This gave an insight into the 
distribution of C-α atoms within the protein [51,52]. The plots for all the systems are shown in 
Figure 7.4. From the graph, a difference can be seen in the compactness of the three systems from 
the beginning of the simulation. Ivermectin shows a lower average RoG (22.23Å) when 
compared to HMC-HO1α (22.30Å) and Lapachol (22.33Å), indicating that Ivermectin exhibits a 
very good structural stability at the ssRNA site when it binds to the ZIKV NS3 helicase. Also at 
the ATPase site, the result indicates that HMC-HO1α is more compact and therefore exhibit more 
stability than Lapachol. The RoG of the Apo protein correlates with the RMSD and RMSF 
results, showing a wide distribution of C-α atoms for the duration of the simulation, thus 




Figure 7.4: Radius of gyration Plot for Lapachol, HMC-HO1α and Ivermectin systems when 
compared to the free protein. 
 
3.3.4 Free Energy Calculations and Residue-Ligand Interaction Network 
Studies have shown that free binding energies calculations are important parameters for the 
validation of ligand-protein binding [43]. Based on the Systems’ stability, we can deduce that 
during the simulation, binding of the three best-docked molecules, being, Lapachol, HMC-HO1α 
and Ivermectin, stabilized the fluctuating free Protein. This may be due to non-covalent 
interactions taking place between the ligands and the active site’s residues. To estimate the 
binding affinities of each of the ligands to the protein, the binding free energies were calculated 
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using the Molecular Mechanics/Generalized-Born Surface Area method (MM/GBSA)[54]. Table 
3 summarizes the binding free energy of HMC-HO1α-ATPase and Lapachol-ATPase systems to 
be -42.81 kcal/mol and -39.32kcal/mol respectively. The non-polar solvation (-103.51 kcal/mol) 
contributed greatly towards the total binding free energy of HMC-HO1α-NS3 helicase system 
while other favorable binding contributions also came from intermolecular electrostatic 
interactions (-62.53 kcal/mol) and van der Waals interactions (-40.98kcal/mol). Lapachol-NS3 
helicase system had its greatest binding contribution from non-polar solvation energy (-
65.96kcal/mol), followed by van der Waals interactions (-38.23kcal/mol) and then intermolecular 
electrostatic interactions (-27.73 kcal/mol). A polar solvation of 60.69 kcal/mol and 26.64 
kcal/mol for HMC-HO1α-NS3 helicase system and Lapachol-NS3 helicase system respectively 
were also observed. This indicates that HMC-HO1α has a preferable binding energy than 
Lapachol at the ATPase site. Ivermectin had a relatively higher binding energy (-84.56 kcal/mol) 
at the ssRNA site with the greater energy contribution from the non-polar solvation (-136.32 
kcal/mol) and van der Waals interactions (-104.36 kcal/mol). 
The active site residues of proteins are important for the protein’s functionality; therefore it is 
important to understand the interactions of these potential inhibitors with the amino acids residues 
in the protein [52]. In order to gain more insight into the contribution of each residue towards the 
binding of the ligand, per residue interaction energy decomposition analysis was carried out on 











At the ATPase binding site, Lapachol illustrated a favorable energy contribution with residues 
Glu112 (-3.05kcal/mol), sharing the highest total energy, while other contributions came from 
residues Leu20 (-0.24 kcal/mol), Gly23 (-0.29 kcal/mol), Ala24 (-0.25 kcal/mol), Glu57 (-0.30 
kcal/mol), Ala43 (-0.32 kcal/mol), Asn243 (-0.89 kcal/mol) and Arg285 (-0.8 kcal/mol). 
However, Lys26 (0.45 kcal/mol) and Arg288 (0.8 kcal/mol) showed unfavorable energy 
contributions (Figure 7.5). 
 
Energy Components (kcal/mol) 
Compound ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Ivermectin -104.36±3.95 -32.26±7.87 -136.32±11.07 52.07± 5.34 -84.56±7.77 
HMC-HO1α -40.98±3.40 -62.53±10.17 -103.51±8.78 60.69± 7.39 -42.81±4.16 
Lapachol -38.23±2.99 -27.73±6.87 -65.96±5.71 26.64± 4.12 -39.32±3.52 
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Figure 7.5: Free energy decomposition and ligand-residue interaction network at the ATPase site 
of the Lapachol- NS3 Helicase system. 
HMC-HO1α-ATPase System 
As evident from Figure 7.5 and 7.6, HMC-HO1α and Lapachol interact with the ATPase active 
sites residues by forming a hydrogen bond with residue Arg285 and hydrophobic interactions 
with residues His21, Gly23, Glu112 and Ala143. In addition, HMC-HO1α exhibited hydrophobic 
interactions with residues Pro22, Lys26, Gly25, Arg28, and Asn243. Subsequent to HMC-HO1α 
binding at the ATPase site, significant energy contributions came from residues Leu20 (-
1.412kcal/mol), His21 (-1.24 kcal/mol), Pro22 (-1.75 kcal/mol), Gly25 (-1.55 kcal/mol), Lys26 (-
1.40 kcal/mol), and Thr27 (-2.87 kcal/mol), with the highest contribution coming from Glu112 (-
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Figure 7.6: HMC-HO1α docked into the ATPase site of Zika NS3 helicase, illustrating ligand-
residue interactions and active-site residue energy contributions. 
 
The ligand-residue interaction network elucidates on the binding interactions between Ivermectin 
and the ssRNA active site residues, forming a hydrogen bond with Arg214 and hydrophobic 
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interactions with residues Ser94, Leu319, Asp117, Val369, Pro368, Thr235, Met240, Glu218, 
Lys215, Ala90 and Met362. The plot also reveals that residue Arg214 (-5.84 kcal/mol) had the 
highest total energy contribution to the binding of Ivermectin to the NS3 helicase protein at the 
ssRNA site. Other favorable energy contributions came from residues Ala90 (-1.48kcal/mol), 
Ser119 (-2.464 kcal/mol), Thr235 (-1.52 kcal/mol), Asp236 (-1.65 kcal/mol), Leu319 (-1.11 
kcal/mol), Met 362 (-1.87 kcal/mol), Pro368 (-1.14 kcal/mol) and Val369 (-1.32 kcal/mol) while 
the unfavorable energy contribution came from Asp117 (3.0 kcal/mol). 
 
Figure 7.7: Free energy decomposition and ligand-residue interaction network at the ssRNA site 
of the Ivermectin- NS3 Helicase system. 
4. Conclusions 
In this study, we report the binding analysis of three potential inhibitors of Zika NS3 helicase at 
the ATPase site (Lapachol and HMC-HO1α) and ssRNA site (Ivermectin).  Results showed that 
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the binding of Ivermectin to ssRNA site and Lapachol and HMC-HO1α to the ATPase site allows 
for conformational rigidity of the Zika NS3 helicase, thus stabilizing residue fluctuations. The 
interactions between the active site residues and ligands allowed for key structural flexibility at 
two loop regions of the NS3 helicase, thus allowing for protein stability and a possible structural 
mechanism of action for competitive inhibition of natural substrates.  
This study aims to contribute toward the repurposing of potent flavivirus inhibitors against the 
devastating ZIKV epidemic. This strategy overcomes the concept of “shooting the dark” with 
experimental screening as the compounds utilized in the study have already been synthesized, 
thus reducing the drug discovery time-line. These potential inhibitors have been pre-clinically 
tested against other arboviruses and have proven to be effective [6,12–14]. Drugs such as 
Ivermectin have multiple functions, including anti-parasitic and more recently anti-viral 
properties [7,11,15]. Lapachol and HMC-HO1α have been shown to have potent effects as 
flavivirus inhibitors including Dengue and Yellow fever virus[13].  
 
The findings of this study provide fundamental insights toward the structural dynamics of the two 
active site regions on the NS3 Helicase and the ligand-receptor interaction network. The 
pharmacophoric characteristics found in Lapachol, HMC-HO1α and Ivermectin may be utilized 
in the design of a potent hybrid drug that is able to show efficient inhibition of a multitude of 
diseases including the detrimental co-infection of ZIKV, Dengue and Chikungunya. 
 
 
5. Future Perspective  
To our knowledge, this is the first account of detailed computational investigations aimed to 
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provide an insight into the binding features of Lapachol, HMC-HO1α and Ivermectin to ZIKV 
NS3 helicase. Based on the structural dynamics of the two active site regions on the NS3 Helicase 
and the ligand-receptor interaction network, it may be noted that the chemical characteristics 
found in these flavivirus inhibitors play a fundamental role in releasing a potent multi-purpose 
inhibitor against arboviruses. This will allow for pregnant females in endemic areas to take the 
drug as a precautionary measure against arboviruses such as Dengue and ZIKV. By having a 
lower toxicity and higher efficiency, a multi-purpose drug will be safe to consume by pregnant 
females and may diminish the risk of drug resistance due to the multiple diseases it is effective 
against. Distribution on a global scale and at lower cost compared to a vaccine that may need 
optimal storage conditions.  
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Since the outbreak of the epidemic in 2015, ZIKV has been evidenced to manifest in a calamitous 
manner. One of the most devastating effects of the disease is the onset of ZIKV-related 
microcephaly in neonates primarily through prenatal transmission from the infected mother. 
Finding a preventative cure or treatment regimen against this virus has thus become paramount. 
During 2016, a flood of previously unknown information regarding the disease was released, with 
researchers worldwide working tireless in the design of potential vaccines or small drug 
molecules as potential ZIKV inhibitors.  
 
This study sought to augment the structural and molecular characteristics of this previously 
neglected tropical disease by identifying the principal target proteins of ZIKV, being the NS3 
Helicase, NS5 MTase and NS5 RdRp, creating CADD route map to identify potential ZIKV 
inhibitors and finally, implementation of the route map to investigate potential inhibitors for all 
three viral targets.  
 
Upon commencement of the study, no crystal structures of ZIKV target proteins were available; 
therefore a homology modeling was implemented to generate a 3D model of the NS5 protein, 
proving to be an invaluable computational tool. Thereafter, the NS5 MTase and RdRp were 
subjected to “per-residue energy decomposition pharmacophore” virtual screening to identify 
favorable molecules that are more effective and less toxic than the experimentally tested 
inhibitors.  The most favorable inhibitors identified in this study for NS5 MTase and RdRp are 
BG323 and ZINC39563464, respectively.   
 
The NS3 Helicase was also investigated in this study as it plays a major role in viral replication. 
In this domain of the study, the structural characteristics of the ATPase active site were explored 
when bound to a competitive inhibitor. A clear ligand-dependent flexibility was noted in the 
active site/P-loop and a stabilizing α-Helix formed after ligand binding. These insights into the 
binding landscape will aid other researchers in finding a potent, yet effective inhibitor against 
ZIKV. To round up this study, potent Flavivrus inhibitors were selected based on ZIKV’s 
structural similarity to other Flaviviruses, including Dengue and West Nile (Jain et al. 2016; Tian 
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et al. 2016). These inhibitors were then assessed, based on their free binding energies at their 
respective ATPase or ssRNA active; HMC-HO1α and Ivermectin were reported as the most 
favorable compounds.   
 
Overall, this study has provided valuable insights into the design and development of ZIKV 
inhibitors through molecular modeling and CADD. 
 
8.2 Future Perspectives 
The potential inhibitors of the study have presented promising protein-ligand interactions and 
binding energies and therefore maybe utilized as the lead compounds. However, prospective 
biological testing of these compounds is still required to verify these in silico studies.  
 
The ramifications of ZIKV infection have led to a multitude of potential small molecule inhibitors 
and at least two vaccines that are currently in clinical trials. However, the virus has other 
challenging defense mechanisms that may render most drugs ineffective. Zika is able to penetrate 
the blood-brain-barrier (BBB) as evidenced by its downstream pathological effects on the nervous 
system (Huang et al. 2016; White et al. 2016; Anaya et al. 2016; Barrows et al. 2016). The BBB 
however, only allows entry to hydrophilic drugs due to their tight junctions that form as a point of 
entry. If drugs are not able to pass the BBB, the ability of the drug to inhibit the target protein in 
neuronal cells becomes unsuccessful. In order to overcome this obstruction, two approaches may 
be used: 
 
1. The design (in silico) and synthesis of potential compounds that adhere to the 
requirements for permittivity.  
2. The use of a drug delivery system to allow for the drug to pass through the BBB. This 
system may be in the form of a nanoparticle, polymer or aptmer.  
 
With regard to this investigative study, a purely computational perspective was used. However, to 
further the ZIKV drug design research toward targeted therapy, an experiment will need to be 
designed to analyze the efficacy of the two approaches mentioned above.  
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Zika virus drug targets: a missing link in drug design
and discovery – a route map to fill the gap†
Pritika Ramharack and Mahmoud E. S. Soliman*
Zika virus is an emerging virus that has been defined by the World Health Organization as a serious global
biological-threat. Zika virus is an arbovirus from the flavivirus genus that is linked to microcephaly after
prenatal transmission from the infected mother and most recently Guillain–Barrè Syndrome. The need
for innovative research methods is urgent due to the ambiguity surrounding Zika virus. The lack of
experimental data regarding potential drug targets, strategies for design and drug resistance has
prompted us to provide a comprehensive framework with structured theoretical and technical guidelines
on potential drug targets, modeling and design of inhibitors against the virus, thus assisting and
encouraging scientists from different research domains to fill the gap in this research area. We have also
presented a 3D homology model of the ideal Zika viral target, the non-structural protein 5, identified the
active binding sites of each domain of the protein and found potential compounds that may act as
inhibitors. This report will be immensely beneficial toward the design of Zika virus drug inhibitors.
1. Introduction
Zika virus (ZIKV) is a re-emerging arthropod-borne virus that is
predominantly found in the tropics. However, rapidly evolving
climate conditions coupled with increasing distribution of
Aedesmosquito vectors and emerging modes of transmission of
the virus have increased the potential to cause outbreaks in
previously unaffected areas.1 The virus is a member of the
Spondweni sercocomplex of the genus avivirus, family
aviviradae. Other arboviruses related to ZIKV include Dengue
virus, Japanese encephalitis viruses and West Nile virus.2,3
The rst cases of ZIKV infection were reported in Nigera in
the 1950's. Since then, ZIKV has shown erratic cases in coun-
tries such as Uganda, Tanzania, Egypt, Gabon, and in parts of
Asia including India and Indonesia, with the most devastating
pandemic occurring in Brazil in 2015.4,5 Since the outbreak in
Brazil, infection has spread rapidly throughout South America
and Mexico, with Colombia being one of the most-affected
countries with over 20 000 suspected cases.6 As of June 2016,
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thirteen countries have reported Central Nervous System (CNS)
malformations such as microcephaly and Guillain–Barrè
syndrome (GBS) which may potentially be linked to ZIKV;
during the recent circulation of the virus, eight countries had
reported cases of GBS, where laboratory testing conrmed ZIKV
infection in a number of those cases.7 Globally, the prevalence
of ZIKV infection may be greatly underestimated (Fig. 1) due to
the recently veried prenatal and sexual transmission in
humans,8 as well as the abstruseness surrounding the patho-
genicity and thus, in turn the search of inhibitors of this
“neglected disease”.
Most cases of ZIKV have reported febrile u-like conditions
that may be mistaken for other viral infections such as yellow
fever. Other symptoms include swollen lymph nodes, mac-
ulopapular skin rashes and joint pains.5,9,10 Current research
has raised concerns that the virus could cause dramatic
increases in microcephaly in newborns aer prenatal trans-
mission.6,11–13 Complications associated with prenatal infection
encompass fetal growth restriction, neurological and ocular
abnormalities, intracranial calcication and in some cases
perinatal death or stillbirth.10,14
The virus is transmitted via an Aedes mosquito vector,
congenital and perinatal transmission, as well as sexual inter-
course.8,11,14–17 Studies have also reported transmission via
blood transfusion and laboratory exposure.8,18 Commercial
assays have been utilized in the diagnosis of ZIKV infection,
including Real Time Polymerase Chain Reaction (RT-PCR) kits
and IgM-based enzyme-linked immunosorbent assay
(ELISA).10,19 Sample DNA and RNA for these kits may be
extracted from blood serum, semen, amniotic uid, plasma,
saliva and urine. In Dengue infection, NS1 protein may be
detected in a host's blood serum at the onset of clinical
symptoms, this may prove to be another method by which ZIKV
infection may be identied.16,20–22
Although recent publications have described the global
spread, pathogenicity and bioinformatics of ZIKV and its
comparison between other aviviruses including Dengue, West
Nile, Yellow fever and Japanese Encephalitis virus,1,3,8,10,13,19,20,23–30
fundamental research into ZIKV small molecule drug design will
be key in developing inhibitors of target proteins of the virus.
Ekins et al. (2016) described possible drug discovery and poten-
tial homology models of multiple proteins of ZIKV, however,
despite the execution of research methods, there are currently no
known FDA approved drugs of ZIKV.31 This prompted us to
conduct a concise route map depicting the steps taken toward
identifying potential inhibitors of drug targets with no 3D crystal
structure and by following the guide to create a homology model
of a non-structural protein of the virus, thus assisting scientists
fromdifferent research domains. These in silico guidelines will be
vastly benecial in aiding and accelerating ZIKV experimental
drug discovery.
2. Overview of ZIKV protein assembly
ZIKV is an enveloped virus comprising of an 11 kilobase, single-
stranded positive sense RNA genome consisting of 10, 794
nucleotides encoding 3, 419 amino acids.25 The open reading
frame (ORF) of the 50 and 30 untranslated region (UTR) encodes
a polyprotein that is cleaved into three structural proteins being
the capsid, precursor membrane, and envelope. Seven non-
structural (NS) proteins are also found in this assembly,
namely, NS1, NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5
(largest viral protein).24 These viral assembly proteins may act as
crucial molecules in drug discovery.
Fig. 1 Global reports of ZIKV transmission, infection and sporadic viral antibody reports prior to 2015, as of April 2016 (adapted from Centers for
Disease Control and Prevention).
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3. Potential biological drug targets
against ZIKV
3.1 Viral drug targets
Hughes et al. (2010) stated that the potential of a protein as
a therapeutic target and its effectiveness in drug design is
essential for determining the biological utility of the protein.32
ZIKV contains viral proteins that may act as targets in drug
design (Table 1).
The structural proteins of ZIKV, being the capsid, precursor
membrane and envelope form the viral particle.33 The envelope
(E) protein is the key surface protein as it is able to mediate
various aspects, including binding and membrane fusion of the
viral replication cycle, making it a signicant target in drug
design.5
The nonstructural proteins participate in the replication of
the RNA genome, virion assembly and invasion of the innate
immune system. Of the nonstructural proteins, NS5, NS3 and
NS1 have shown enzyme activity in other viruses of the avivirus
genus, creating ideal targets in inhibitor development.33
NS5 is a bifunctional enzyme with a methyltransferase
domain at its N-terminal end and a RNA-dependent RNA poly-
merase (RdRp) at its C-terminal end. Both N- and C-terminal
domains contain an S-adenosyl-Methonine-dependent MTase
core structure that folds into an a/b/a sheet cradled between the
N- and C-terminal subdomains.34 The protein engages in virus–
host interactions and actively interacts with the host environ-
ment.1 To our knowledge, there is currently no available 3D
crystal structure of the ZIKV NS5 protein.
The NS3 protein is a multifunctional, viral replication
protein. The protease comprises of the N-terminal third of NS3
and nucleotide triphosphatase, the RNA triphosphatase, and
nally the helicase components. NS3 can be considered a serine
protease and contains a classical catalytic triad (His-51, Asp-75,
Ser-135).1,35 Agnihotri et al. (2012) reported an in silico study in
which a homology model of the avivirus NS3 protein was
created using 22 species of the avivirus genus. This study is
a critical tool in the understanding the avivirus NS3 protein
and thus the impact of the protein as a ZIKV target.36 The 3D-
crystal structure of the NS3 helicase protein has recently been
reported in Protein and Cell where a conserved triphosphate
pocket and a positively-charged tunnel were identied to be
critical for the hydrolysis of nucleoside triphosphates and the
accommodation of RNA respectively.37
The 3D crystal structure of the noteworthy NS1 glycoprotein
viral target was released earlier this year and was classied as
a major antigenic marker of ZIKV infection.38 The NS1 is
synthesized as a monomer and dimerizes aer post-translation
modication in the replication cycle.39 The mature NS1 protein
has signicant immune evasive functions on the surface of
cells, in the extracellular space and in cells by directly regulating
the translation of viral RNA. Recent studies on Dengue virus
have also evidenced NS1 to be associated with vascular leak and
shock due to the disruption of TLR3 signaling pathways.40 Song
et al. (2016) reported NS1 to display a loop-surface interface with
divergent electrostatic potential that may result in unique
interactions with host machinery compared to that of other
aviviruses.38 This makes ZIKV NS1 an ideal target for chemo-
informatics studies.
Inhibitors of these viral proteins may be designed using
computer-aided drug design techniques to select structural
molecules that may inhibit the replication of viruses such as
ZIKV in a host.
3.2 ZIKV host targets
During the ZIKV replication cycle, host cell machinery is
imperative in the translation of viral RNA and maturation of the
replicated virus, thus targeting host proteins and pathways may
be key to effective inhibition of viral replication.
One of the most researched host proteins in avivirus
infection is the endoplasmic reticulum glucosidase. These
proteins allow for the cleavage of the terminal glucose from the
glycan found at the glycosylation-site of the prM and envelope
protein, thus leading to its maturation of the envelope protein.41
Table 1 Potential ZIKV target proteinsa
Protein NCBI reference sequence PDB code Residue count
Structural proteins
Capsid YP_009227206.1 5IZ7/5IRE 122aa
Precursor membrane YP_009227197.1 5IZ7/5IRE 168aa
Envelope YP_009227198.1 5JHM/5JHL 500aa
Nonstructural proteins
NS1 YP_009227199.1 5IY3 352aa
NS2A YP_009227200.1 Not available 226aa
NS2B YP_009227201.1 Not available 130aa
NS3 YP_009227202.1 5JMT 617aa
NS4A YP_009227203.1 Not available 127aa
2K YP_009227209.1 Not available 23aa
NS4B YP_009227204.1 Not available 251aa
NS5 YP_009227205.1 Not available 903aa
a aa-amino acid.
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Studies have shown that many aviviruses, including ZIKV,
have a N-glycosylation at Asn154.31,42 Castanospermine (CST)
and deoxynojirimycin (DNJ) have been established as potent
inhibitors of alpha-glucosidases, thus preventing the early
stages of glycosylation.43
Hamel et al. (2015) described the importance of dendritic
cell-specic intracellular adhesion molecule 3-grabbing non-
integrin (DC-SIGN), TIM and TAM receptors in the attachment
and entry of ZIKV into the host cell before replication can
occur.44 Small interfering RNA (siRNA) was also shown to
completely inhibit the expression of the above proteins aer 48
hours. Other informative publications on siRNA inhibition of
avivirus host machinery include a review by Hirsch (2010), an
in silico based experimental study on Dengue virus by Noppa-
kunmongkolchai et al. (2016) and the silencing of the 30 UTR of
ZIKV genome by Shawan et al. (2015).5,45,46
A recent study published in June by Nature identied host
endoplasmic reticulum-associated signal peptidase complex
(SPCS) to be necessary for the proper cleavage of ZIKV prM and
envelope proteins. The authors also demonstrated that the loss
of SPCS signaling leads to a dramatic decrease in Dengue,
Yellow fever, West Nile, JEV and Hepatitis C viruses. This study
Fig. 3 Protocol for building a homology model in our laboratory.
Fig. 2 Route map toward the in silico design of ZIKV inhibitors using the homology modeled viral NS5 protein.
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could be a critical cornerstone in targeting host proteins and
pathways in ZIKV infection.47
4. In silico studies conducted on ZIKV
Prior to 2016, only two in silico reports have been made toward
the development of ZIKV inhibitors. Computational studies by
Shawan et al. (2014) showed the viral envelope glycoprotein to
be the most immunogenic structural protein of the virus, thus,
making it a candidate for vaccine development.5 Mahfuz et al.
(2015) also looked at small interfering RNA (siRNA) in gene
silencing of the 30 UTR of ZIKV genome.48 Following the Brazil
outbreak, an inux of research output has ooded the scientic
community. There has been numerous computational studies
regarding ZIKV target proteins; crystals structures of the NS1,
NS3, envelope and the 2 cryo-EM structures of the stable virus
have been released.37,38,42,49,50 Ekins et al. (2016) described in
silico studies in both drug discovery and the homology models
of both structural and nonstructural proteins.9,31 There have
also been reports comparing the structural and sequence
conformations of ZIKV to other aviviruses including Dengue
and West Nile viruses.51,52
5. In silico route map toward the
design and discovery of ZIKV inhibitors
Rational drug design may be classied into two groups, the rst
being the development of small molecules with the desired
effects of the target, whose structural information is known and
the second group being development of small molecules whose
cell functions and structural information may not be known.53
To date, there is no available 3D crystal structure of the ZIKV
NS5 protein. This prompted us to create a route map (Fig. 2)
describing the techniques of the second group, thereby
beneting scientists from different research domains by
informing them of fundamental computational techniques in
the design of novel small drugmolecules, allowing for increased
output of validatory experimentation.
Computer-Aided Drug Design (CADD) represents computa-
tional methods and resources used in the design and discovery
of new therapeutic solutions.54 Numerous bioinformatics tools
and resources have been developed to advance the drug
discovery process.55,56 The recent improvements made in
computational chemistry soware, CADD and molecular
dynamic simulations have led to innovative research methods
in the pharmaceutical industry.57
Details on how the homology model was created are
described under Section 5.1.
The initial step of any modeling work is having a valid 3D
structure, from X-ray crystallography, Nuclear Magnetic Reso-
nance (NMR) or computational design using homology
modeling. Homology modeling is used to predict and generate
a plausible 3D structure of ZIKV's biological target from
a template sequence based on the structure of one or more
homologous viral proteins of which crystal assemblies have
been reported (Fig. 3).58
In order to create a ZIKV target 3D homology model, a typical
procedure needs to be followed, with validation taking place at
each step. Once the 3D structure has been generated and vali-
dated using 3D proles and a Ramachandran plot,59 the pre-
dicted active binding site of the ZIKV target molecule may be
identied. If the drug target is an enzyme, such as the NS3 or
NS5 protein of the ZIKV viral assembly, designed chemical
molecules may be able to t within an active site pocket.56 The
results establish the locality of possible binding pockets of the
protein.60 Aer each pocket has been identied, we can identify
the size of a pocket (volume, surface area and depth), possible
interacting residues and surface atoms.61
Subsequent to the ZIKV protein homology model and target
site determination, several paths may be utilized in the
Fig. 5 The potential binding sites, identified by Site-hound,71 of ZIKV
NS5 protein. (A) Site 1 (methyltrasferase active binding site) (red) and
Site 2 (RdRp active binding site) (magenta), (B) active binding site
residues of the NS5 protein at Site 1 and Site 2.
Fig. 4 Homology model of ZIKV NS5 protein.
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development of inhibitors. Structure-based virtual screening will
assist in searching through combinatorial chemistry libraries for
molecules that may be potential inhibitors of the target protein
and automatically dock these molecules into the 3D target's
active pocket at a rapid rate.62 Thousands of molecules may be
able to match the active site of the target protein, thus, a scoring
function is utilized to rank ligands based on the free binding
energy calculated aer each docking pose.63,64 Molecules with the
lowest free binding energy subsequent to screening may be used
as inhibitor candidates, which may then be employed in a series
of validatory molecular dynamic simulations.
Molecular dynamic simulations calculate the trajectory of
a generated docking pose by utilizing Newtonian mechanics.65
It is an important tool of CADD as it avoids analytic intracta-
bility in complex systems.57 Molecular dynamics is not essential
in CADD but it can provide validation of docking results
between a protein and its potential inhibitors.66
By implementing in silico studies in the design of ZIKV
protein inhibitors, putative drug-like compounds may be
identied and their potency veried using in vitro and in vivo
testing.
Studies report that in vitro testing of potential inhibitors may
utilize cultured monkey cell lines such as LLC-MK2 and Vero.30
Delvichio et al. (2016) also reported choloroquine as potential
ZIKV inhibitor in Vero, hBMEC, hNSC and mouse neuro-
spheres. Dowall et al. (2016) developed the rst in vivo murine
Fig. 6 Docked conformation of 20-C-methyladenosine with ZIKV NS5 RdRp (binding affinity: !6.3 kcal mol!1).
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Table 2 Representation of top ten compounds docking to NS5 RdRpa
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Table 2 (Contd. )
a DG: binding affinity.
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model, where adult female mice were subcutaneously inocu-
lated with similar doses of ZIKV from natural infection of
a mosquito bite.67,68 This model is a critical cornerstone in
accelerated testing of new ZIKV inhibitors.
Larroca et al. (2016) have made a signicant contribution to
the protection against the ZIKV virus by creating the rst full-
length prM-envelope DNA vaccine. The vaccine is currently
undergoing clinical trials aer the success in an in vivo study
using infected mice. This vaccine may be the potential ‘holy-
grail’ in ZIKV prevention.69
5.1 A homology model for ZIKV NS5
In order for CADD of ZIKV to occur, a 3D crystal structure of
a target protein is needed. Fig. 4 shows the rst account of
a homology model for the ZIKV NS5 protein, which was created
and validated as described in our previous publications
(Fig. 4).60,70 The PDB coordinates of the homology model are
provided as.
The protein comprises of three domains, the N-terminal,
methyltrasferase domain (residues 1–262) (green), the inter-
domain region (residues 263–272) (blue) and the C-terminal,
RdRp domain (residues 273–903) (yellow).
5.2 Active site identication
Active site residues need to be identied for the docking of
potential inhibitors to the active site pocket. The active site
residues were determined using Chimera Multi-align Viewer
and validated using the Site-Hound web program.71 Fig. 5
highlights the best active sites and active site residue numbers
of the NS5 protein (Fig. 5).
This homology model will be implemented in the design of
small molecules that may act as inhibitors of the NS5 protein,
thus inhibiting the translation of viral RNA. Experimental drug
therapy on other aviviruses41,72,73 may be used as a guide
toward the identication of new specied small molecules that
inhibit ZIKV replication.
5.3 Possible small molecule inhibitors of NS5 RdRp
Of the ZIKV target proteins, NS5 RdRp is one of the most favor-
able for drug discovery due to its role in viral replication.1 A study
by Eyer et al. (2016) looked at an in vitro study of nucleoside
inhibitors against ZIKV and found one particular molecule, 2-C-
methyladenosine, to show promising inhibition of RdRp.74 The
purine and hydroxymethyl structural features of 2-C-
Table 3 Physical representation of top ten compounds displaying molecular weight, x log P, H-bond donors/acceptors and rotatable bonds
ZINC ID Molecular weight x log P Rotatable bonds H-Bond donors H-Bond acceptors
ZINC35325271 291.27 !0.70 0 2 7
ZINC14987423 277.243 0.95 0 3 7
ZINC35325268 291.27 2.67 0 2 7
ZINC00351019 287.231 !5.47 0 5 8
ZINC13633807 299.246 !0.86 0 3 9
ZINC40563785 288.263 0.83 3 4 8
ZINC40563886 290.279 !0.89 3 4 8
ZINC13121997 289.206 !0.40 2 3 9
ZINC00043707 283.247 !1.01 1 4 8
Table 4 Proposed computational software used in ZIKV drug design
Computational method Soware available Soware to be utilized in study
Homology modeling Sequence alignment-Insight, Prime, Prot,
LOOK, ICM, Sybyl, CLUSTALW Model
construction-DS Modeller, Prime, LOOK, ICM,
Sybyl, MODELLER, MOE, SWISS-MODEL,
RaptorX, LOMETS, Phyre, I-Tasser
Sequence alignment-CLUSTALW77
Model construction-MODELLER78
Active binding site determination CASTp, POOL, PASS, Pocket-Finder,





Molecular graphic systems Avogadro, Chemlab, Athena, Maestro, Jmol,
PyMOL, UCSF chimera, VMD, Vimol, Webmol,
Zeus
UCSF chimera12
Virtual screening databases PubChem, MMsINC, ZINC, ZincPharmer, 4SC




Docking soware PyRx, Autodock Vina, Dock Blaster, Vis3d,
Schrodinger, GOLD, Libdock, FlexX, Glide, Fred,
ICM
Autodock Vina83
Molecular dynamic simulation soware Gromacs, Amber, CHARM, Gromos, ADF,
Desmond, NWChem
Amber84
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methyladenosine were screened through ZINC database, criteria
was imposed to ensure the inclusion of the maximum number of
compounds, such that compounds had to have an x log P
between!4 and 5, a net charge 0, rotatable bonds between 0 and
8, a polar surface area of between 0 and 150, have hydrogen bond
donors/acceptors between 0 and 10, and polar desolvation
between 0 and 1 kcal mol!1 whereas compounds must have an
apolar desolvation between !100 and 40 kcal mol!1. Thereaer,
the 4113 hits were downloaded and docked together with 2-C-
methyladenosine (Fig. 6) at the RdRp active site and the nine best
docked poses comprising the highest binding affinities were re-
ported in Table 2. Table 3 shows the physical representation of
the compounds. These compounds may be a basis for further
validation and experimental verication.
Further information, including extensive procedures, can be
found in our previous publications on structure-based enzy-
matic drug design.58,75 We believe that the robust computational
tools implemented in the route map will provide a fundamental
platform in the development of inhibitors against multiple
ZIKV target molecules.
6. Proposed computational software
that can be used in ZIKV drug design
and discovery
The soware available for techniques used in drug design have
simplied the development of inhibitors allowing for specic
binding to a target molecule, thus, decreasing its biological
adverse effects.76 There are various types of soware available in
structure-based drug design, allowing for faster and more
comprehensive research into ZIKV inhibitors (Table 4).
7. Conclusion
The future of the ZIKV pandemic is uncertain and thus new,
accelerated techniques are necessary to assist the medical and
scientic community in the identication and validation of
inhibitors to this global threat. The chemoinformatics discussed
in this paper will not only in the identication and design of
potential ZIKV inhibitors but also in parallel, butmay assist in the
early analysis of potential biological mutations that may occur
due to the rapid international transmission of this avivirus.
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The re-emerging Zika virus (ZIKV) is an arthropod-borne virus that has been described to have explosive potential as a
worldwide pandemic. The initial transmission of the virus was through a mosquito vector, however, evolving modes of
transmission has allowed the spread of the disease over continents. The virus has already been linked to irreversible
chronic central nervous system conditions. The concerns of the scientific and clinical community are the consequences
of Zika viral mutations, thus suggesting the urgent need for viral inhibitors. There have been large strides in vaccine
development against the virus but there are still no FDA approved drugs available. Rapid rational drug design and
discovery research is fundamental in the production of potent inhibitors against the virus that will not just mask the
virus, but destroy it completely. In silico drug design allows for this prompt screening of potential leads, thus decreasing
the consumption of precious time and resources. This study demonstrates an optimized and proven screening technique
in the discovery of two potential small molecule inhibitors of ZIKV Methyltransferase and RNA dependent RNA poly-
merase. This in silico ‘per-residue energy decomposition pharmacophore’ virtual screening approach will be critical in
aiding scientists in the discovery of not only effective inhibitors of Zika viral targets, but also a wide range of anti-viral
agents.
Keywords: Zika virus per-residue decomposition based pharmacophore; virtual screening; NS5 protein potential
inhibitors; binding free energy; molecular dynamic simulations
1. Introduction
Zika virus (ZIKV) is an arthropod-borne virus that has
been described to have potential as a worldwide pandemic
(Troncoso, 2016). The virus is a member of the spodweni
sercocomplex of the flavivirus genus and was first
discovered in 1947 by its isolation from the Rhesus 766
monkey in Uganda (Faye et al., 2014; Haddow et al.,
2012). Sporadic cases of the virus have been reported in
countries such as Uganda, Tanzania, Egypt, Gabon, and in
parts of Asia including India and Indonesia, with the most
devastating epidemic occurring in Brazil in 2015
(Campos, Bandeira, & Sardi, 2015; Mahfuz et al., 2015).
As of June 2016, 11 countries had reported central nervous
system (CNS) malformations potentially linked to ZIKV.
During 2015 and early 2016, eight countries had reported
cases of Gullian–Barrè syndrome (GBS), where laboratory
testing confirmed ZIKV infection was found in a number
of GBS cases (WHO, 2016).
Transmission of the virus was thought to be only via
the Aedes mosquito vector but studies during 2016,
have evidenced congenital, perinatal, and sexual trans-
mission (Singh et al., 2016; Turmel, Hubert, Maquart,
Guillou-Guillemette, & Leparc-Goff, 2016). The virus
triggers febrile like influenza conditions in the host,
including swollen lymph nodes, skin rashes, and joint
pains (Brito, 2016; Ekins et al., 2016; Shapshak, Sinnott,
Somboonwit, & Kuhn, 2016). The concerns of the scien-
tific community involve the dramatic increase in ZIKV-
related CNS disorders including neonatal-microcephaly
and GBS (Lissauer, Smit, & Kilby, 2016; Panchaud,
Stojanov, Ammerdorffer, & Vouga, 2016; Roa, 2016).
Complications associated with prenatal infection encom-
pass fetal growth restriction, neurological and ocular
abnormalities, intracranial calcification and in some cases
perinatal death or stillbirth (Chibueze et al., 2017; Singh
et al., 2016).
The virus is able to enter a host via receptor-
mediated endocytosis, followed by fusion from within
the endosomal cell compartment (Mahfuz et al., 2014).
The enveloped virus comprises an 11 kilo base, single-
stranded positive sense RNA genome which consists of
10,794 nucleotides encoding 3419 amino acids (Hayes,
2009). The open reading frame of the 5! and 3! untrans-
lated region encodes a polyprotein cleaved into three
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structural proteins being the capsid, premembrane/mem-
brane, and envelope. Seven non-structural proteins may
also be found in this assembly, namely, NS1, NS2A,
NS2B, NS3, NS4A, 2K, NS4B, and NS5 (largest viral
protein) (Haddow et al., 2012).
Being the largest and most imperative protein in the
genome replication and RNA capping of ZIKV, NS5 pre-
sents as a novel antiviral target (Tambunan, Zahroh,
Utomo, & Parikesit, 2014). The protein consists of three
domains: a Methyltransferase (MTase) domain at resi-
dues 1–262 of its N-terminal, an RNA dependent RNA
polymerase (RdRp) at residues 273–903 of its C-terminal
and an inter-domain region at residues 263–272 (Zou
et al., 2014).
The MTase domain belongs to the family of
S-Adenosyl Methionine (SAM)-dependent enzymes, con-
taining a SAM-dependent MTase fold comprising of an
!/"/! structure (Zou et al., 2014). The MTase domain is
one of the key targets in drug design as the enzyme per-
forms nucleoside-2’O and N-7 methylation of the viral
RNA cap which is essential in the replication of the
virus (Egloff, Benarroch, Selisko, Romette, & Canard,
2002). Upon the completion of methylation, SAM is
converted to S-Adenosyl Homocysteine and gets released
from the MTase domain (Brecher et al., 2015). Inhibition
of MTase will be detrimental to the progression of
ZIKV.
The conserved RdRp domain allows for the initiation
of RNA synthesis, generating both plus and minus strand
RNAs. As with most polymerases, the structure of the
enzyme resembles a shape analogous to a right hand
with a finger, thumb, and palm region (Papageorgiou
et al., 2014; Shanmugam, Velmurugan, & Gromiha,
2016). The human body does not contain an RdRp
enzyme or analogs of it, thus inhibitors may not cause
severe toxic effects, making it an optimal target in drug
design (Shanmugam et al., 2016).
To date, no anti-ZIKV drugs are clinically available,
thus, new research methods are being developed with the
purpose of identifying target molecules. Recent research
has found that ZIKV targets neuronal cells (Millichap,
2016; Miner & Diamond, 2016; Mlakar et al., 2016;
Tang et al., 2016). Consequently, any new drugs that
may be discovered will have to pass through the blood–
brain barrier. Molecular modeling and computational
methods are important tools in the development of novel
inhibitors of ZIKV (Ekins et al., 2016; Ramharack &
Soliman, 2016). A number of inhibitors of the flavivirus
NS5 protein have been discovered via virtual screening
and computational analysis (Brecher et al., 2015; Idrus,
Tambunan, & Zubaidi, 2012; Lim & Shi, 2013). Struc-
ture-based virtual screening (SBVS) identifies energeti-
cally advantageous binding affinities of ligands into a
target’s active binding site. This allows for new insights
on the nature of the active site and the protein–ligand
interactions (Kumalo & Soliman, 2015). The method
identifies selective molecules from an extensive library
of compounds to dock within a target’s active site.
Although scoring techniques are used when molecules
are docked to the target, literature shows that a large
number of final hits are generated, as the compounds
docked may be in various geometric poses (Kroemer,
2007). Ligand-based virtual screening generates libraries
of compounds based on a known compound or com-
pounds and its illustrative interactions with a particular
target (Cele, Muthusamy, & Soliman, 2016).
In an attempt to develop pharmacophore-based mod-
eling, we previously presented a per residue energy
decomposition (PRED) protocol where candidates for
SBVS were chosen on the position of 3D moieties with
an experimentally known compound, thus creating a
pharmacophore model based on highly contributing
amino acid residues to the bound inhibitor. This
approach is based on interactions that occur at a molecu-
lar level, including charge, hydrophobic interactions and
hydrogen bonding (Cele et al., 2016). The highly con-
tributing residues are identified based on free energy
footprints from molecular dynamic (MD) and thermody-
namic calculations (Cele et al., 2016; Kumalo &
Soliman, 2015; Soliman, 2013). This proves to be an
incredibly concise method, rather than ‘shooting in the
dark’ with millions of available small molecules.
In our previous work, we created a possible homol-
ogy model of the NS5 protein containing both MTase
and RdRp domains (Ramharack & Soliman, 2016). Due
to the indeterminateness surrounding the ZIKV NS5 pro-
tein and potential inhibitors, we will compare our top
hits against known inhibitors of the flavivirus NS5
protein.
This study will implement the above-mentioned
PRED pharmacophore technique in the discovery of
potential ZIKV NS5 protein inhibitors, thus aiding
medicinal chemists in the synthesis of possible drug
candidates.
2. Computational methods
A route map to PRED-based pharmacophore virtual
screening approach is depicted in Figure 1.
2.1. Homology modeling and identification of active
binding sites of NS5
In our previous article and during the current study, due
to the absence of a crystal structure of ZIKV NS5 pro-
tein, a homology model was created using the protein
sequence obtained from NCBI (Accession number:
YP_009227205) (Ramharack & Soliman, 2016). The
templates for sequence alignment were identified from
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NCBI using BLASTp (accessed on 5 March 2016)
(Madden, Tatusov, & Zhang, 1996) to find suitable tem-
plates, from RCSB protein databank (Berman et al.,
2002), for homology modeling. Based on the criteria of
identity score, e-value and query cover accuracy
(Table 1), the NS5 protein was modeled by using four
crystal structures of flavivirus enzymes as templates:
Chain A of full-length Japanese Encephalitis Virus NS5
(PDB Code: 4K6M_A); Chain A of full-length NS5
from Dengue virus Type 3 (PDB Code: 5CCV_A);
Chain A of RNA Dependent RdRp domain from Nile
West Virus (PDB Code: 2HFZ_A); and Chain A of
Dengue Serotype 3 RNA-dependent RdRp bound to
Nitd-107 (PDB Code: 3VWS_A).
Figure 1. A PRED-based approach outline applied in the study.
Table 1. Criteria summary of chosen templates used in Building the ZIKV NS5 homology model.
Template PDB code Query cover (%) Structural identity (%) E-value
4K6M_A 97 69 0
5CCV_A 98 67 0
2HFZ_A 67 72 0
3VWS_A 68 69 0
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Homology modeling was performed using the Mod-
eller Software version 9.1 (Eswar et al., 2006) add-on in
chimera (Yang et al., 2012), in which all three templates
were selected to build the model. Multiple sequence
alignment was performed using the CLUSTALW server
(Sievers et al., 2011), where Chain A of the full-length
Japanese Encephalitis Virus NS5 was evidenced to have
the best template with the highest identity score (Fig-
ure S1). The sequence of the target protein was uploaded
to PSIPRED V3.3 (Buchan, Minneci, Nugent, Bryson, &
Jones, 2013) in order to obtain a predicted 2D secondary
structure of the enzyme. Comparing the homolog to the
predicted 2D structure and assessment of the bond angles
and torsional strain validated the homology model. A
Ramachandran plot for the analyses of bond angles and
torsional strain was generated using Maestro (Schrodin-
ger). MolProbity (Chen et al., 2010) results showed
97.2% of all residues were in the favored regions and
99.2% of all residues were in the allowed regions, which
left a list of 7 outliers. The active-site residues were
determined using Chimera Multi-align Viewer and vali-
dated using the SiteHound-web program (Hernandez,
Ghersi, & Sanchez, 2009). The list shows that none of
the active-site residues are part of these outliers. All
results can be found in our previous article and supple-
mentary material (Figure S5) (Ramharack & Soliman,
2016). After completion of the study, the crystal structure
of the ZIKV NS5 protein was released. To validate the
homology model of the NS5, it was superimposed with
the newly released crystal structure (PDB code: 5TFR),
showing their structural similarity and validating the
model’s use for subsequent analysis (Figure 2).
2.2. System preparation
The NS5 modeled structure was separated into two
domains, being the MTase of the C-terminal and the
RNA-Dependent RdRp of the N-terminal. Experimental
drug inhibitors of flaviviruses were chosen to dock
within each domain’s active site.
2.3. Molecular docking of experimental flaviviruses
The small molecules, BG323 and Ribavirin, potent inhi-
bitors of flavivirus NS5, were chosen to dock at the
MTase site and the RdRp site, respectively (Leyssen, De
Clercq, & Neyts, 2000; Lim & Shi, 2013; Tambunan
et al., 2014).
Docking of the compounds was conducted using the
AutoDock Vina (Trott & Olson, 2010) software. The
procedure was run using the software default settings.
The grid box used to define the screening site was eluci-
dated using the AutoDock Vina functionality built into
Chimera (Pettersen et al., 2004). The gridbox size and
center parameters for the MTase were x(54, !63.23), y
(80, 56.72), and z(54, 10.22), respectively, and the RdRp
gridbox dimensions were x(40, !9.69), y(38, 20.41), and
z(40, 16.50). AutoDock Vina generated results in the
pdbqt format and the optimal geometric conformation
having the best binding energy was selected from the
ViewDock feature and saved in complex with the refer-
ence enzyme. The enzyme and ligand for each system
was prepared using Chimera (Yang et al., 2012) and
MMV molecular modeling suites (Kusumaningrum,
Budianto, Kosela, Sumaryono, & Juniarti, 2014) and
subsequently subjected to MD simulations.
2.4. Molecular dynamic (MD) simulations
The MD simulation was performed using the GPU ver-
sion of the PMEMD engine provided with the Amber 14
package. The FF14SB force field of the Amber package
(Nair & Miners, 2014) was used to describe the
complex.
ANTECHAMBER (Wang, Wang, Kollman, & Case,
2006) was used to generate atomic partial charges for
the ligands by utilizing the Restrained Electrostatic
Potential (RESP) and the General Amber Force Field
(GAFF) procedures. The Leap module of Amber 14
allowed for addition of hydrogen atoms to the systems
as well as Na+ and Cl! counter ions for neutralization.
The system was suspended implicitly within an
orthorhombic box of TIP3P water molecules such that
all atoms were within 8 Å of any box edge.
An initial minimization of 2000 steps was carried out
with an applied restraint potential of 500 kcal/mol Å2 for
both complexes. An additional full minimization of 1000
steps was further carried out by conjugate gradients
algorithm without restrain.
Figure 2. Superimposition of homology model (yellow) with
the newly released crystal structure (green-PDB code: 5TFR),
showing their structural similarity and validating the model’s
use for subsequent analysis.
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A gradual heating MD simulation from 0–300 K was
executed for 50 ps, such that the system maintained a
fixed number of atoms and fixed volume, i.e. a canonical
ensemble (NVT). The solutes within the system are
imposed with a potential harmonic restraint of 10 kcal/-
mol Å2 and collision frequency of 1.0 ps!1. Following
heating, an equilibration estimating 500 ps of the each
system was conducted, the operating temperature was
kept constant at 300 K. Additional features such as a
number of atoms and pressure were also kept constant
mimicking an isobaric–isothermal ensemble (NPT). The
systems pressure was maintained at 1 bar using the
Berendsen barostat.
The total time for the MD simulation conducted was
5 ns. In each simulation the SHAKE algorithm was
employed to constrict the bonds of hydrogen atoms. The
time step of each simulation was 2 fs and an SPFP preci-
sion model was used. The simulations coincided with
isobaric–isothermal ensemble (NPT), with randomized
seeding, constant pressure of 1 bar maintained by the
Berendsen barostat, a pressure-coupling constant of 2 ps,
a temperature of 300 K, and Langevin thermostat with
collision frequency of 1.0 ps!2.
Coordinates were saved every 1 ps and the trajecto-
ries were analyzed every 1 ps using the PTRAJ module
employed in Amber14.
2.5. Binding free energy calculations
To estimate the binding affinities of each system,
the binding free energies were calculated using the
molecular mechanics/GB surface area method (MM/
GBSA) (Genheden & Ryde, 2015). Binding free energies
were averaged over 5000 snapshots extracted from the
5 ns trajectory. The free binding energy (ΔG) computed
by this method for each molecular species (complex,
ligand and receptor) can be represented as:
Figure 3. The steps taken toward creating the pharmacophore model from the MTase–BG323 complex. The yellow circles spotlight
the pharmacophoric moieties that were chosen for the model, based on the highest contributing residues, depicted in the binding
affinity graph.
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DGbind ! Gcomplex " Greceptor " Gligand (1)
DGbind ! Egas # Gsol " TS (2)
Egas ! Eint # Evdw # Eele (3)
Gsol ! GGB # GSA (4)
GSA ! c SASA (5)
The term Egas denotes the gas-phase energy, which con-
sist of the internal energy Eint; Coulomb energy Eele, and
the van der Waals energies Evdw. The Egas was directly
estimated from the FF14SB force field terms. Solvation
free energy, Gsol, was estimated from the energy contri-
bution from the polar states, GGB and non-polar states,
G. The non-polar solvation energy, SA.
GSA, was determined from the solvent accessible sur-
face area, using a water probe radius of 1.4 Å, whereas
the polar solvation, GGB, contribution was estimated by
solving the GB equation. S and T denote the total
entropy of the solute and temperature, respectively.
To obtain the contribution of each residue to the total
binding free energy profile between the inhibitors Riba-
virin and BG323 with RdRp and MTase, respectively,
per-residue free energy decomposition was carried out at
the atomic level for imperative residues using the MM/
GBSA method in Amber 14.
2.6. Pharmacophore model creation and library
generation
The inhibitors Ribavirin and BG323 were first simulated
at the active site of RdRp and MTase respectively, for
5 ns, to create the bound conformation of the ligands.
Both these compounds have experimentally exhibited
ZIKV inhibition in in vitro and in vivo models (Mumtaz,
van Kampen, Reusken, Boucher, & Koopmans, 2016;
Sweeney et al., 2015; Zmurko et al., 2016). Per-residue
energy decomposition analysis was used to determine the
amino acids that contribute the most towards ligand
binding. The pharmacophoric moieties that interacted
with the highly contributing residues were then chosen
Figure 4. RdRp–Ribavirin complex ligplot analysis – creating the pharmacophore model to virtually screen for new RdRp potential
lead compounds. The yellow circles spotlight the pharmacophoric moieties that were chosen for the model based on the highest
contributing residues, depicted in the binding affinity graph.
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Table 2. Representation of the top three compounds bound to MTase and RdRp. The compounds, ZINC64717952 and
ZINC39563464 showed the best binding affinity to MTase and RdRp, respectively.
MTase
Compound Docked structure
ZINC64717952  G= -6.1 kcal/mol
ZINC85652269
 G= -5.4 kcal/mol
ZINC09304524  G= -5.1 kcal/mol
(Continued)




 G= -9.1 kcal/mol
ZINC39588253  G= -7.9 kcal/mol
ZINC11758496 
 G= -7.5 kcal/mol
Table 2. (Continued ).
8 P. Ramharack and M.E.S. Soliman
to construct our model. The model was then added to
ZincPharmer (Koes & Camacho, 2012), with specific
selection criteria (molecular weight of <500 Da, rotatable
bonds <6, hydrogen bond donors <5, and hydrogen bond
acceptors <10), to screen the ZINC database (Irwin &
Shoichet, 2005). Lipinski’s rule of five and toxicity
(ADMET) properties were used as filters to remove non-
drug-like hits (Lipinski, Lombardo, Dominy, & Feeney,
2012).
2.7. Structure-based virtual screening
The drug-like hits identified using our protocol were sub-
jected to SBVS. Docking was carried out to differentiate
between ligands based on the molecules’ geometric char-
acteristics that allow it to bind to the enzyme’s active site
(Forli et al., 2016). The docking calculations were per-
formed using Autodock Vina (Trott & Olson, 2010).
During docking, Gasteiger partial chargers were assigned
and the Autodock atom types were defined using the
Autodock Graphical user interface supplied by MGL
tools (Sanner, Olson, & Spehner, 1996). The docked
conformations were generated using the Lamarckian
Genetic Algorithm (Morris & Huey, 2009). The Raccoon
software was used to convert the files into a compatible
pdbqt format required for docking. The gridbox was
defined using Autodock Vina. The calculation reports for
each ligand conformation in its respective complex were
analyzed to obtain affinity energy (kcal/mol). During the
docking process, a maximum of 50 conformers was con-
sidered for each compound. After screening, molecular
docking and filtering, the ligand with the highest affinity
towards the agonist was selected from the library.
2.8. Validation of docking approach
Previous experiences have verified that docking may
result in the best geometric conformation of the docked
complex, however, short MD simulations may not be
able to maintain the stability of the complex and thus
lead to the molecules being disorientated. Thus, to vali-
date the approach applied in this study, the most favor-
able Mtase and RdRp complex was subjected to further
MDs studies (20 ns). The procedure for MDs simulation
was the same as in ‘‘MD simulations’ section and
thermodynamic calculations as ‘Binding Free Energy
Calculations’ section.
2.9. Assessment of drug likeness
The online software SwissADME was used to compute
the physicochemical descriptors as well as predict the
pharmacokinetic properties and drug-like nature of the
screened compounds compared to that of BG323 and
Ribavirin. to (Bultet et al., 2016; Daina, Michielin, &
Zoete, 2014). SwissADME utilizes the ‘Brain Or Intesti-
nal Estimated permeation (BOILED-Egg)’ method which
computes the lipophilicity and polarity of small mole-
cules (Daina & Zoete, 2016).
3. Results and discussion
3.1. Homology model and active binding site
determination
Due to the absence of a crystal structure for the Zika
NS5 enzyme, a homology model, having a zDope score
of !0.76 was generated, and validated using a ramachan-
dran plot. The active site residues were determined for
both the MTase and RdRp region (Figure S1–S3). The
comprehensive set of results are presented in our previ-
ous publication (Ramharack & Soliman, 2016). To fur-
ther validate both the MTase and RdRp, the homology
model was superimposed to the newly released crystal
structure of the Zika NS5 (Figure 2), using Chimera
(Pettersen et al., 2004).
Figure 5. The Cα RMSF of MTase–BG323 and MTase–
ZINC64717952 during the molecular dynamic simulation.
Table 3. The comparison of MTase’s binding affinity with BG323 and ZINC64717952.
Energy components (kcal/mol)
Compound ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind
BG323 !33.32 ± 1.82 !11.84 ± 1.68 !49.16 ± 1.86 20.83 ± 1.80 !28.33 ± 1.87
ZINC64717952 !35.77 ± 2.66 !10.47 ± 2.68 !46.24 ± 3.97 19.74 ± 2.14 !26.50 ± 3.14
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3.2. PRED pharmacophore model
In this study, a pharmacophore hypothesis was adopted
by utilizing per residue decomposition energy-based
approach. The structural features of a protein as well as
the chemical characteristics of a ligand are employed
in the construction of a pharmacophore model. To gener-
ate the pharmacophore model, a 5 ns MD simulation
was run on complexes (MTase–BG323) and (RdRp–
Ribavirin), followed by PRED computed from MM/
GBSA calculations. The MM/GBSA approach has
proven to be, in principle, accurate in both scoring
function and binding free energy results (Genheden &
Ryde, 2015; Hayes, 2009). This allows for improved
pharmacophore modeling and thus the generation of a
concise library of small molecules. The MTase–BG323
complex showed His104 (!2.176 kcal/mol), Glu143
(!1.846 kcal/mol), Thr210 (!1.192 kcal/mol), and
Lys176 (!1.061 kcal/mol) to be the highest contributing
residues to interact with the ligand. Strong hydrophobic
interactions were formed between Glu143 and the ben-
zene ring of BG323, while, energetically favorable resi-
due, Asp140, formed hydrogen bonds with the terminal
hydroxyl groups of the ligand (Figure 3).
Hydrogen bonds between the RdRp–Ribavirin com-
plex included residues Asn444 (!1.296 kcal/mol) and
His460 (!0.956 kcal/mol), while the contributing resi-
dues; namely, GLU573 (!1.521 kcal/mol), TRP576
(!1.744 kcal/mol) and Cys577 (!2.202 kcal/mol) were
involved in hydrophobic interactions with the ligand.
The features from each complex were used as a query
on ZINCpharmer (Koes & Camacho, 2012) to create the
PRED-based pharmacophore (Figure 4). Results revealed
18 hits obtained from the MTase–BG323 pharmacophore
and 23 hits from the RdRp–Ribavirin pharmacophore.
Figure 6. MTase–ZINC64717952 complex interactions (A) Per-residue decomposition analysis showing Arg51 and Glu105 to have
the greatest bond fluctuations (B) Ligplot depiction of hydrophobic and hydrogen bond interactions in the complex which was
validated by (C) The time evolution of RMSD of the C-alpha atom backbone of the MTase–ZINC64717952 complex.
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3.3. Molecular docking
To further refine and reduce false positives retrieved
from the hit compounds, the hits for each complex were
subjected to molecular docking within the actives sites
of MTase (18 hits) and RdRp (23 hits). This assessed
their geometric feasibility at each domain, leading to
only three top ranked compounds (Table 2). Based on
the interactions and binding affinities of the respective
three top-ranked compounds to MTase and RdRp,
ZINC64717952 and ZINC39563464 were chosen as
respective top hits. Each complex was subsequently sub-
jected to MD studies to elucidate on the enzyme–ligand
interactions of the two potential inhibitors under virtual
conditions.
3.4. MD simulations and binding free energy analysis
The MTase–ZINC64717952 and RdRp–ZINC39563464
complexes were subjected to a 20 ns MD simulation in
order to check the convergence dynamic stability and to
analyze the energetics of each complex. The RMSD pro-
files of the MTase-complex and RdRp-complex indicate
that both systems were stable during the simulation
(Figures 6(C) and 7(C)).
Figure 7. RdRp–ZINC39563464 complex interactions (A) Per-residue decomposition analysis showing Arg459 and Glu435 to have
the greatest bond fluctuations, (B) Ligplot depiction of hydrophobic and hydrogen bond interactions in the complex which was
validated by (C) The time evolution of RMSD of the C-alpha atom backbone of the MTase–ZINC39563464 complex.
Table 4. The comparison of RdRp’s binding affinity with Ribavirin and ZINC39563464.
Energy components (kcal/mol)
Compound ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind
Ribavirin !23.20 ± 3.13 !40.92 ± 13.03 !64.12 ± 13.34 47.59 ± 9.93 !16.53 ± 4.84
ZINC39563464 !38.17 ± 5.39 !17.32 ± 5.99 !55.49 ± 8.85 30.45 ± 4.85 !25.04 ± 5.35
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3.4.1. MTase–ZINC64717952 Complex
The docked MTase–ZINC64717952 complex showed
ionic interactions involving seven residues common to
MTase–BG323 (Glu143, Arg207, Lys176, Thr210,
Ile141, Asp140, and Gly142). Interestingly, however, a
hydrogen bond was noted between the nitrogen of Arg35
and the aromatic ring of ZINC64717952, this was pecu-
liar, as Arg35 was not involved in any ionic interactions
of the MTase–BG323 complex. The MTase–
ZINC64717952 complex used Asp140 as a hydrogen
bond acceptor, whereas, the MTase–BG323 complex
depicted hydrophobic interactions between Asp140 and
the benzene ring of BG323. These ionic bond deviations
between systems may be due to the size of
ZINC64717952 in comparison to BG323.
ZINC64717952 was significantly reduced in size, con-
taining predominantly the heterocyclic rings from the
pharmacophore model. Due to the size of
ZINC64717952, the nitrogen of aromatic ring was
allowed to form a hydrogen bond with the amine group
(Arg35) further into the hydrophobic pocket of MTase.
Docking results showed the same binding affinity in both
complexes, however, receptor residue stability showed
increased fluctuations in the ZINC64717952–MTase
complex compared to the experimental complex
(Figure 5). The overall compactness of the receptor was
measured by the radius of gyration (around the C!
atoms) and was indicative of greater fluctuations of the
MTase–ZINC64717952 complex compared to the experi-
mental complex (Figure S6), verifying the root mean
square fluctuations (RMSF) seen in Figure 5. Although
ZINC64717952 docked in a structurally favorable man-
ner, MM/GBSA analysis showed free binding energy of
the MTase–BG323 complex (!28.70 kcal/mol) to be
higher in magnitude than that of MTase–ZINC64717952
(!26.50 kcal/mol).
The tetrazole aromatic ring in ZINC64717952 contains
highly active nitrogen atoms, increasing electronegativity
and steric hindrance (Ostrovskii, Trifonov, & Popova,
2012). The Generalized Borne (GB) method is used to cal-
culate the molecular electrostatic forces in solvent. Table 3
shows ZINC64717952 to have elevated columbic energy,
thus leading to increased gas-phase energy, validating the
free energy analysis (Figure 6(A)) (Genheden & Ryde,
2015). This, however, does not rule-out the possibility of
ZINC64717952 as a potential inhibitor of the MTase
enzyme as the intermolecular forces between the receptor
and ligand were favorable. This study will have to be
evaluated in vitro, where the further analysis may reveal
the inhibitory potential of the compound.
3.4.2. RdRp–ZINC39563464 complex
The docked RdRp–ZINC39563464 complex showed
ZINC39563464 to interact with nitrogen atoms of two
residues; Asn444 and His460. Notably, the nitrogen
atoms from the same residues form hydrogen bonds with
the terminal oxygen of the Ribavirin, showing consistent
residue interactions of the experimental ligand and
ZINC39563464. These hydrogen interactions are formed
from non-covalent bonding of the hydrogen donor
(Asn444 and His460) with the acceptors (oxygen and
nitrogen) of the ligand. This articulates the directionality
and specificity of the active site’s "-strand recognition of
both Ribavirin and ZINC39563464. The complex
exhibiting a relatively stable RMSD profile during the
simulation further validated this (Figure 7(C)). The phar-
macophoric hot spot residue, His442, formed hydropho-
bic bonds with the aromatic rings of both Ribavirin and
ZINC39563464. It is noteworthy that four other
hydrophobic-interacting residues; Cys577, Tryp576,
Glu573 and Glu435 were common to both ligands, thus
stabilizing both energetically favorable ligands in the
available hydrophobic pocket. Table 4 depicts the analy-
sis of binding free energy by the use of MM/GBSA of
the RdRp–ZINC39563464 complex was used to support
the docking results.
The predicted binding free energy for the complex
was !25.04 kcal/mol, which is considerably higher in
magnitude than that achieved by the RdRp–Ribavirin
complex (!16.53 kcal/mol), thus confirming the docking
results and indicating a stronger binding of
ZINC39563464 to RdRp compared to the experimental
ligand (Figure 7(A) and (B)). The relatively large size of
the ligand could explain the increased number of resi-
dues encompassing apparent hydrophobic interactions
with ZINC39563464, and could substantiate the
exhibition of stable RdRp residues by RMSF profiling
Figure 8. The stable C! RMSF of RdRp–Ribavirin
and RdRp–ZINC39563464 during the molecular dynamic
simulation.
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(Figure 8). As an additional check, the radius of gyration
(Rg of the C! atoms) was compared in both simulations
to provide a measure of overall compactness of the pro-
tein (Figure S6). The fluctuations of Rg stayed with 1 Å
in both simulations indicative of a stable protein com-
plex with both experimental and screened compound.
3.4. Assessment of drug likeness
Ribavirin has a plethora of side effects including throm-
bocytopenia, myalgia, leucopoenia, and cognitive impair-
ment (Hinton et al., 2016; Kryger, Wohl, Smith, &
Zelikin, 2013; Munir et al., 2010). This proves to be a
challenge when trying to inhibit a virus that already
causing these symptoms. BG323 is a new compound that
has been proven to have potent effects on flavivirus NS5
proteins, however, the compound is unable to pass the
blood–brain barrier, making it difficult to act on ZIKV-
targeted neuronal cells (Miner & Diamond, 2016; Tang
et al., 2016). The possible pro-drugs of ribavirin and
BG323, being, ZINC39563464 and ZINC64717952,
respectively, can be described as potential lead com-
pounds after assessment through SwissADME (Table 5)
(Bultet et al., 2016).
4. Conclusion
ZIKV is a rapidly evolving virus that has had detrimental
long-term effects over a very short period of time. This
study proposes two new compounds that have shown
promising physicochemical properties and strong interac-
tions with ZIKV MTase and RdRp, thus validating the
PRED model as an effective strategy to enhance typical
virtual screening methods for the rapid identification of
potential lead compounds as inhibitors against patho-
genic biological targets such as ZIKV. This strategic in
silico technique will serve as a beneficial tool to enhance
drug discovery and decrease excessive wastage of finan-
cial and experimental resources by synthesizing large
numbers of compounds that may not be beneficial in the
inhibition of target enzymes. The lead compounds,
ZINC64717952 and ZINC39563464, have shown sub-
stantial stability in complex with the target enzymes and
thus further experimental analysis is necessary for effi-
cacy and toxicity validation.
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Delving into Zika virus structural dynamics –
a closer look at NS3 helicase loop flexibility
and its role in drug discovery†
Pritika Ramharack,a Sofiat Oguntadea and Mahmoud E. S. Soliman *abcd
The Zika virus has emerged as a pathogen of major health concern. The rapid spread of the virus has led to
uproar in themedical domain as scientists frantically race to develop effective vaccines and small molecules
to inhibit the virus. In the past year, there has been a flood of Zika knowledge published including its
characteristics, transmission routes and its role in disease conditions such as microcephaly and Gullian–
Barŕe syndrome. Targeted therapy against specific viral maturation proteins is necessary in halting the
replication of the virus in the human host, thus decreasing host–host transmission. This prompted us to
investigate the structural properties of the Zika NS3 helicase when bound to ATP-competitive inhibitor,
NITD008. In this study, comparative molecular dynamic simulations were employed for APO and bound
protein to demonstrate the molecular mechanism of the helicase. Results clearly revealed that
NITD008-binding caused significant residue fluctuations at the P-loop compared to the rigid nature of
the APO conformation. The NITD008-helicase complex also revealed residues 339–348 to transition
from a 310-helix to a stable a-helix. These protein fluctuations were verified by investigation of dynamic
cross correlation and principal component analysis. The fundamental dynamic analysis presented in this
report is crucial in understanding Zika NS3 helicase function, thereby giving insights toward an inhibition
mechanism. The information reported on the binding mode at the ATPase active site may also assist in
designing effective inhibitors against this detrimental viral target.
1 Introduction
The re-emerging Zika virus (ZIKV) has evolved into a cata-
strophic epidemic over the past year, with scientic community
announcing that the long-term effects associated with the virus
will have to be dealt with in the decades to follow.1 The virus was
declared an international public health emergency by the World
Health Organization,2 based on growing evidence of the virus
being linked with congenital neurological diseases such as
Guillain–Baŕre, cranial nerve dysfunction and microcephaly.3,4
The ZIKV made its devastating re-appearance in Brazil and has
now spread on a global scale, with an estimated 75 countries
with reported mosquito-borne ZIKV transmission as of
December 2016.5
Zika virus is an arthropod-borne Flavivirus initially discov-
ered in the Zika forest area of Uganda in 1947.6 Of the Flavivirus
genera, ZIKV is most closely related to the Spondweni virus
from the Spondweni group; however, ZIKV shares structural
similarities with other Flaviviruses, including Dengue virus and
West Nile virus.7 The ZIKV genome is made up of structural
proteins, being the capsid, precursor membrane and envelope
form the viral particle and seven non-structural proteins, being
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, which participate
in the replication of the RNA genome, virion assembly and
invasion of the innate immune system.8–10 In our previous
review, we explicated on the key viral target proteins, including
the multifunctional viral replication NS3 helicase protein.11 The
ZIKV helicase comes from the superfamily helicases, SF2,12 with
the inhibition of either one of the binding sites, the RNA-
binding groove or the ATP-binding site (Fig. 1), leading to the
virus becoming incapable of sufficient maturation and repli-
cation. The structural characteristics of the ZIKV NS3 protein
includes three domains: domain I (residues 182–327), domain
II (residues 328–480) and domain III (residues 481–617), as well
as a P-loop (residues 196–203) which is located at the ATP-
binding site of domain I.12,13
The co-crystallization of MnATP2! and RNA with ZIKV heli-
case, reported by Tian et al. (2016) and Cao et al. (2016), have
paved the way to understanding the mechanism by which these
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substrates bind to the enzyme, initiating viral RNA replica-
tion.14,15 Despite the ood of integrated knowledge on ZIKV over
the past year, the molecular and structural mechanism for
helicase inhibition is yet to be established.12
Another battle being fought by researchers is the discovery of
new modes of transmission of the virus, from initially being
transmitted from vector to host, to now being inclusive of blood
transfers from host to host as well as secondary sexual trans-
mission.16–18 This has allowed for rapid diffusion of the virus
between continents. In the plethora of strategic characteristics
of the virus, its ability to target neuronal cells has been one of
the most problematic tasks that pharmaceutical chemists have
had to overcome.19–24 The design of ZIKV inhibitors will not only
need to be target-specic, effective and have minimal toxicity,
but it will also have to pass through the blood-brain-barrier.25
Although there are currently vaccine clinical trials under
way, there are still no FDA approved small molecule inhibitors
against the virus.26–30 This may be due to a number of reasons
including time-consuming experimental testing of large
libraries of compounds or minimal literature available on the
functionality of the virus in host cells. These possible barriers
have prompted us to utilize computational drug design tools,
such as molecular dynamic (MD) simulations to explore the
conformational landscape of this biological system's ATP-
binding region. The crystallographic structures have revealed
evidence of residue mobility, including the rotation of motor
domains, however, the precise structural characteristics of the
helicase upon small molecule binding, is yet to be
determined.12,31–36
In this study we investigate the conformational changes at
the ATP-binding region aer a 130 ns MD simulation of the free
enzyme state as well as a NITD008-bound complex.37 This study
will be critical in understanding how the ZIKV NS3 helicase




The ZIKV NS3 helicase in complex with ATP and a magnesium
ion (PDB code: 5GJC)14 was obtained from RSCB Protein Data
Bank.38 The 3-D structure of the experimental ZIKV inhibitor,
NITD008, was obtained from PubChem39 and prepared on
Molegro Molecular Viewer (MMV).40 In the ZIKV crystal struc-
ture of the ATP-bound helicase, residues A247-S253 were
absent, thus the free enzyme (PDB code: 5JMT)13 was utilized in
the docking of NITD008. Deng et al. (2016) reported conclusive
in vivo evidence of the inhibition of ZIKV by NITD008. The
compound is classied as an adenosine nucleoside analog that
competitively inhibits ATP, thus sharing an active site.37
Fig. 1 Cartoon and surface representation of the three domains of the ZIKV helicase and the two active-binding regions (yellow) that form
profound hydrophobic cavities in the electrostatic surface area, allowing ATP and ssRNA to bind.





















































































Molecular docking is a conventional method in computational
chemistry which is utilized in the prediction optimized
geometric conformations of a ligand within an appropriate
binding site.41 The molecular docking soware utilized
included Raccoon,42 Autodock Graphical user interface
supplied by MGL tools43 and AutoDock Vina44 with default
docking parameters. Prior to docking, Gasteiger charges were
added to NITD008 and the non-polar hydrogen atoms were
merged to carbon atoms. Water molecules were removed and
polar hydrogen was added to the crystal structure of the NS3
helicase. NITD008 was then docked into the ATPase binding
pocket of the NS3 helicase (by dening the grid box with spacing
of 1 Å and size of 32 ! 26! 30 pointing in x, y and z directions).
Due to the lack of experimental data describing ZIKV approved
inhibitors, validation of molecular docking based on the lowest
energy pose becomes unreliable.45 To overcome any experi-
mental bias, the ve best conformational poses, based on
binding affinities (kcal mol"1), were subjected to MD
simulations.
2.3 Molecular dynamic (MD) simulations
Molecular dynamic (MD) simulations provide a robust tool to
explore the physical movements of atoms and molecules, thus
providing insights on the dynamical evolution of biological
systems. The MD simulation was performed using the GPU
version of the PMEMD engine provided with the AMBER
package, FF14SB variant of the AMBER force eld46 was used to
describe the protein.
ANTECHAMBER was used to generate atomic partial charges
for the ligand by utilizing the restrained electrostatic potential
(RESP) and the General Amber Force Field (GAFF) procedures.
The leap module of AMBER 14 allowed for addition of hydrogen
atoms, as well as Na+ and Cl" counter ions for neutralization to
both the APO- and bound system.
Both systems were then suspended implicitly within an
orthorhombic box of TIP3P water molecules such that all atoms
were within 10 Å of any box edge.
An initial minimization of 2000 steps was carried out with an
applied restraint potential of 500 kcal mol"1 Å"2 for both
solutes, were performed for 1000 steps using a steepest descent
method followed by a 1000 steps of conjugate gradients. An
additional full minimization of 1000 steps was further carried
out by conjugate gradient algorithm without restrain.
A gradual heating MD simulation from 0 K to 300 K was
executed for 50 ps, such that the system maintained a xed
number of atoms and xed volume, i.e., a canonical ensemble
(NVT). The solutes within the system are imposed with
a potential harmonic restraint of 10 kcal mol"1 Å"2 and colli-
sion frequency of 1.0 ps"1. Following heating, an equilibration
estimating 500 ps of the each system was conducted; the
operating temperature was kept constant at 300 K. Additional
features such as a number of atoms and pressure where also
kept constant mimicking an isobaric–isothermal ensemble
(NPT). The systems pressure was maintained at 1 bar using the
Berendsen barostat.
The total time for the MD simulation conducted was 130 ns.
In each simulation the SHAKE algorithm was employed to
constrict the bonds of hydrogen atoms. The step size of each
simulation was 2 fs and an SPFP precision model was used. The
simulations coincided with isobaric–isothermal ensemble
(NPT), with randomized seeding, constant pressure of 1 bar
maintained by the Berendsen barostat, a pressure-coupling
constant of 2 ps, a temperature of 300 K and Langevin ther-
mostat with collision frequency of 1.0 ps"2.
2.4 Post-dynamic analysis
The coordinates of the free enzyme and NITD008 complex were
each saved every 1 ps and the trajectories were analyzed every 1
ps using PTRAJ, followed by analysis of RMSD, RMSF and radius
of gyration using the CPPTRAJ module employed in AMBER 14
suit.
2.4.1 Binding free energy calculations. Binding free energy
calculations is an important end point method that may eluci-
date on the mechanism of binding between a ligand and
enzyme, including both enthalpic and enthropic contribu-
tions.47 To estimate the binding affinity of the docked systems,
the free binding energy was calculated using the Molecular
Mechanics/GB Surface Area method (MM/GBSA).48 Binding free
energy was averaged over 15 000 snapshots extracted from the
130 ns trajectory. The free binding energy (DG) computed by
this method for each molecular species (complex, ligand and
receptor) can be represented as:
DGbind # Gcomplex " Greceptor " Gligand (1)
DGbind # Egas + Gsol " TS (2)
Egas # Eint + EvdW + Eele (3)
Gsol # GGB + GSA (4)
GSA # gSASA (5)
The term Egas denotes the gas-phase energy, which consist of
the internal energy Eint; Coulomb energy Eele and the van der
Waals energies EvdW. The Egas was directly estimated from the
FF14SB force eld terms. Solvation free energy, Gsol, was esti-
mated from the energy contribution from the polar states, GGB
and non-polar states, G. The non-polar solvation energy, SA.
GSA, was determined from the solvent accessible surface area
(SASA), using a water probe radius of 1.4 Å, whereas the polar
solvation, GGB, contribution was estimated by solving the GB
equation. S and T denote the total entropy of the solute and
temperature respectively.
To obtain the contribution of each residue to the total
binding free energy prole at the ATPase site, per-residue free
energy decomposition was carried out at the atomic level for
imperative residues using the MM/GBSA method in AMBER 14
suit.
The system displaying the most favorable binding interac-
tion and energy contributions were subjected to further
analysis.




















































































2.4.2 Dynamic cross-correlation analysis (DCC). Dynamic
cross correlation is a widespread method in MD simulations in
which the correlation coefficients of motions between atoms of
a protein may be quantied.49 The dynamic cross correlation
between the residue-based uctuations during simulation was
calculated using the CPPTRAJ module incorporated in AMBER












The cross-correlation coefficient (Cij) varies within a range of
"1 to +1 of which the upper and lower limits correspond to
a fully correlated and anti-correlated motion during the simu-
lation process. Where, i and j stands for ith and jth residue
respectively and Dri or Drj represents displacement vectors
correspond to ith and jth residue respectively. The generated
dynamic cross correlation matrix was constructed in Origin
soware.
2.4.3 Principal component analysis (PCA). Principal
component analysis (PCA) is a covariance-matrix-based mathe-
matical technique that is able to demonstrate atomic
displacement and the loop dynamics of a protein.50 Prior to
processing the MD trajectories for PCA, the trajectories of the
free enzyme (APO) and the NITD008-bound complex (complex)
were stripped of solvent and ions using the PTRAJ module in
AMBER 14. The stripped trajectories were then aligned against
their corresponding fully minimized structures. PCA was per-
formed for C-a atoms on 900 snapshots each. Using in-house
scripts, the rst two principal components were calculated
and the covariance matrices were generated. The rst two
principal components (PC1 and PC2) generated from each
trajectory were averaged for both the free-enzyme and NITD008-
complex. The rst two principal components (PC1 and PC2)
were computed and a 2 # 2 covariance matrix were generated
using Cartesian coordinates of Ca atoms. PC1 and PC2 corre-
spond to rst two eigenvectors of covariant matrices. Origin
soware51 was used to construct PCA plots.
3 Results and discussion
3.1 NITD008–NS3 helicase complex
3.1.1 Binding of NITD008 with ZIKV helicase. Research
into ZIKV inhibitors has been minimal before 2016. However,
NITD008, a Flavivirus adenosine analogue was evidenced, both
in vitro and in vivo, to inhibit ZIKV replication. The adenosine
nucleoside analogue competes with natural ATP substrates,
which are incorporated into the growing RNA chain. By this
substitution, NITD008 is incorporated into the RNA chain, thus
terminating the RNA elongation and inhibiting ZIKV
maturation.37
Molecular docking has become a major computational tool
that is used to predict the orientation of a ligand at a binding
site on the receptor. Results from docking oen display
multiple predicted orientations of the ligand within the active
pocket.52
In this study, NITD008 docked at the ATP-binding site in 6
favorable conformations (Fig. S2–S6†), with the highest
binding-affinity being "8.2 kcal mol"1. Scoring functions oen
attempt to reproduce experimental binding affinities, but most
soware do not always yield the best prediction. Validation of
the docked structure with experimentally known drugs was also
not possible due to the lack of FDA inhibitors against
ZIKV.45,53,54
In an attempt to improve the binding affinity prediction of
NITD008, all 6 predicted complexes were subjected to 130 ns
molecular dynamic simulations, allowing for more realistic
receptor exibility in an implicit solvent. Each complex was
then analyzed using the accurate, MM/GBSA, free binding
energy calculation to determine the most favorable pose of
NITD008 at the NS3 ATPase active site.47,55–57
3.1.2 Free energy calculations. The total binding free
energy for each of the 6 poses of the NITD008–NS3 helicase
complex were calculated using the MM/GBSA approach to better
understand the various energy contributions within the binding
pocket and assess which binding pose would show the most
favorable intermolecular interactions at the helicase active site.
Per residue decomposition analysis was also assessed and the
residue–ligand interaction network of each pose were depicted
as “ligplot”maps (Fig. S2–S6†). Of the six systems, the pose with
the highest docking score, "8.2 kcal mol"1, showed the most
favorable free binding energy ("55.90 kcal mol"1) supported
the molecular docking score, indicating a favorable structural
pose of NITD008 at the binding site.
The thermodynamic energy contribution of NITD008 to the
total binding free energy of the complex surmounts to the
stability of NITD008 in the ATP binding pocket and thus the
stability of the complex during the simulation. Table 1
summarizes the free binding energy of the system taking into
account the energies of the NS3 helicase and NITD008.
Fig. 2 represents the residue interaction plot of NITD008
within the active site. The active site residues Gly199, Lys200
Table 1 Summary of free binding energy contributions to the NITD008–NS3 helicase system
Energy components (kcal mol"1)
DEvdW DEelec DGgas DGsolv DGbind
ZIKV helicase "3429.35 $ 30.09 "28 758.51 $ 159.37 "32 187.86 $ 155.05 "5121.93 $ 115.09 "37 309.79 $ 71.27
NITD008 "4.69 $ 0.85 18.12 $ 5.27 13.43 $ 5.28 "221.12 $ 3.35 "207.68 $ 3.72
Complex "37.71 $ 4.12 "382.94 $ 28.72 "420.64 $ 28.59 364.75 $ 22.80 "55.90 $ 7.71




















































































and Glu286 formed stable hydrogen bonds with highly elec-
tronegative oxygen atoms of NITD008. The residues pocketing
NITD008 within the active site included Gly197, Ala198, Gly199,
Lys200, Thr201, Arg202, Glu288, Gly415, Asn417 and Arg456.
It was also interesting to note that the most favorable
NITD008-pose shared ve active residues with the ATP-bound
helicase reported by Tian et al. (2016). The crystal structure of
the ATP-bound helicase showed Lys200 to stabilize the
triphosphate of the ATP.14 The Lys200 of the NITD008-bound
helicase showed a similar stabilizing hydrogen bond with the
terminal hydroxyl group located on the ribose of NITD008.
Superimposition of NITD008-docked NS3 helicase with the
ATP–NS3 helicase complex demonstrated both compounds to
bind in a hydrophilic conformation despite the carbon and
acetylene substitutions at N-7 of the purine and the 20 position
of the ribose, respectively (Fig. 3).
Fig. 2 Energy contributions of the highest interacting residues at the ATPase active site. The residue ligand interaction network illustrates
stabilizing hydrophobic interactions pocketing NITD008 at the active site. The highest energy contribution was a hydrogen bond interaction
shared between Glu286 and the 3rd oxygen of the ribose component of NITD008.
Fig. 3 Superimposed conformation of structurally similar NITD008 and ATP docked at ATPase site of ZIKV NS3 helicase.




















































































The structural similarities between NITD008 and ATP, as
well as the active site residue interactions and accurate free-
binding energy prompted the further analysis of NITD008-
complex.
3.2 Systems stability
The length of a MD simulation is paramount when establishing
insights into the structural dynamics of a biological system.
With an extended simulation time, a system is able to reach
convergence, thus becoming stable. To assure the equilibration
of the simulation, the potential energy and temperature where
monitored (Fig. S1†). The average potential energy (!145 774
kcal mol!1) was measured at 300 K, suggesting a stable
conformation at this temperature.
3.2.1 Stability of NS3 helicase APO and bound system. The
C-a backbone root mean square deviations (RMSD) were
monitored throughout the 130 ns MD simulation for both the
free (APO) enzyme and the complex. Both systems reached
convergence aer 60 ns (RMSD deviation < 2 Å). It can be noted
that the C-a backbone atoms in both systems stabilized aer
a 40 ns time period, although, uctuations in rigidity did
increase during the 47–52 ns period in the NITD008 complex
(Fig. 4). This could possibly be due to the occurrence of
conformational changes because of the bond interactions
taking place between NITD008 and the active site residues as
seen in the per-residue energy decomposition.
3.2.2 Conformational uctuations of the NS3 helicase. To
better understand the structural changes that may be occurring
upon ligand binding, the root mean square uctuation (RMSF)
of the C-a atoms of each residue in the APO system and
NITD008-complex were calculated. Fig. 5 clearly demonstrates
greater exibility of residues of the NITD008-complex when
compared to the APO enzyme. Fluctuations take place between
residues 198–204, which form distinct hydrophobic and
hydrogen bond interactions with NIT008D at the active site.
This region, the P-loop, is found in all Flavivirus helicases and
has been shown to have exibility during binding of ATP.14 The
P-loop adopts structural modications to accommodate the
binding of ATP and Mn2+. This exibility extends greatly in
comparison to the APO enzyme, thus verifying ZIKV P-loop
exibility upon ligand-binding. Other uctuations occurred in
domain II, and I around the ATP-active site, at residues 244–248
and 325–348.
Fig. 4 C-a backbone RMSD for NS3 helicase APO enzyme and NITD-
complex conformation. The average C-a RMSD was calculated to be
3.62 Å and 3.77 Å, respectively. Increased fluctuations occurred at 47–
52 ns in the NITD008-complex.
Fig. 5 The RMSF of APO enzyme and NITD008-complex. The
structural flexibility in domain I and II is highly attributed to the binding
of NITD008 to the ATP-active site. This is substantiated by the average
RMSF of the NITD008-complex (2.17 Å), which is significantly higher
than that of the APO enzyme (1.90 Å).
Fig. 6 The radius of gyration (Rg) plot illustrating the difference in
enzyme compactness of the NITD008-complex compared to the APO
enzyme.




















































































3.2.3 Distribution of atoms around the NS3 helicase
backbone. The radius of gyration around the C-a atoms can
measure the shape and folding of NS3 helicase before and aer
NITD008 binding. The radius of gyration measures the distri-
bution of atoms from the center of mass (COM), thus indicating
how compact a system is. Both the APO (22.05 Å) and NITD008
(22.17 Å) showed very similar structural compactness, however,
there was an atomic distribution in the NITD008-complex from
40–58 ns (Fig. 6). This correlates with the escalated instability of
the complex at 47–52 ns demonstrated in the RMSD plot.
The exibility calculated from the RMSD, RMSF and Rg
encouraged us to explore the dynamic structural modications
of the NS3 helicase aer NITD008 binding.
3.3 Investigation of the dynamic structural features ATP-
active binding region
3.3.1 Loop exibility and distance metrics. The ZIKV NS3
helicase is made up of three known exible loops that are
common to all Flaviviruses: the P-loop (residues 196–203), the
RNA-binding loop (residues 244–255) and the b-hairpin loop
(residues 431–444). These loops may vary in size depending on
the type of virus; however, they all have the same fundamental
structural exibility. The RMSF plot demonstrated major uc-
tuations at the P-loop as well as the RNA-binding loop, the b-
hairpin loop however, showed no signicant conformational
change compared to the APO enzyme. The plot also illustrated
a exible “325–338” region. Fig. 7 depicts three snapshots of the
Fig. 7 Structural flexibility of the P-loop (196–203), RNA-binding loop (244–255), and the 310 helix (339–348) along the trajectory. The RNA-
binding loop (orange) showed the loop shifting down in the APO structure but an upward shift in the NITD008-helicase complex. The P-loop
(yellow) shifted away from the active site in the bound complex but closed in on the active site when no ligand was present. In the APO structure,
the helix-loop-helix stayed, with vibrational movement during the simulation, although, in the bound complex, the 310 helix (pink) was modified
into a a-helix due to ligand motional shifts further into the hydrophobic pocket.




















































































APO enzyme and NITD008-complex, taking at different intervals
along the trajectory. Clear conformational shis are illustrated
along the trajectory in both APO and bound systems.
To further investigate the conformational changes of the NS3
helicase upon ligand binding, dynamic cross-correlation matrix
(DCCM) analysis was performed at different conformational
positions of the Ca backbone atoms of the free protein and
ligand-bound complex. Highly correlated motions of residues
are represented in the red to yellow regions, whereas, the
negative/anti-correlated movements of residue Ca atoms are
represented by blue-navy regions. It is evident from the corre-
lation map that more globally correlated motion is observed in
the case of the free protein, conrming conformational shis
aer ligand binding. The latter residues of the NS3 helicase,
being residues 500–600, displayed anti-correlated movements
in both the APO and bound complex, supporting the residue
uctuations in Fig. 5. Fig. 7 also depicts anti-correlation
motions at residues “340–390”, which may be explained by
the snapshots, in which, the exible region in the NITD008-
bound complex was converted from a 310-helix to a a-helix.
The P-loop clearly illustrates that when NS3 helicase is in its
APO form and exposed to a 130 ns simulation, the P-loop closes
on the active site by uncoiling the a-helix at Arg203 to form part
of the loop. The loop tip (Ala198) and the adjacent catalytic
residue (Gly451) had an average distance of 9.71 Å compared to
the NITD008-complex distance of 12.75 Å, whereby, as NITD008
becomes more stable at the active site and forms bond inter-
actions, the P-loop is directed away from NITD008 and a larger
Fig. 8 Residue fluctuations at the P-loop region. The APO enzyme illustrates closing of the loop at the active site due to a vacant hydrophobic
pocket. Subsequent to ligand binding and the initiation of stabilizing hydrogen and hydrophobic bond interactions, the P-loop shifts down to
accommodate the ligand, thus increasing the size of the hydrophobic pocket.




















































































catalytic space becomes available for the ligand as it forms
stable hydrophobic interactions deeper within the hydrophobic
pocket (Fig. 8).
The “325–348” region demonstrates opposing conforma-
tional modications between the APO and complex systems
compared to that of the P-loop. The distance between the two
catalytic residues from the loop tips; residue Ser324 and residue
Asn448, measured for the APO and NITD008-complex was 6.34
Å and 8.34 Å, respectively (Fig. 9). The NITD008-complex had
a greater distance between the residues due to the unraveling of
2 b-sheets found in domain II. This led to a “325–338” loop shi
behind the active site and the “339–348” region being modied
from a 310 helix to a a-helix (Fig. 7). The 310 helix conversion
could be due to many reasons including changes in pH, inter-
actions with other proteins and in this case, ligand binding. The
ligand–protein interactions lead to distances between nitrogen
and oxygen atoms from the protein backbone to uctuate and
as NITD008 moved further into the hydrophobic pocket, these
uctuations and hydrogen bond conversions caused the 310
helix to convert to an a-helix. These changes are important in
illustrated the conformational uctuations upon ligand
binding.
3.3.2 Principal component analysis. Conformational tran-
sitions of the free protein and NITD008-bound complex were
characterized using PCA, a technique that has been widely
employed to present experimentally detected conformational
variations. Fig. 10 highlights the motional shis across two
principle components in the case of NITD008-bound and
unbound NS3 helicase. It is evident that eigenvectors computed
from the respective simulations varied immensely between the
Fig. 9 Residue fluctuations at the “325–348” region. The APO enzyme illustrates widening of the loops of the APO enzyme. The rear loop shifts
down as the P-loop closes in on the active site. The largest fluctuation is seen after system stabilization at 40–60 ns. The NITD008-helicase
enzyme shows instability in both loops throughout the simulations, although, there was no widening of the loops as the rear loop shifted back
rather than downward movement seen in the APO system.




















































































two systems, further elaborating on the dynamic conforma-
tional uctuations from free to ligand-bound protein. The
unbound system shows restricted structural motions of residue
Ca atoms, whereby the NITD008-bound system shows a larger
spatial occupancy, thus substantiating the rigidity of the
unbound system. This corresponds with the stability of the
systems, illustrating greater distribution of the atoms around
the center of mass and the system stability deviations for the
NITD008-bound system. Correlation from analysis of both the
free and bound protein demonstrates structural loop exibility
aer binding of NITD008 to the ATPase active site.
4 Conclusion
The detailed MD analyses provided in this report demonstrate
the structural alterations in ZIKV NS3 helicase loop exibility
subsequent to binding of potent inhibitor, NITD008.37 Molec-
ular simulations revealed profound motional shis of the ZIKV
P-loop at the ATPase active site. This exibility was revealed in
the RMSF analysis and veried by graphical investigation of the
loop at different time intervals during the simulation. Investi-
gation into the dynamic cross-correlation of the unbound and
bound systems as well as a plot of conformational poses along
the rst two principal components resulted in strongly signi-
cant structural exibility of the NITD008–NS3 helicase system
compared to the rigid unbound protein. The P-loop has
demonstrates similar motional shis in other Flaviviruses as
well as in ZIKV, when natural substrate, ATP binds at the active
site. The competitive inhibitor, NITD008, has been proven to
effectively constrain ZIKV replication both in vitro and in vivo.
Complex stability measured through the 130 ns simulation
showed consistency of NITD008 at the ATPase active site and
binding free energy calculations and residue–ligand networks
revealed strong stabilizing hydrophobic and hydrogen bond
interactions pocketing NITD008 in the active site. Further
conformational changes were illustrated by the “325–338” loop
shi behind the active site and the “339–348” region being
modied from a uctuating 310 helix to a more stable a-helix.
Crystallographic studies have identied the P-loop, speci-
cally Lys200, to be critical in stabilizing the triphosphate moiety
of an NTP, thus allowing exibility upon ligand binding and
activation.12–14 To augment these key ndings, Lys200 showed
strong hydrogen bonds with the NTP-analogue, NITD008. Other
active-hotspot residues included P-loop residues: Gly197–
Arg202, Ala198, Glu286, Gly415, Asn417 and Arg456. The
insights demonstrating the above binding landscape of the
ZIKV NS3 helicase will aid researchers in the identication of
targeted-small molecule inhibitors through structure based
drug design and to utilize pharmacophore models in screening
for effective drugs with minimal toxicity.
Future experimental analysis is needed to fully understand
these loop shis toward inhibition of the enzyme as well as
investigations into possible mutational resistance as seen in
other Flavivirus helicase NTPase sites.
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Figure S1: Potential Energy Fluctuations of the NITD008-NS3 Helicase System at varying 
temperatures during the 100ns simulation. The average temperature of the system was 300K and 
the average potential energy was -145774 kcal/mol. 
Figure S2: Complex of NITD008-NS3 Helicase with a Docking score of -7.7 kcal/mol. 
MM/GBSA calculations yielded a result of -30.00 kcal/mol. The ligand shifted further out of the 
hydrophobic pocket after 150ns of the simulation. This may possibly be due to the ligand not 
interacting with the stabilizing residues of the P-loop. 
Figure S3: Complex of NITD008-NS3 Helicase with a Docking score of -7.6 kcal/mol. 
MM/GBSA calculations yielded a result of -13.67 kcal/mol. The ligand docked out of the 
hydrophobic pocket and during the simulation, due to the lack of stabilizing interactions, the 
ligand moved further out of the active site and into the solvent. 
Figure S4: Complex of NITD008-NS3 Helicase with a Docking score of -7.1 kcal/mol. 
MM/GBSA calculations yielded a result of -11.86 kcal/mol. This ligand showed a similar pose to 
that of the -7.6 kcal/mol-docked pose, however, there was only one residue, Arg462, which 
showed stabilizing hydrogen bonds with the terminal oxygen located on the ribose group of 
NITD008. 
Figure S5: Complex of NITD008- NS3 Helicase with a Docking score of -7.1 kcal/mol. 
MM/GBSA calculations yielded a result of -23.99 kcal/mol. This pose showed the same docking 
score as the above ligand, however, three residues: Arg462, Asn417, and Glu231, were involved 
in stabilizing hydrogen bonds.
Figure S6: MM/GBSA calculations yielded a result of -5.90 kcal/mol, which was lower than that 
of the docking score of 6.9 kcal/mol. This was due to the ligand binding out of the active site of 
the enzyme, thus leading to minimal intermolecular forces at the hydrophobic pocket. 
